



Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists

Harold P. Adams, Jr, Gregory del Zoppo, Mark J. Alberts, Deepak L. Bhatt, Lawrence Brass, Anthony Furlan, Robert L. Grubb, Randall T. Higashida, Edward C. Jauch, Chelsea Kidwell, Patrick D. Lyden, Lewis B. Morgenstern, Adnan I. Qureshi, Robert H. Rosenwasser, Phillip A. Scott and Eelco F.M. Wijdicks

Stroke 2007;38;1655-1711; originally published online Apr 12, 2007;

DOI: 10.1161/STROKEAHA.107.181486

Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75214
Copyright © 2007 American Heart Association. All rights reserved. Print ISSN: 0039-2499. Online
ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://stroke.ahajournals.org/cgi/content/full/38/5/1655>

Subscriptions: Information about subscribing to Stroke is online at
<http://stroke.ahajournals.org/subscriptions/>

Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, a division of Wolters Kluwer Health, 351 West Camden Street, Baltimore, MD 21202-2436. Phone: 410-528-4050. Fax: 410-528-8550. E-mail:
journalpermissions@lww.com

Reprints: Information about reprints can be found online at
<http://www.lww.com/reprints>

Guidelines for the Early Management of Adults With Ischemic Stroke

A Guideline From the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups

*The American Academy of Neurology affirms the value of this guideline
as an educational tool for neurologists.*

Harold P. Adams, Jr, MD, FAHA, Chair; Gregory del Zoppo, MD, FAHA, Vice Chair;
Mark J. Alberts, MD, FAHA; Deepak L. Bhatt, MD;

Lawrence Brass, MD, FAHA†; Anthony Furlan, MD, FAHA; Robert L. Grubb, MD, FAHA;
Randall T. Higashida, MD, FAHA; Edward C. Jauch, MD, FAHA; Chelsea Kidwell, MD, FAHA;
Patrick D. Lyden, MD; Lewis B. Morgenstern, MD, FAHA; Adnan I. Qureshi, MD, FAHA;
Robert H. Rosenwasser, MD, FAHA; Phillip A. Scott, MD, FAHA; Eelco F.M. Wijdicks, MD, FAHA

Purpose—Our goal is to provide an overview of the current evidence about components of the evaluation and treatment of adults with acute ischemic stroke. The intended audience is physicians and other emergency healthcare providers who treat patients within the first 48 hours after stroke. In addition, information for healthcare policy makers is included.

Methods—Members of the panel were appointed by the American Heart Association Stroke Council's Scientific Statement Oversight Committee and represented different areas of expertise. The panel reviewed the relevant literature with an emphasis on reports published since 2003 and used the American Heart Association Stroke Council's Levels of Evidence grading algorithm to rate the evidence and to make recommendations. After approval of the statement by the panel, it underwent peer review and approval by the American Heart Association Science Advisory and Coordinating Committee. It is intended that this guideline be fully updated in 3 years.

Results—Management of patients with acute ischemic stroke remains multifaceted and includes several aspects of care that have not been tested in clinical trials. This statement includes recommendations for management from the first contact by emergency medical services personnel through initial admission to the hospital. Intravenous administration of recombinant tissue plasminogen activator remains the most beneficial proven intervention for emergency treatment of stroke. Several interventions, including intra-arterial administration of thrombolytic agents and mechanical interventions, show promise. Because many of the recommendations are based on limited data, additional research on treatment of acute ischemic stroke is needed. (*Stroke*. 2007;38:1655-1711.)

Key Words: AHA Scientific Statements ■ emergency medical services ■ stroke ■ acute cerebral infarction
■ tissue plasminogen activator

†Deceased.

The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.

This guideline was approved by the American Heart Association Science Advisory and Coordinating Committee on January 6, 2007. A single reprint is available by calling 800-242-8721 (US only) or writing the American Heart Association, Public Information, 7272 Greenville Ave, Dallas, TX 75231-4596. Ask for reprint No. 71-0398. To purchase additional reprints, call 843-216-2533 or e-mail kelle.ramsay@wolterskluwer.com.

This guideline has been copublished in *Circulation*.

Expert peer review of AHA Scientific Statements is conducted at the AHA National Center. For more on AHA statements and guidelines development, visit <http://www.americanheart.org/presenter.jhtml?identifier=3023366>.

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at <http://www.americanheart.org/presenter.jhtml?identifier=4431>. A link to the "Permission Request Form" appears on the right side of the page.

© 2007 American Heart Association, Inc.

Stroke is available at <http://www.strokeaha.org>

DOI: 10.1161/STROKEAHA.107.181486

TABLE OF CONTENTS

I. PREHOSPITAL MANAGEMENT AND FIELD TREATMENT . . .	1657	VII. INTRA-ARTERIAL THROMBOLYSIS	1677
A. EMS Assessment	1659	A. Conclusions and Recommendations	1678
B. EMS Management	1660	<i>Class I Recommendations</i>	1678
C. Air Medical Transport	1660	<i>Class II Recommendation</i>	1678
D. Conclusions and Recommendations	1661	<i>Class III Recommendation</i>	1678
<i>Class I Recommendations</i>	1661	VIII. ANTICOAGULANTS	1678
<i>Class II Recommendation</i>	1662	A. Heparin	1678
II. DESIGNATION OF STROKE CENTERS	1662	B. Low-Molecular-Weight Heparins	
A. Stroke Center Certification	1662	and Danaparoid	1679
B. Conclusions and Recommendations	1663	C. Anticoagulants as an Adjunctive Therapy	1679
<i>Class I Recommendations</i>	1663	D. Conclusions and Recommendations	1679
III. EMERGENCY EVALUATION AND DIAGNOSIS OF		<i>Class III Recommendations</i>	1680
ACUTE ISCHEMIC STROKE	1663	IX. ANTIPLATELET AGENTS	1680
A. Immediate Evaluation	1663	A. Single Oral Antiplatelet Agent	1680
1. History	1663	B. Combination of Oral Antiplatelet Agents	1680
2. Physical Examination	1664	C. Intravenous Antiplatelet Agents	1680
3. Neurological Examination and Stroke Scale Scores	1664	D. Conclusions and Recommendations	1681
4. Diagnostic Tests	1665	<i>Class I Recommendation</i>	1681
5. Cardiac Tests	1665	<i>Class III Recommendations</i>	1681
B. Conclusions and Recommendations	1665	X. VOLUME EXPANSION, VASODILATORS, AND INDUCED	
<i>Class I Recommendations</i>	1666	HYPERTENSION	1681
<i>Class III Recommendations</i>	1666	A. Hemodilution in Acute Ischemic Stroke	1681
IV. EARLY DIAGNOSIS: BRAIN AND VASCULAR IMAGING	1666	Conclusions and Recommendations	1681
A. Brain Imaging	1666	<i>Class III Recommendation</i>	1682
1. Non-Contrast-Enhanced CT Scan of the Brain	1666	B. Vasodilators in Acute Ischemic Stroke	1682
2. Multimodal CT	1667	Conclusions and Recommendations	1682
3. Multimodal MRI	1667	<i>Class III Recommendation</i>	1682
4. Other Brain Imaging Techniques	1668	C. Induced Hypertension for the Management	
B. Other Vascular Imaging	1668	of Acute Ischemic Stroke	1682
C. Conclusions and Recommendations	1668	Conclusions and Recommendations	1683
<i>Class I Recommendations</i>	1668	<i>Class I Recommendation</i>	1683
<i>Class II Recommendations</i>	1668	<i>Class III Recommendation</i>	1683
<i>Class III Recommendations</i>	1669	XI. SURGICAL INTERVENTIONS	1683
V. GENERAL SUPPORTIVE CARE AND TREATMENT OF		A. Carotid Endarterectomy	1683
ACUTE COMPLICATIONS	1669	B. Other Surgical Procedures	1683
A. Airway, Ventilatory Support,		C. Conclusions and Recommendations	1683
and Supplemental Oxygen	1669	XII. ENDOVASCULAR INTERVENTIONS	1683
B. Temperature	1669	A. Angioplasty and Stenting	1683
C. Cardiac Monitoring and Treatment	1670	B. Mechanical Clot Disruption	1684
D. Arterial Hypertension	1670	C. Clot Extraction	1684
E. Arterial Hypotension	1672	D. Conclusions and Recommendations	1684
F. Hypoglycemia	1672	<i>Class II Recommendations</i>	1684
G. Hyperglycemia	1672	XIII. COMBINATION REPERFUSION THERAPY	
H. Conclusions and Recommendations	1673	IN ACUTE STROKE	1684
<i>Class I Recommendations</i>	1673	A. Combination of Thrombolysis and	
<i>Class II Recommendations</i>	1674	Neuroprotective Therapies	1685
<i>Class III Recommendations</i>	1674	B. Thrombolysis and Antiplatelet Agents	1685
VI. INTRAVENOUS THROMBOLYSIS	1674	C. Conclusions and Recommendations	1685
A. Recombinant Tissue Plasminogen Activator	1674	<i>Class III Recommendation</i>	1685
B. Other Thrombolytic Agents	1675	XIV. NEUROPROTECTIVE AGENTS	1685
C. Defibrogenating Enzymes	1675	Conclusions and Recommendations	1687
D. Conclusions and Recommendations	1675	<i>Class III Recommendation</i>	1687
<i>Class I Recommendations</i>	1676		
<i>Class II Recommendations</i>	1676		
<i>Class III Recommendations</i>	1677		

XV. ADMISSION TO THE HOSPITAL AND GENERAL
 ACUTE TREATMENT (AFTER HOSPITALIZATION)1687
 A. Admission to the Hospital1687
 B. Specialized Stroke Care Units1687
 1. General Care1688
 2. Nutrition and Hydration1688
 3. Infections1688
 C. Deep Vein Thrombosis and Pulmonary Embolism1689
 1. Other Care1689
 D. Conclusions and Recommendations1689
 Class I Recommendations1689
 Class II Recommendations1690
 Class III Recommendations1690

XVI. TREATMENT OF ACUTE NEUROLOGICAL COMPLICATIONS1690
 A. Ischemic Brain Swelling1690
 B. Hemorrhagic Transformation1691
 C. Seizures1691
 D. Conclusions and Recommendations1691
 Class I Recommendations1691
 Class II Recommendations1692
 Class III Recommendations1692
 E. Palliative Care1692

DISCLOSURES1693
 REFERENCES1694

The present document is a comprehensive guideline statement on the management of patients with acute ischemic stroke that supercedes the prior statement and interim updates.¹⁻³ These guidelines have been developed by a panel of physicians with a broad range of expertise, including vascular neurology, neurocritical care, emergency medicine, neurosurgery, and interventional neuroradiology/endovascular neurosurgery. The intended audience for these guidelines includes physicians, emergency medical services (EMS) personnel, and other medical personnel who deal with the emergency diagnosis and treatment of patients with suspected ischemic stroke. In addition, components of these guidelines are very relevant to health policy decision makers and administrators. The goal of these guidelines is to provide updated recommendations that may be used by physicians who provide acute stroke care within the first hours to time of initial diagnosis, treatment, and initial hospitalization. In addition, the guideline also includes information that should be useful for nonphysician EMS personnel and for hospitals. The emphasis of these guidelines is the diagnosis and emergency treatment of patients with acute ischemic stroke. Information about the management of acute and subacute neurological and medical complications is also included. The panel recognizes that measures to prevent early recurrent stroke are also a component of acute management. In general, the medical or surgical interventions administered to prevent recurrent stroke are similar to those prescribed to patients with recent transient ischemic attacks or to other high-risk persons. The reader is referred to another recent statement that addresses the management of risk factors, the prescription of antithrombotic medications, and the use of surgical or endovascular interventions to prevent recurrent stroke.⁴

In writing these guidelines, the panel applied the rules of evidence and the formulation of strength of recommendations used by other panels of the American Heart Association (AHA)⁴ (see the Figure and Table 1). The data were collected through a systematic review of the literature. Because of the wide scope of the guidelines, the members of the panel were assigned primary reviews for individual sections. Then the panel assessed the complete guidelines. If the panel concluded that data supported or did not support the use of a specific intervention, appropriate recommendations were made. In some cases in which definitive data were not available, no specific recommendation was made. *Italics* indicate recommendations that have been changed or added since the publication of the previous guideline. In other instances, supporting evidence based on clinical trial research was not available for a specific intervention, but the panel has made a specific recommendation on the basis of pathophysiological reasoning and expert practice experience. For many of these interventions, it is unlikely that randomized trials will ever be performed. An example is the recommendation to perform endotracheal intubation to protect the airway in a comatose patient.

I. Prehospital Management and Field Treatment

Recent data indicate that 29% to 65% of patients with signs or symptoms of acute stroke access their initial medical care via local EMS (Table 2), which confirms the role of EMS in the chain of survival.⁵⁻¹³ Notably, an estimated 19% to 60% of stroke patients present within 3 hours of stroke and 14% to 32% of those arrive within 2 hours of symptom onset. Although just over half of all stroke patients use EMS access to health care, those who do utilize EMS comprise the majority of patients presenting within the 3-hour window.¹³⁻¹⁶

EMS activation appears to be a function primarily of individuals other than the patient, with one report indicating that a family member, paid caregiver, coworker, or other bystander accounted for 62% to 95% of 9-1-1 activation calls.^{6,9} In addition to bystander recognition of a problem, other reported predictors of EMS use by stroke patients include stroke severity,¹⁷ presence of intracranial hemorrhage,^{9,18} age,^{9,18} sense of urgency,⁹ unemployment,⁶ and race (black).¹⁸

The benefits of EMS activation by patients with stroke symptoms appear to occur in both the prehospital and in-hospital settings. Hospital arrival is faster for patients who use EMS/9-1-1 as their initial medical contact than for those who contact their primary physician or hospital directly¹⁸ or a primary care site.¹⁹ Not surprisingly, EMS use is strongly associated with shorter time periods from symptom onset to hospital arrival, although this may reflect a greater sense of urgency on the patient's or bystander's part rather than reduced transport time.^{8,9,12} Similarly, EMS use is strongly associated with decreased time to initial physician examination,^{9,10,13,20} initial computed tomography (CT) imaging,^{9,10,12} and neurological evaluation.⁹

"Estimate of Certainty (Precision) of Treatment Effect"		"Size of Treatment Effect"		
		Class I <i>Benefit >>> Risk</i> Procedure/Treatment SHOULD be performed/administered	Class IIa <i>Benefit >> Risk</i> Additional studies with focused objectives needed	Class IIb <i>Benefit ≥ Risk</i> Additional studies with broad objectives needed; Additional registry data would be helpful
Level A <i>Multiple (3-5) population risk strata evaluated*</i> <i>General consistency of direction and magnitude of effect</i>	<ul style="list-style-type: none"> • Recommendation that procedure or treatment is useful/effective • Sufficient evidence from multiple randomized trials or meta-analyses 	<ul style="list-style-type: none"> • Recommendation in favor of treatment or procedure being useful/effective • Some conflicting evidence from multiple randomized trials or meta-analyses 	<ul style="list-style-type: none"> • Recommendation's usefulness/efficacy less well established • Greater conflicting evidence from multiple randomized trials or meta-analyses 	<ul style="list-style-type: none"> • Recommendation that procedure or treatment not useful/effective and may be harmful • Sufficient evidence from multiple randomized trials or meta-analyses
Level B <i>Limited (2-3) population risk strata evaluated*</i>	<ul style="list-style-type: none"> • Recommendation that procedure or treatment is useful/effective • Limited evidence from single randomized trial or non-randomized studies 	<ul style="list-style-type: none"> • Recommendation in favor of treatment or procedure being useful/effective • Some conflicting evidence from single randomized trial or non-randomized studies 	<ul style="list-style-type: none"> • Recommendation's usefulness/efficacy less well established • Greater conflicting evidence from single randomized trial or non-randomized studies 	<ul style="list-style-type: none"> • Recommendation that procedure or treatment not useful/effective and may be harmful • Limited evidence from single randomized trial or non-randomized studies
Level C <i>Very limited (1-2) population risk strata evaluated*</i>	<ul style="list-style-type: none"> • Recommendation that procedure or treatment is useful/effective • Only expert opinion, case studies, or standard-of-care 	<ul style="list-style-type: none"> • Recommendation in favor of treatment or procedure being useful/effective • Only diverging expert opinion, case studies, or standard-of-care 	<ul style="list-style-type: none"> • Recommendation's usefulness/efficacy less well established • Only diverging expert opinion, case studies, or standard-of-care 	<ul style="list-style-type: none"> • Recommendation that procedure or treatment not useful/effective and may be harmful • Only expert opinion, case studies, or standard-of-care
Suggested phrases for writing recommendations †	<p>should be recommended</p> <p>is indicated</p> <p>is useful/effective/beneficial</p>	<p>is reasonable</p> <p>can be useful/effective/ beneficial</p> <p>is probably recommended or indicated</p>	<p>may/might be considered</p> <p>may/might be reasonable</p> <p>usefulness/effectiveness is unknown /unclear/uncertain or not well established</p>	<p>is not recommended</p> <p>is not indicated</p> <p>should not</p> <p>is not useful/effective/beneficial</p> <p>may be harmful</p>

*Data available from clinical trials or registries about the usefulness/efficacy in different sub-populations, such as gender, age, history of diabetes, history of prior MI, history of heart failure, and prior aspirin use. A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Even though randomized trials are not available, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.

†In 2003, the ACC/AHA Task Force on Practice Guidelines developed a list of suggested phrases to use when writing recommendations. All recommendations in this guideline have been written in full sentences that express a complete thought, such that a recommendation, even if separated and presented apart from the rest of the document (including headings above sets of recommendations), would still convey the full intent of the recommendation. It is hoped that this will increase readers' comprehension of the guidelines and will allow queries at the individual recommendation level.

Figure. Applying classification of recommendations and level of evidence.

TABLE 1. Definition of Classes and Levels of Evidence Used in AHA Recommendations

Classification	
Class I	Conditions for which there is evidence for and/or general agreement that the procedure or treatment is useful and effective
Class II	Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment
Class IIa	The weight of evidence or opinion is in favor of the procedure or treatment.
Class IIb	Usefulness/efficacy is less well established by evidence or opinion.
Class III	Conditions for which there is evidence and/or general agreement that the procedure or treatment is not useful/effective and in some cases may be harmful
Level of evidence	
A	Data derived from multiple randomized clinical trials
B	Data derived from a single randomized trial or nonrandomized studies
C	Consensus opinion of experts
Level of evidence for diagnostic recommendation	
A	Data derived from multiple prospective cohort studies that used a reference standard applied by a masked evaluator
B	Data derived from a single grade A study or one or more case-control studies or studies that used a reference standard applied by an unmasked evaluator
C	Consensus opinion of experts

On the basis of the aforementioned information, communities should encourage 9-1-1 activation and use for patients with symptoms of acute stroke.

Data from the TLL Temple Foundation Stroke Project controlled trial indicate that educational interventions on stroke identification and management targeting patients, EMS, hospitals, and community physicians increased thrombolytic use in patients with ischemic stroke from 2.21% to 8.65% as compared with communities that did not have such programs, which saw only a 0.06% increase. For patients with ischemic stroke who were eligible for thrombolytic therapy, rates of tissue-type plasminogen activator (tPA) use increased from 14% to 52% in intervention communities. The benefit from this aggressive intervention program was sustained at 6 months after intervention.^{21,22}

A. EMS Assessment

EMS assessment begins with the initial 9-1-1 contact (Table 2). The role of the dispatch system is to ensure immediate triage and dispatch of appropriate EMS providers when acute stroke is suspected by either the caller or the dispatcher.²³ Data from 2 systems indicate that dispatchers correctly suspected or identified 52% of patients ultimately proven to have had a stroke on initial telephone evaluation.^{7,24} These data imply that educational programs should be aimed at dispatchers to increase their awareness of stroke symptoms.

TABLE 2. Stroke Chain of Survival

Detection	Recognition of stroke signs and symptoms
Dispatch	Call 9-1-1 and priority EMS dispatch
Delivery	Prompt transport and prehospital notification to hospital
Door	Immediate ED triage
Data	ED evaluation, prompt laboratory studies, and CT imaging
Decision	Diagnosis and decision about appropriate therapy
Drug	Administration of appropriate drugs or other interventions

Stroke should be given a priority dispatch similar to that for acute myocardial infarction or trauma.²⁵

After ambulance arrival on the scene, EMS providers should obtain a focused history and patient assessment, provide necessary stabilization and treatment, and transport immediately to the closest, most appropriate facility (Table 3). The word *appropriate* is key because it means that an ambulance may bypass a hospital that does not have the resources or institutional commitment to treat patients with stroke if a more appropriate hospital is available within a reasonable transport interval. Advance notice to the receiving emergency department (ED) of the impending arrival of a potential stroke patient, along with information on comorbid conditions and estimated time of symptom onset, will speed the subsequent ED assessment.

Critical elements of the patient’s history must include information on time of symptom onset (Table 4). This may require obtaining information from bystanders or, preferably, transporting witnesses with the patient. Similarly, next of kin, if available, may be needed for information or consent and should travel to the receiving hospital concurrently. Telephone numbers, including cellular telephone numbers, of witnesses or relatives may help the ED to clarify the history or seek consent for treatment. A list of the patient’s medications, or the medication containers themselves, should be sought, with particular attention paid to identifying anticoagulant (both oral and injectable), antiplatelet, and antihypertensive drug use.

After the patient’s airway, breathing, and circulation (ABCs) are assessed and stabilized, common presenting signs of stroke should be sought and a focused examination completed. Prehospital stroke assessment tools have proved effective in identifying stroke patients in the field. The Los Angeles Prehospital Stroke Screen uses patient history, physical findings, and finger stick glucose determination to identify stroke patients.²⁶ The Cincinnati Prehospital Stroke

TABLE 3. Guidelines for EMS Management of Patients With Suspected Stroke

Recommended	Not Recommended
Manage ABCs	Dextrose-containing fluids in nonhypoglycemic patients
Cardiac monitoring	Hypotension/excessive blood pressure reduction
Intravenous access	Excessive intravenous fluids
Oxygen (as required O ₂ saturation <92%)	
Assess for hypoglycemia	
<i>Nil per os</i> (NPO)	
Alert receiving ED	
Rapid transport to closest appropriate facility capable of treating acute stroke	

Scale is an alternative instrument with fewer data elements (Table 5), requiring only 30 to 60 seconds to complete.²⁷ Other prehospital stroke evaluation tools exist, although data on their validity are limited.

B. EMS Management

Guidelines for EMS management are presented in Table 3.^{25,28} After initial stabilization, it is recommended that patient transport commence as soon as possible, with cardiac monitoring and intravenous access established during transport, if possible. Isotonic crystalloids (most commonly normal saline solution) are recommended for resuscitation, if needed. Dextrose-containing fluids should be avoided unless hypoglycemia is present or strongly suspected because excessive glucose may be injurious to stroke patients. No recommendations can be offered on the prehospital management of hypertension in patients with suspected stroke, and intervention is best accomplished after hospital arrival.

It is well recognized that hypoglycemic patients may have symptoms that mimic an acute stroke, manifesting focal symptoms, altered speech, and/or cognitive changes, and therefore EMS assessment of blood glucose has been a routine practice for many years. A single report suggests that a more selective approach may be possible, with blood glucose measurement advocated only in the presence of a history suspicious for hypoglycemia or inability to obtain

adequate patient information.²⁹ That study is limited, however, by its retrospective methodology and an upper confidence interval of 2.4% for the likelihood of failing to identify a hypoglycemic patient. At present, checking blood glucose concentrations in most patients with stroke is a prudent step, even among patients without a history of diabetes mellitus or use of insulin.

The availability of resources to care for patients with acute stroke varies widely both among and within communities. The National Institutes of Health (NIH) Task Force report, "Improving the Chain of Recovery for Acute Stroke in Your Community," recommends identifying hospitals capable of providing acute stroke care and creating a transport system to these centers based on patient location. Such systems require advanced planning and frequent updating and should incorporate EMS representatives, community leaders, hospitals, and physicians to ensure clear guidance for EMS providers with regard to patient destination.

Identification of an effective neuroprotective therapy may further expand the role of EMS in the treatment of acute stroke. The feasibility of initiation of hypothermia has also been demonstrated in the prehospital setting.³⁰ Of importance for future research is the fact that it appears possible to incorporate EMS into the research process, with EMS personnel having demonstrated success in facilitating physician cell phone elicitation of consent from patients and in delivering experimental stroke therapy.^{31,32}

TABLE 4. Key Components of History

Onset of symptoms
Recent events
Stroke
Myocardial infarction
Trauma
Surgery
Bleeding
Comorbid diseases
Hypertension
Diabetes mellitus
Use of medications
Anticoagulants
Insulin
Antihypertensives

C. Air Medical Transport

Air medical (helicopter) transport for patients with acute stroke appears beneficial, although the data are limited. Helicopters may extend the range of thrombolytic therapy to rural areas.³³ They could deliver teams to administer tPA and subsequently transfer treated patients,³⁴ expand enrollment for acute stroke studies,³⁵ and facilitate early definitive diagnosis and operative intervention in nontraumatic intracranial hemorrhage.³⁶ It is important to note that helicopter transfer of stroke patients for potential thrombolysis is cost-effective for a wide range of system variables.³⁷

Protocols for the use of air medical transfer from facilities unable to provide acute stroke care should be developed in advance. Air medical transfer should be considered for patients who cannot receive treatment locally and who could reach a treating facility within the available time window.^{33,38}

TABLE 5. Prehospital Stroke Identification Instruments

Los Angeles Prehospital Stroke Screen			
Last time patient known to be symptom free, Date _____ Time _____			
Screening criteria			
Age >45 y	Yes	Unknown	No
No history of seizures or epilepsy	Yes	Unknown	No
Symptoms present <24 h	Yes	Unknown	No
Not previously bedridden or wheelchair bound	Yes	Unknown	No
If unknown or yes			
Blood glucose 60 to 400 mg/dL	Yes	No	
Examination			
Facial smile grimace	Normal	Right droop	Left droop
Grip	Normal	Right weak	Left weak
		No grip	No grip
Arm strength	Normal	Right drift	Left drift
		Right falls	Left falls
Based on examination, patient has unilateral weakness	Yes	No	
If items are yes or unknown, meets criteria for stroke			
Cincinnati Prehospital Stroke Scale			
Facial droop			
Normal—both sides of face move equally			
Abnormal—one side of face does not move as well as the other			
Arm drift			
Normal—both arms move the same or both arms do not move at all			
Abnormal—one arm either does not move or drifts down compared to the other			
Speech			
Normal—says correct words with no slurring			
Abnormal—slurs words, says the wrong words, or is unable to speak			

Reprinted from Kothari et al,²⁷ with permission from Elsevier. Copyright 1999.

In addition, telemedicine may be used as a way to bring stroke expertise to patients in rural or small hospitals. Preliminary data suggest that such electronic methods may be increasingly useful.^{39–43}

D. Conclusions and Recommendations

Public educational programs likely will increase the proportion of patients with stroke who will utilize EMS as their first contact with the healthcare system. This trend should be encouraged. In response, EMS should have protocols in place to rapidly assess, treat, and transport patients. The objectives of the EMS phase of stroke care are as follows: (1) rapid identification of stroke as the cause of the patient’s findings, (2) elimination of comorbid conditions that could mimic stroke, (3) stabilization, (4) rapid transportation of the patient to the closest appropriate ED, and (5) notification of the receiving institution about impending arrival of a patient with suspected stroke. Such steps are especially critical for the use of time-dependent therapies. Community and physician educational programs on acute stroke treatment appear to enhance the use of recombinant tPA (rtPA), and these programs should be encouraged. Strategies such as telemedicine or air medical transport (helicopter) may provide access to specialized stroke care when it is not available locally. Such approaches may increase the number of patients who can be

treated, especially in rural or otherwise underserved areas. To maximize therapeutic options, treatment guidelines and transfer protocols should be established in advance to ensure orderly patient transition from a prehospital to a hospital environment.

The recommendations that follow were not included in the previous guidelines.

Class I Recommendations

- 1. Activation of the 9-1-1 system by patients or other members of the public is strongly supported because it speeds treatment of stroke (Class I, Level of Evidence B). 9-1-1 Dispatchers should make stroke a priority dispatch.**
- 2. To increase the number of patients who can be seen and treated within the first few hours after stroke, educational programs to increase public awareness of stroke are recommended (Class I, Level of Evidence B).**
- 3. To increase the number of patients who are treated, educational programs for physicians, hospital personnel, and EMS personnel also are recommended (Class I, Level of Evidence B).**
- 4. Brief assessments by EMS personnel as outlined in Tables 3 and 5 are recommended (Class I, Level of Evidence B).**

5. The use of a stroke identification algorithm such as the Los Angeles or Cincinnati screens is encouraged (Class I, Level of Evidence B).
6. The panel recommends that EMS personnel begin the initial management of stroke in the field, as outlined in Table 3 (Class I, Level of Evidence B). The development of stroke protocols to be used by EMS personnel is strongly encouraged.
7. Patients should be transported rapidly for evaluation and treatment to the closest institution that provides emergency stroke care as described in the statement (Class I, Level of Evidence B). In some instances, this may involve air evacuation. EMS personnel should notify the receiving ED so that the appropriate resources may be mobilized.

Class II Recommendation

1. Telemedicine can be an effective method to provide expert stroke care to patients located in rural areas (Class IIa, Level of Evidence B). Additional research and experience on the usefulness of telemedicine are encouraged.

II. Designation of Stroke Centers

In an attempt to improve the organization and delivery of care to stroke patients, the Brain Attack Coalition published 2 sets of recommendations, one for primary stroke centers (PSCs) and, more recently, one for comprehensive stroke centers (CSCs).^{44,45} A PSC has the personnel, programs, expertise, and infrastructure to care for many patients with uncomplicated strokes, uses many acute therapies (such as intravenous rtPA), and admits such patients into a stroke unit. The CSC is designed to care for patients with complicated types of strokes, patients with intracerebral hemorrhage or subarachnoid hemorrhage, and those requiring specific interventions (eg, surgery or endovascular procedures) or an intensive care unit type of setting.

The specific elements of a PSC and a CSC will not be reviewed in the present document because they are well covered in the articles cited above. Many of the elements in a PSC or a CSC, including stroke units, written care protocols, availability of physicians with neurological expertise, and neurosurgical volumes, are associated with improved outcomes among patients treated for stroke.^{44,45} Since the publication of the PSC article in 2000,⁴⁴ numerous published studies have demonstrated the utility and effectiveness of such centers.^{22,46–51} One study found that a PSC increased the use of intravenous rtPA from 1.5% to 10.2% in 2 years.⁴⁶ Another study found that 7 of the 11 elements of a PSC were associated with increased use of intravenous tPA.⁴⁷ Additional areas of disease performance that may be added include performance of a lipid profile, dysphagia screening, and the presence of a rehabilitation plan.

The utility of a CSC is beginning to emerge. Studies show that a CSC increases the use of lytic agents and that a CSC may improve overall care and outcomes.^{52,53} In-hospital death rates were reduced by almost 50% in hospitals with a vascular neurologist and were reduced by 24% in those with a stroke team.⁵⁴ Such centers have acted as a regional resource for stroke care with good results and will be pivotal for further

TABLE 6. Standardized Measures for Stroke: JCAHO Primary Stroke Centers

tPA considered
Screen for dysphagia
Deep vein thrombosis prophylaxis
Lipid profile during hospitalization
Smoking cessation
Education about stroke
Plan for rehabilitation considered
Antithrombotic medications started within 48 hours
Antithrombotic medications prescribed at discharge
Anticoagulants prescribed to patients with atrial fibrillation

advancements in acute stroke care, stroke prevention, and rehabilitation.^{38,55,56}

A. Stroke Center Certification

The certification or designation of some hospitals as PSCs or CSCs is progressing rapidly. The American Stroke Association convened an expert panel to study this issue for PSCs, with the conclusion that a variety of certification processes might be developed and lead to improved care and outcomes.⁵⁷ Another panel is currently meeting to evaluate various options for CSC certification. One study showed that self-certification was likely to lead to a significant overestimation of a hospital's compliance with published recommendations for a PSC.⁵⁸ Thus, these data and anecdotal experience suggest that outside independent evaluations of hospitals as stroke centers should lead to more accurate assessment of a facility's true capabilities.

The Joint Commission on the Accreditation of Healthcare Organizations (JCAHO) began a formal process for the certification of PSCs in February 2004 (Table 6). As of February 2006, ≈200 hospitals in the United States had been certified as PSCs by the JCAHO. The JCAHO certification process includes a detailed evaluation of a hospital's staffing, education, disease management programs, outcomes, and infrastructure (see www.JCAHO.org for details). Several states have developed or are exploring a state-based certification process for PSCs, primarily using the state health department or a related government agency as the certifier. At this time the American Stroke Association and JCAHO have taken preliminary steps that may lead to a formal certification process for CSCs.

The preferential routing of acute stroke patients to a PSC has been demonstrated to increase the proportion of patients cared for at stroke-capable centers and to increase the proportion of patients treated with thrombolytic therapy to >10%.⁴⁸ Direct routing of stroke patients whose symptoms started <3 hours ago to a PSC or a CSC has been implemented or is in the process of implementation in 7 states, covering >25% of the US population. The states of Florida, New Jersey, Maryland, Massachusetts, Michigan, New Mexico, and Texas have laws or policies mandating that acute stroke patients be taken to the nearest stroke center. In other states, the limited number of such centers makes preferential routing logistically infeasible. Stroke centers in rural areas

TABLE 7. Stroke Mimics and Clinical Features

Conversion disorder	Lack of cranial nerve findings, neurological findings in a nonvascular distribution, inconsistent examination
Hypertensive encephalopathy	Headache, delirium, significant hypertension, cerebral edema
Hypoglycemia	History of diabetes, serum glucose low, decreased level of consciousness
Complicated migraine	History of similar events, preceding aura, headache
Seizures	History of seizures, witnessed seizure activity, postictal period

often use helicopter transportation or telemedicine technologies to provide rapid transportation and expertise to expedite treatment at outlying hospitals.^{33,53} However, this is clearly an area that will evolve as the number of stroke centers increases, their geographic distribution expands, and the concept is embraced by the medical community.

Stroke centers should not be viewed in isolation. Rather, they should be part of a larger support network sometimes referred to as a *stroke system of care*. Such a system would encompass issues such as prevention, education, acute care, rehabilitation, and quality improvement.⁵⁹ In addition, as the number of stroke centers increases, such facilities may form a network of hospitals that would be useful for testing new therapies for acute stroke.

B. Conclusions and Recommendations

Robust data demonstrate the efficacy of specialized stroke services in improving outcomes of patients with stroke. Thus, there is a strong impetus to develop such specialized stroke services across the United States. Both primary (PSC) and comprehensive (CSC) centers are needed. At present, the process of identification of PSCs is ahead of that used to develop CSCs. The details of the organization of such services may vary among institutions or in different parts of the country to reflect demographic or geographic variables. Statewide or regional programs are being developed. A method to designate stroke centers, such as the JCAHO program, is being used to ensure that centers have the expertise and resources to provide modern stroke care. Plans for EMS to bypass institutions that do not have the capability to provide modern stroke care need to be developed.

The following recommendations were not included in the prior stroke guidelines.

Class I Recommendations

- 1. The creation of PSCs is strongly recommended (Class I, Level of Evidence B). The organization of such resources will depend on local variables. The design of several community-based PSCs that provide emergency care and that are closely associated with a CSC, which provides more extensive care, has considerable appeal.**
- 2. The development of CSC is recommended (Class I, Level of Evidence C).**
- 3. Certification of stroke centers by an external body, such as JCAHO, is encouraged (Class I, Level of Evidence B). The panel encourages additional medical centers to seek such certification.**
- 4. For patients with suspected stroke, EMS should bypass hospitals that do not have resources to treat stroke and go to the closest facility capable of treating acute stroke (Class I, Level of Evidence B).**

III. Emergency Evaluation and Diagnosis of Acute Ischemic Stroke

Given the narrow therapeutic windows for treatment of acute ischemic stroke, timely evaluation and diagnosis of ischemic stroke are paramount.⁶⁰ Hospitals that maintain an ED must create efficient pathways and processes to rapidly identify and evaluate potential stroke patients. The physician's evaluation, diagnostic testing, including neuroimaging, and contact with a physician with stroke expertise should be performed concurrently. A consensus panel convened by the National Institute of Neurological Disorders and Stroke (NINDS) established goals for time frames in these steps in the evaluation of stroke patients in the ED.^{25,61} At this same symposium, the "Stroke Chain of Survival" was promoted as a template for identifying critical events in the ED identification, evaluation, and treatment of stroke patients (Table 2).⁶¹ By using this template and the time goals, hospitals and EDs can create effective systems for optimizing stroke patient care.⁶²

All patients with suspected acute stroke should be triaged with the same priority as patients with acute myocardial infarction or serious trauma, regardless of the severity of the deficits. Roughly half of all acute stroke patients access the ED through 9-1-1 and EMS. Prehospital notification of the arrival of a patient with a potential stroke expedites evaluation and diagnosis, and therefore hospitals should request notification from local EMS providers.^{63,64} For the remaining 50% of stroke patients, the ED staff should maintain a high level of suspicion for stroke in patients presenting through the ED lobby to minimize delays in triage. Early implementation of stroke pathways and stroke team notification should occur in parallel with the ED evaluation and management.

A. Immediate Evaluation

The initial evaluation of a potential stroke patient is similar to that of other critically ill patients: stabilization of the ABCs. This is quickly followed by a secondary assessment of neurological deficits and possible comorbidities. The overall goal is not only to identify patients with possible stroke but also to exclude stroke mimics (conditions with stroke-like symptoms), identify other conditions requiring immediate intervention, and determine potential causes of the stroke for early secondary prevention (Table 7).

1. History

The single most important piece of historical information is the time of symptom onset. The current definition of the time of stroke onset is when patients were at their previous baseline or symptom-free state. For patients unable to provide this information or who awaken with stroke symptoms, the time of onset is defined as when the patient was last awake

and symptom free or known to be “normal.” Often a patient’s current symptoms were preceded by similar symptoms that subsequently resolved. Currently, for patients who had neurological symptoms that completely resolved, the therapeutic clock is reset, and the time of symptom onset begins anew. It is important to note, however, that the longer the transient neurological deficits last, the greater is the chance of detecting neuroanatomically relevant focal abnormalities on diffusion-weighted and apparent diffusion coefficient imaging.⁶⁵ Whether this represents an increased risk of hemorrhage with thrombolysis remains to be determined.

Additional historical items include circumstances around the development of the neurological symptoms and features that may point to other potential causes of the symptoms. Although not absolutely accurate, some early historical data and clinical findings may direct the physician toward a diagnosis of another cause for the patient’s symptoms (Table 7). It is important to ask about risk factors for arteriosclerosis and cardiac disease in all patients, as well as any history of drug abuse, migraine, seizure, infection, trauma, or pregnancy. Historical data related to eligibility for therapeutic interventions in acute ischemic stroke are equally important.⁶⁶ Bystanders or family witnesses should be asked for information about onset time and historical issues, and therefore EMS personnel should be encouraged to identify witnesses and bring them in the ambulance when patients are unable to speak or provide history. Validated tools for identification of stroke patients within an ED are available.⁶⁷

2. Physical Examination

The general physical examination continues from the original assessment of the ABCs and should include pulse oximetry and body temperature. Examination of the head and neck may reveal signs of trauma or seizure activity (eg, contusions, tongue lacerations), carotid disease (bruits), or congestive heart failure (jugular venous distention). The cardiac examination focuses on identifying concurrent myocardial ischemia, valvular conditions, irregular rhythm, and, in rare cases, aortic dissection, which could precipitate a cardioembolic event. Similarly, the respiratory and abdominal examinations seek to identify other comorbidities. Examination of the skin and extremities may also provide insight into important systemic conditions such as hepatic dysfunction, coagulopathies, or platelet disorders (eg, jaundice, purpura, petechia).

3. Neurological Examination and Stroke Scale Scores

The emergency physician’s neurological examination should be brief but thorough. It is enhanced by use of a formal stroke score or scale, such as the NIH Stroke Scale (NIHSS). The scale may be used by a broad spectrum of non-neurological healthcare providers (Table 8).^{24,68,69} Use of a standardized examination helps to ensure that the major components of a neurological examination are performed in a timely fashion. These scores not only help to quantify the degree of neurological deficit but also facilitate communication between healthcare professionals, identify the possible location of vessel occlusion, provide early prognosis, and help to identify patient eligibility for various interventions and the potential for complications.^{42,70–72} Several studies have demonstrated that emergency physicians committed to stroke care may

TABLE 8. National Institutes of Health Stroke Scale

Tested Item	Title	Responses and Scores
1A	Level of consciousness	0—alert 1—drowsy 2—obtunded 3—coma/unresponsive
1B	Orientation questions (2)	0—answers both correctly 1—answers one correctly 2—answers neither correctly
1C	Response to commands (2)	0—performs both tasks correctly 1—performs one task correctly 2—performs neither
2	Gaze	0—normal horizontal movements 1—partial gaze palsy 2—complete gaze palsy
3	Visual fields	0—no visual field defect 1—partial hemianopia 2—complete hemianopia 3—bilateral hemianopia
4	Facial movement	0—normal 1—minor facial weakness 2—partial facial weakness 3—complete unilateral palsy
5	Motor function (arm)	0—no drift 1—drift before 5 seconds 2—falls before 10 seconds 3—no effort against gravity 4—no movement
	a. Left	
	b. Right	
6	Motor function (leg)	0—no drift 1—drift before 5 seconds 2—falls before 5 seconds 3—no effort against gravity 4—no movement
	a. Left	
	b. Right	
7	Limb ataxia	0—no ataxia 1—ataxia in 1 limb 2—ataxia in 2 limbs
8	Sensory	0—no sensory loss 1—mild sensory loss 2—severe sensory loss
9	Language	0—normal 1—mild aphasia 2—severe aphasia 3—mute or global aphasia
10	Articulation	0—normal 1—mild dysarthria 2—severe dysarthria
11	Extinction or inattention	0—absent 1—mild (loss 1 sensory modality) 2—severe (loss 2 modalities)

correctly identify and safely treat stroke patients, especially with the use of such standardized scales.^{73,74} All hospital systems should ensure access to neurological expertise when required.⁷⁵

TABLE 9. Immediate Diagnostic Studies: Evaluation of a Patient With Suspected Acute Ischemic Stroke

All patients
Noncontrast brain CT or brain MRI
Blood glucose
Serum electrolytes/renal function tests
ECG
Markers of cardiac ischemia
Complete blood count, including platelet count*
Prothrombin time/international normalized ratio (INR)*
Activated partial thromboplastin time*
Oxygen saturation
Selected patients
Hepatic function tests
Toxicology screen
Blood alcohol level
Pregnancy test
Arterial blood gas tests (if hypoxia is suspected)
Chest radiography (if lung disease is suspected)
Lumbar puncture (if subarachnoid hemorrhage is suspected and CT scan is negative for blood)
Electroencephalogram (if seizures are suspected)

MRI indicates magnetic resonance imaging.

*Although it is desirable to know the results of these tests before giving rtPA, thrombolytic therapy should not be delayed while awaiting the results unless (1) there is clinical suspicion of a bleeding abnormality or thrombocytopenia, (2) the patient has received heparin or warfarin, or (3) use of anticoagulants is not known.

Reprinted from Christensen et al,⁷⁶ with permission from the *Journal of Neurological Science*.

4. Diagnostic Tests

Several tests should be performed routinely in patients with suspected ischemic stroke to identify systemic conditions that may mimic or cause stroke or that may influence therapeutic options (Table 9). These tests include blood glucose, electrolytes, complete blood count with platelet count, prothrombin time, activated partial thromboplastin time, international normalized ratio, and renal function studies. Hypoglycemia may cause focal symptoms and signs that mimic stroke, and hyperglycemia is associated with unfavorable outcomes. Determination of the platelet count and, in patients taking warfarin or with liver dysfunction, the prothrombin time/international normalized ratio is important. Because time is critical, thrombolytic therapy should not be delayed while waiting for the results of the prothrombin time, activated partial thromboplastin time, or platelet count unless a bleeding abnormality or thrombocytopenia is suspected, the patient has been taking warfarin and heparin, or anticoagulation use is uncertain.

5. Cardiac Tests

A clinical cardiovascular examination, cardiac enzyme tests, and a 12-lead ECG should be performed in all stroke patients (Table 9).⁷⁶ Cardiac abnormalities are prevalent among patients with stroke, and the patient can have an acute cardiac condition that mandates urgent treatment. For example, acute

myocardial infarction can lead to stroke, and acute stroke can lead to myocardial ischemia.^{77–79} In addition, cardiac arrhythmias can occur among patients with acute ischemic stroke.^{77,78,80,81} Atrial fibrillation, an important potential cause of stroke, can be detected in the acute setting.⁸² Cardiac monitoring should be conducted routinely after an acute cerebrovascular event to screen for serious cardiac arrhythmias.⁸³

Chest radiography was previously recommended for the evaluation of all patients with acute ischemic stroke.¹ A subsequent study found that clinical management was altered in only 3.8% of patients who had routine chest radiographs at the time of admission for stroke, which suggests that the test is of modest, but not nil, value.⁸³

Examination of the cerebrospinal fluid is indicated if the patient has symptoms suggestive of subarachnoid hemorrhage and a CT scan does not demonstrate blood. Fortunately, the clinical features of subarachnoid hemorrhage differ considerably from those of ischemic stroke. Electroencephalography may be helpful for evaluating patients in whom seizures are suspected as the cause of the neurological deficits or in whom seizures could have been a complication of the stroke.⁸⁴ Seizure in the absence of imaging confirmation of acute ischemia is a relative contraindication for the use of rtPA in acute ischemic stroke.

Additional tests may be performed as indicated by the patient's history, symptoms, physical findings, or comorbidities (Table 9). A toxicology screen, blood alcohol level, arterial blood gas, and pregnancy test should be obtained if the physician is uncertain about the patient's history or as suggested by findings on examination.

B. Conclusions and Recommendations

The evaluation and initial treatment of patients with stroke should be performed as a priority in the hospital ED. The development of an organized protocol and stroke team should speed the clinical assessment, the performance of diagnostic studies, and decisions for early management. The clinical assessment (history, general examination, and neurological examination) remains the cornerstone of the evaluation. This evaluation should be performed by the physicians in the ED. The goals are to determine whether the patient has had a stroke and to establish potential contraindications for emergency treatment with agents such as rtPA. A stroke rating scale, such as the NIHSS, provides important information about the severity of stroke. It provides prognostic information, and the score may influence decisions about acute treatment. Some of the recommendations included in the present statement are influenced by the NIHSS. This scale can be performed with a reasonable degree of accuracy by practitioners in a broad range of specialties. Education in the nuances of NIHSS can improve the accuracy of this scale.

Because time is critical, a limited number of diagnostic tests are recommended. These tests should be available on a 24-hours-per-day, 7-days-per-week basis. These tests are used to screen for ischemic stroke, to exclude important alternative diagnoses (especially intracerebral hemorrhage), to assess for serious comorbid diseases, and to search for acute medical or neurological complications of the stroke

(Table 9). Examination of the cerebrospinal fluid has a limited role in the evaluation of patients with suspected stroke. Additional diagnostic studies, including cardiac and vascular imaging, often are time consuming and may delay emergency treatment. Thus, most of these tests are not done until after the acute treatment or after the patient is admitted to the hospital.

The recommendations that follow are similar to those included in previous statements except recommendation 1 under Class III.

Class I Recommendations

- 1. An organized protocol for the emergency evaluation of patients with suspected stroke is recommended (Class I, Level of Evidence B). The goal is to complete an evaluation and to decide treatment within 60 minutes of the patient's arrival in an ED. Designation of an acute stroke team that includes physicians, nurses, and laboratory/radiology personnel is encouraged. Patients with stroke should have a careful clinical assessment, including neurological examination.**
- 2. The use of a stroke rating scale, preferably the NIHSS, is recommended (Class I, Level of Evidence B). Hospitals (ie, administration) must provide the necessary resources to use such a scale.**
- 3. A limited number of hematologic, coagulation, and biochemistry tests are recommended during the initial emergency evaluation (Table 9) (Class I, Level of Evidence B).**
- 4. Patients with clinical or other evidence of acute cardiac or pulmonary disease may warrant chest x-ray (Class I, Level of Evidence B).**
- 5. An ECG is recommended because of the high incidence of heart disease in patients with stroke (Class I, Level of Evidence B).**

Class III Recommendations

- 1. Most patients with stroke do not need a chest x-ray as part of their initial evaluation (Class III, Level of Evidence B). This is a change from the previous guideline.**
- 2. Most patients with stroke do not need an examination of the cerebrospinal fluid (Class III, Level of Evidence B). The yield of brain imaging is very high for detection of intracranial hemorrhage. The clinical course of subarachnoid hemorrhage or acute central nervous system infections usually is distinct from that of ischemic stroke. Examination of the cerebrospinal fluid may be indicated for evaluation of a patient with a stroke that may be secondary to an infectious illness.**

IV. Early Diagnosis: Brain and Vascular Imaging

A. Brain Imaging

As therapeutic options evolve, brain imaging strategies are playing an increasingly important role in the initial evaluation of patients with acute stroke (Table 9). Brain imaging findings, including the size, location, and vascular distribution of the infarction, as well as the presence of bleeding, affect both short-term and long-term treatment decisions. In addition, information about the possible degree of reversibility of ischemic injury, intracranial vessel status, and cerebral

hemodynamic status may be obtained by modern imaging studies.⁸⁵ Neuroimaging tests might improve selection of patients who could be treated with reperfusion therapies by identifying those with regions of salvageable brain tissue, a low risk for hemorrhagic transformation, or occlusions of large arteries that might or might not be amenable to therapy. CT and magnetic resonance imaging (MRI) are being used as initial imaging options. The most commonly obtained brain imaging test is noncontrast CT, but individual centers able to obtain MRI with efficiency equal to that of CT are using an MRI strategy in patients without MR contraindications.^{86–90} Additional research is required.^{91,92} As a result, it is generally agreed that the performance of these tests should not delay treatment with intravenous rtPA.^{86,91–93}

1. Non-Contrast-Enhanced CT Scan of the Brain

It is agreed that emergency, non-contrast-enhanced CT scanning of the brain accurately identifies most cases of intracranial hemorrhage and helps discriminate nonvascular causes of neurological symptoms (eg, brain tumor). The prior guidelines recommended that CT be the primary diagnostic brain imaging study for evaluation of patients with suspected stroke.⁹⁴ Although CT is the "criterion standard" with which other brain imaging studies are compared, it is relatively insensitive in detecting acute and small cortical or subcortical infarctions, especially in the posterior fossa.⁹⁵ In most cases, the use of a contrast infusion does not provide additional information and is not necessary unless it is required for CT angiography (and, more recently, CT perfusion) or concern exists about a brain tumor or infectious process.

With the advent of rtPA treatment, interest has grown in using CT to identify subtle, early signs of ischemic brain injury (early infarct signs) or arterial occlusion (hyperdense vessel sign) that might affect decisions about treatment. In addition, the loss of the gray-white differentiation in the cortical ribbon (particularly at the lateral margins of the insula) or the lentiform nucleus and sulcal effacement can often be detected within 6 hours in up to 82% of patients with large-vessel anterior circulation occlusions.^{96,97} These signs are associated with poorer outcomes.^{98,99}

In addition, widespread signs of early infarction are correlated with a higher risk of hemorrhagic transformation after treatment with thrombolytic agents. In combined data from 2 trials of intravenous rtPA administered within 3 hours of symptom onset, CT evidence of early edema or mass effect was accompanied by an 8-fold increase in the risk of symptomatic hemorrhage.⁶⁶ In a second analysis, early infarct signs involving more than one third of the territory of the middle cerebral artery (MCA) were not independently associated with increased risk of adverse outcome after rtPA treatment, and as a group these patients still benefited from therapy.¹⁰⁰ In a European trial in which thrombolytic therapy was administered within 6 hours of symptom onset, patients estimated to have involvement of more than one third of the territory of the MCA had an increased risk of intracerebral hemorrhage, whereas those with less involvement benefited the most from thrombolytic treatment.^{99,101} However, physicians' ability to reliably and reproducibly recognize the early CT changes is variable.^{102–106} Use of scoring systems for

early CT changes may improve identification of cerebral ischemia and may provide valuable prognostic information but is not validated for outcome or patient selection for acute treatments.^{107,108} Further studies are needed to determine the significance of early infarct signs and their role in treatment decision making.¹⁰⁹

For patients who are candidates for treatment with rtPA, the goal is to complete the CT examination within 25 minutes of arrival at the ED, with the study interpreted within an additional 20 minutes (door-to-interpretation time of 45 minutes).⁶¹ A subsequent CT scan often is obtained if the patient worsens neurologically and may be especially helpful in identifying hemorrhagic transformation after administration of rtPA.⁶⁶

2. Multimodal CT

Recent technological advances have led to increased interest in more sophisticated multimodal approaches to acute stroke imaging. The multimodal CT approach may include noncontrast CT, perfusion CT, and CT angiography studies. Two types of perfusion techniques are currently available. Whole-brain perfusion CT provides a map of cerebral blood volume, and it is postulated that regions of hypoattenuation on these cerebral blood volume maps represent the ischemic core.¹¹⁰ Although this technique has the advantage of providing whole-brain coverage, it is limited by its inability to provide measures of cerebral blood flow or mean transit time. Alternatively, the second technique, dynamic perfusion CT, has the potential to provide absolute measures of cerebral blood flow, mean transit time, and cerebral blood volume. Dynamic perfusion CT is currently limited to 2 to 4 brain slices and provides incomplete visualization of all pertinent vascular territories.

Recent reports demonstrate a high degree of sensitivity and specificity for detecting cerebral ischemia with both of these perfusion CT techniques.^{111–113} In addition, several studies have suggested that perfusion CT may be able to differentiate thresholds of reversible and irreversible ischemia and thus identify the ischemic penumbra.^{114,115}

Helical CT angiography provides a means to rapidly and noninvasively evaluate the vasculature, both intracranially and extracranially, in acute, subacute, and chronic stroke settings and thus to provide potentially important information about the presence of vessel occlusions or stenoses.^{116,117} The feasibility of this technique has been demonstrated in the acute stroke setting, with preliminary data suggesting high diagnostic accuracy for evaluation of large-vessel intracranial occlusions as compared with ultrasound and digital subtraction angiography.^{118–120}

These techniques have the advantage of relatively rapid data acquisition and can be performed with conventional CT equipment. Disadvantages include iodine contrast and additional radiation exposure. The role of perfusion CT and CT angiography in making acute treatment decisions has not yet been established.

3. Multimodal MRI

The multimodal MRI approach for acute stroke evaluation includes diffusion-weighted imaging (DWI), perfusion-weighted imaging (PWI), MR angiography, gradient echo,

and often fluid-attenuated inversion recovery or T2-weighted sequences. Standard MRI sequences (T1 weighted, T2 weighted, and proton density) are relatively insensitive to the changes of acute ischemia.¹²¹ DWI allows visualization of ischemic regions within minutes of symptom onset^{122–131} and early identification of the lesion size, site, and age. It can detect relatively small cortical or subcortical lesions, including those in the brain stem or cerebellum, areas often poorly visualized with standard CT scan techniques. DWI also provides information about the involved vascular territory and has a high sensitivity (88% to 100%) and specificity (95% to 100%) for detecting ischemic lesions, even at very early time points.

PWI, usually performed with the rapid administration of an intravenous paramagnetic contrast agent, provides relative measures of cerebral hemodynamic status. Investigations of the best PWI analytical method focus on identifying the highest correlation of ischemic volume with acute clinical deficits (symptomatic hypoperfusion) or with volume of chronic infarct (tissue at risk).

Studies have demonstrated that the initial volumes of the lesions seen on DWI and PWI correlate well with the final size of the stroke found on follow-up brain imaging.^{129,132,133} In addition, these lesion volumes correlate well with severity of stroke as rated by both clinical scales and outcomes. These findings suggest that DWI might provide helpful early prognostic information.^{125,132}

The ischemic penumbra is roughly approximated on MRI as regions of perfusion change without a corresponding diffusion abnormality (diffusion–perfusion mismatch). However, several studies indicate that, at least in some circumstances, the initial diffusion abnormality is reversible and the visually thresholded perfusion volumes overestimate the penumbra.^{134,135} Sequential MRI studies performed in patients being treated with thrombolytic therapy have shown that the technique may visualize salvage of mismatch-defined penumbral tissue with smaller volumes of infarction among patients who have successful recanalization.^{134,136}

Efforts are under way to develop multiparametric MRI criteria that could identify regions of irreversible infarction from potentially reversible ischemia or portend a high risk of hemorrhagic complications after thrombolytic therapy.^{137–139} A recent phase II trial of intravenous administration of the thrombolytic agent desmoteplase showed a signal of potential therapeutic benefit when MRI was used to select patients with diffusion–perfusion mismatch for treatment 3 to 9 hours from onset.¹⁴⁰ However, insufficient evidence currently exists to recommend this approach for selecting patients for acute therapies in routine practice.

Two prospective studies recently demonstrated that MRI is as accurate as CT in detecting hyperacute intraparenchymal hemorrhage in patients presenting with stroke symptoms within 6 hours of onset when gradient echo MRI sequences were used.^{88,141} These findings suggest that MRI may be used as the sole imaging modality to evaluate acute stroke patients, including candidates for thrombolytic treatment. However, in patients presenting with symptoms suggestive of subarachnoid hemorrhage, a CT scan should be performed.

Gradient echo sequences also have the ability to detect clinically silent prior microbleeds not visualized on CT. Some data suggest that microbleeds represent markers of bleeding-prone angiopathy and increased risk of hemorrhagic transformation after antithrombotic and thrombolytic therapy.^{142–144} However, other studies have not found an increased risk in patients with small numbers of microbleeds.¹⁴⁵ The importance of the presence of large numbers of microbleeds on MRI in thrombolytic decision making remains uncertain.

MR angiography is increasingly used for noninvasive screening of the extracranial and intracranial circulation. When compared with digital subtraction angiography for detection of cervical and intracranial stenoses, sensitivity and specificity have ranged from 70% to 100%.^{146,147} In the intracranial vasculature, MR angiography is useful in identifying acute proximal large-vessel occlusions but cannot reliably identify distal or branch occlusions.

A potential diagnostic advantage of MRI over CT in non-tPA situations in suspected stroke has been demonstrated. MRI is better at distinguishing acute, small cortical, small deep, and posterior fossa infarcts; at distinguishing acute from chronic ischemia; and at identifying subclinical satellite ischemic lesions that provide information on stroke mechanism.^{95,124,129,148–167} Limitations of MRI in the acute setting include cost, relatively limited availability of the test, and patient contraindications such as claustrophobia, cardiac pacemakers, or metal implants. Advantages include the avoidance of exposure to ionizing radiation and iodinated contrast and greater spatial resolution.

4. Other Brain Imaging Techniques

Oxygen-15 positron-emission tomography may quantify regional brain perfusion and oxygen consumption.^{168–172} However, logistical and pragmatic considerations limit the application of positron-emission tomography in the setting of acute stroke. Xenon-enhanced CT provides a quantitative measurement of cerebral blood flow by using inhaled xenon but is not currently widely available.¹⁷³ Single-photon emission CT, which is minimally invasive and measures relative cerebral blood flow, might be able to identify thresholds for reversible ischemia and could be helpful in predicting outcomes or monitoring responses to treatment.^{174–176} Limitations include lack of availability, expense, and difficulty associated with tracer preparation.

B. Other Vascular Imaging

In addition to the aforementioned CT and MR angiography, transcranial Doppler ultrasonography, carotid duplex sonography, and catheter angiography have been used to detect intracranial or extracranial vessel abnormalities. Transcranial Doppler ultrasonography and angiography have been used to monitor the effects of thrombolytic therapy over time and can help to determine prognosis.^{177–179}

In patients whose symptoms started <8 hours ago, these tests may be helpful in selecting candidates for intervention. A variety of ancillary tests are available to help clinicians reach accurate pathophysiological and etiologic stroke diagnoses and provide information that can be critical for effective prevention of recurrent stroke.^{180,181} Vascular imaging is

a key component of the evaluation. The selection of tests needs to be tailored to the individual patient and clinical setting.

C. Conclusions and Recommendations

Brain imaging remains a required component of the emergency assessment of patients with suspected stroke. Both CT and MRI are options for imaging the brain, but for most cases and at most institutions, CT remains the most practical initial brain imaging test. A physician skilled in assessing CT or MRI studies should be available to examine the initial scan. In particular, the scan should be evaluated for evidence of early signs of infarction. Baseline CT findings, including the presence of ischemic changes involving more than one third of a hemisphere, have not been predictors of responses to treatment with rtPA when the agent is administered within the 3-hour treatment window. Information about multimodal CT and MRI of the brain suggests that these diagnostic studies may help in the diagnosis and treatment of patients with acute stroke. Imaging of the intracranial or extracranial vasculature in the emergency assessment of patients with suspected stroke is useful at institutions providing endovascular recanalization therapies. The usefulness of vascular imaging for predicting responses to treatment before intravenous administration of thrombolytic agents has not been demonstrated.

Class I Recommendations

1. **Imaging of the brain is recommended before initiating any specific therapy to treat acute ischemic stroke (Class I, Level of Evidence A). This recommendation has not changed from the previous guideline.**
2. **In most instances, CT will provide the information to make decisions about emergency management (Class I, Level of Evidence A). This recommendation has not changed from the previous guideline.**
3. **The brain imaging study should be interpreted by a physician with expertise in reading CT or MRI studies of the brain (Class I, Level of Evidence C). This recommendation has been added since the previous guideline.**
4. **Some findings on CT, including the presence of a dense artery sign, are associated with poor outcomes after stroke (Class I, Level of Evidence A). This recommendation has not changed from the previous guideline.**
5. **Multimodal CT and MRI may provide additional information that will improve diagnosis of ischemic stroke (Class I, Level of Evidence A). This recommendation has been added since the previous guideline.**

Class II Recommendations

1. **Nevertheless, data are insufficient to state that, with the exception of hemorrhage, any specific CT finding (including evidence of ischemia affecting more than one third of a cerebral hemisphere) should preclude treatment with rtPA within 3 hours of onset of stroke (Class IIb, Level of Evidence A). This recommendation has not changed from the previous guideline.**
2. **Vascular imaging is necessary as a preliminary step for intra-arterial administration of pharmacological agents, surgical procedures, or endovascular interven-**

tions (Class IIa, Level of Evidence B). *This recommendation has not changed from the previous guideline.*

Class III Recommendations

1. **Emergency treatment of stroke should not be delayed in order to obtain multimodal imaging studies (Class III, Level of Evidence C).** *This recommendation has been added since the previous guideline.*
2. **Vascular imaging should not delay treatment of patients whose symptoms started <3 hours ago and who have acute ischemic stroke (Class III, Level of Evidence B).** *This recommendation has been added since the previous guideline.*

V. General Supportive Care and Treatment of Acute Complications

A. Airway, Ventilatory Support, and Supplemental Oxygen

Maintaining adequate tissue oxygenation is important in the setting of acute cerebral ischemia. The goals are to prevent hypoxia and potential worsening of the brain injury. The most common causes of hypoxia are partial airway obstruction, hypoventilation, aspiration pneumonia, and atelectasis. Patients with decreased consciousness or signs of brain stem dysfunction have the greatest risk of airway compromise because of impaired oropharyngeal mobility and loss of protective reflexes.^{182–184} The prognosis of patients who require endotracheal intubation generally is poor; $\approx 50\%$ of these patients are dead within 30 days after stroke.^{185,186} Pneumonia is among the leading complications of stroke and is an important cause of death after the cerebrovascular event.¹⁸⁷ It is most likely to develop among patients who are seriously ill, and prevention of early aspiration and protection of the airway may be a way to lessen this complication.

Elective intubation also may help in the management of patients who have severely increased levels of intracranial pressure or have malignant brain edema after stroke.^{185,188} No clinical trial has tested the utility of endotracheal intubation in the management of critically ill patients with stroke, and we anticipate that none will be done. It is generally agreed that an endotracheal tube should be placed if the airway is threatened.^{182,188}

After ischemic stroke, some patients develop Cheyne-Stokes pattern of respiration, with decreases in oxygen saturation that can be readily reversed with oxygen supplementation.¹⁸⁹ A small pilot study found that high-flow oxygen may be associated with a transient improvement in neurological impairments.¹⁹⁰ The results of a controlled study do not support the use of supplemental oxygen at 3 L/min for most patients with acute ischemic stroke.¹⁹¹ However, patients with acute stroke should be monitored with pulse oximetry with a target oxygen saturation level $<92\%$.^{25,192} Most patients with acute stroke do not need supplemental oxygen; however, if pulse oximetry or blood gas determination indicates hypoxia, oxygen should be administered.

Hyperbaric oxygen may be used to treat patients with ischemic neurological symptoms secondary to air embolism or caisson disease.¹⁹³ Studies that have tested the use of hyperbaric oxygen in stroke have been inconclusive or have

shown that the intervention does not improve outcomes.^{194–196} Data from a small trial suggest that hyperbaric oxygen therapy may be harmful.¹⁹⁶ A systematic review found no evidence that hyperbaric oxygen improved outcomes after stroke or brain injury.¹⁹⁷ At present, data do not support the routine use of hyperbaric oxygen in the treatment of patients with acute ischemic stroke.

B. Temperature

Increased body temperature (fever) in the setting of acute ischemic stroke is associated with poor neurological outcome (increased risk of morbidity and mortality), possibly secondary to increased metabolic demands, enhanced release of neurotransmitters, and increased free radical production.^{198–205} The source of any fever should be ascertained. The fever may be secondary to a cause of stroke, such as infective endocarditis, or may represent a complication, such as pneumonia.

Because of the negative effects of fever, lowering an acutely elevated body temperature might improve the prognosis of patients with stroke.²⁰⁶ Measures include antipyretic medications and cooling devices. Small clinical trials have tested the utility of aspirin, ibuprofen, or acetaminophen in lowering body temperatures and in improving outcomes after stroke. Sulter et al²⁰⁷ found that either aspirin or acetaminophen was modestly successful in achieving normothermia but that patients with a temperature $>38^{\circ}\text{C}$ were relatively unresponsive to treatment. In a small, randomized trial, Kasner et al²⁰⁸ administered 3900 mg of acetaminophen daily to afebrile patients with stroke. They concluded that the medication might prevent hyperthermia or modestly promote hypothermia but that the effects were not likely to have a robust clinical impact. Dippel et al²⁰⁹ tested 2 different doses of acetaminophen in a small clinical trial. They concluded that a daily dosage of 6000 mg might have a potential beneficial effect in lowering body temperature. A small placebo-controlled trial found that acetaminophen might lower body temperature by a mean of 0.26°C within 4 hours of starting treatment.²¹⁰ In another clinical trial, Dippel et al²¹⁰ compared the effects of placebo, ibuprofen, or acetaminophen on body temperature in 75 patients with recent stroke. Although treating fever after stroke makes intuitive sense, no data demonstrate that the use of medications to lower body temperature among either febrile or afebrile patients improves neurological outcomes after stroke. Seeking and treating the source of fever are reasonable.

Hypothermia has been shown to be neuroprotective in experimental and focal hypoxic brain injury models. Hypothermia may delay depletion of energy reserves, lessen intracellular acidosis, slow influx of calcium into ischemic cells, suppress production of oxygen free radicals, and lessen the impact of excitatory amino acids.²¹¹ Deep hypothermia often is administered to protect the brain in major operative procedures. Mild to moderate hypothermia is associated with improved neurological outcomes among patients with cardiac arrest.^{212–214} Conversely, a multicenter clinical trial found that mild hypothermia administered during surgery for treatment of a ruptured intracranial aneurysm did not improve outcomes after subarachnoid hemorrhage.²¹⁵ Several small clinical studies have evaluated the feasibility of inducing modest

hypothermia for treatment of patients with acute ischemic stroke.^{216–223} Two small studies evaluated the utility of hypothermia in treating patients with malignant cerebral infarctions; results were mixed.^{224,225} Potential side effects of therapeutic hypothermia include hypotension, cardiac arrhythmias, and pneumonia.²²⁶ In a systematic review of available data, Correia et al²²⁷ could find no evidence that physical cooling would improve outcomes after stroke. Although strong experimental and clinical evidence indicates that induced hypothermia can protect the brain in the presence of hypoxia or ischemia, including after cardiac arrest, data about the utility of induced hypothermia for treatment of patients with stroke are not yet available. Hypothermia is discussed in more detail in the neuroprotection section of this statement.

C. Cardiac Monitoring and Treatment

Although patients with heart disease are at high risk for ischemic stroke, both myocardial ischemia and cardiac arrhythmias are potential complications of acute cerebrovascular diseases.^{228,229} Patients with infarctions of the right hemisphere, particularly those involving the insula, may have an increased risk of cardiac complications, presumably secondary to disturbances in autonomic nervous system function.^{78,230–234} ECG changes secondary to stroke include ST-segment depression, QT dispersion, inverted T waves, and prominent U waves.^{235–237} Elevations in blood levels of enzymes attributable to injury to myocardial muscle also may be found.⁷⁹ The most common arrhythmia detected in the setting of stroke is atrial fibrillation, which either may be related to the cause of stroke or may be a complication. Other potentially life-threatening cardiac arrhythmias are relatively uncommon, but sudden death may occur.^{77,238} No clinical trials have tested the utility of cardiac monitoring for most patients with ischemic stroke or the use of cardiac protective agents or medications to prevent serious cardiac arrhythmias. Still, general consensus exists that patients with acute ischemic stroke should have cardiac monitoring for at least the first 24 hours and that any serious cardiac arrhythmia should be treated. The utility of prophylactic administration of medications to prevent cardiac arrhythmias among patients with stroke is not known.

D. Arterial Hypertension

An elevated blood pressure is often detected in the first hours after stroke. Elevations in blood pressure >160 mm Hg are detected in >60% of patients with acute stroke.²³⁹ Both elevated and low blood pressures are associated with poor outcome after stroke.²⁴⁰ For every 10-mm Hg increase >180 mm Hg, the risk of neurological deterioration increased by 40% and the risk of poor outcome increased by 23%. The elevation in blood pressure may be secondary to the stress of the cerebrovascular event, a full bladder, nausea, pain, pre-existing hypertension, a physiological response to hypoxia, or a response to increased intracranial pressure.^{241,242} In a study that correlated acute blood pressure values with other findings in the setting of acute stroke, Vemmos et al²⁴³ found that among patients with most subtypes of ischemic stroke, elevated blood pressure was correlated with a past history of

hypertension or severity of neurological impairments. The same investigators found a U-shaped relationship between death and admission blood pressure; both elevated and low admission levels were associated with high rates of early and late death.²⁴³ They also correlated death due to brain injury and brain edema with high initial blood pressure levels. Castillo et al²⁴⁰ have reported similar findings. Using the data from the Glycine Antagonist in Neuroprotection (GAIN) study, Aslanyan et al²⁴⁴ found that an elevated baseline mean arterial blood pressure was not independently associated with an unfavorable outcome after stroke. However, elevations in mean blood pressure during the first days after stroke had an unfavorable effect on outcomes. The same investigators showed that an elevated pulse pressure (the difference between systolic and diastolic blood pressure values) was independently associated with poor outcomes 3 months after stroke.²⁴⁵

Theoretical reasons for lowering blood pressure include reducing the formation of brain edema, lessening the risk of hemorrhagic transformation of the infarction, preventing further vascular damage, and forestalling early recurrent stroke. In addition, urgent antihypertensive therapy may be needed to treat patients with stroke who also have hypertensive encephalopathy, aortic dissection, acute renal failure, acute pulmonary edema, or acute myocardial infarction.^{242,246} Conversely, aggressive treatment of blood pressure may lead to neurological worsening by reducing perfusion pressure to ischemic areas of the brain.^{242,247,248}

In a majority of patients, a decline in blood pressure occurs within the first hours after stroke even without any specific medical treatment.²⁴¹ The blood pressure often falls spontaneously when the patient is moved to a quiet room, the patient is allowed to rest, the bladder is emptied, or the pain is controlled. In addition, treatment of increased intracranial pressure may result in a decline in arterial blood pressure.

There are several questions about the management of arterial hypertension in the setting of acute stroke.^{249–251} Should patients previously taking antihypertensive medications continue taking them during the first hours after stroke? Are some of these medications contraindicated or indicated? Should new antihypertensive agents be started? What level of blood pressure would mandate initiation of new antihypertensive treatment? Which medication should be administered in this situation? Unfortunately, definite answers to these questions are not available. Since the publication of the last guidelines, several clinical studies have provided additional information.

A randomized trial testing nimodipine found that unfavorable outcomes among patients treated with the medication were associated with lowering of the blood pressure.^{252,253} Reanalyzing some of the data from the studies of nimodipine, Fogelholm et al²⁵⁴ noted that favorable outcomes were associated with higher levels of blood pressure among patients with mild to moderate strokes receiving nimodipine. The converse was true among patients with severe strokes. In a study that involved 115 patients admitted within 24 hours of stroke, Oliveira-Filho et al²⁵⁵ noted that systolic blood pressure dropped by ≈28% during the first day whether or not medications were prescribed. They noted an adverse effect on outcomes with lowering of the blood pressure, with an association found with degree in decline. Each

10% decline was associated with an increased odds ratio of 1.89 in unfavorable outcomes. The impact was similar to the effects of age or NIHSS scores. Castillo et al²⁴⁰ noted that drops in either systolic or diastolic blood pressure of >20 mm Hg were associated with early neurological worsening, higher rates of poor outcomes or death, and larger volumes of infarctions. They noted that the early administration of antihypertensive agents to patients with systolic blood pressures >180 mm Hg was associated with a marked increase in likelihood of early deterioration, poor neurological outcome, or death.

Several small inconclusive studies have tested calcium channel–blocking agents, angiotensin-converting enzyme inhibitors, diuretics, β -blockers, and nitrates, with generally inconclusive or conflicting results.^{256,257} A multicenter, placebo-controlled trial tested the utility of candesartan when started 1 day after stroke.²⁵⁸ The dosage of medication was increased on day 2 if the patient's systolic blood pressure was >160 mm Hg systolic or >100 mm Hg diastolic. Rescue therapy with intravenous antihypertensive agents was permitted for patients with severely elevated blood pressures. At day 7, other antihypertensive agents could be administered to treat persisting elevated blood pressures. The trial was halted prematurely because of a higher rate of deaths and recurrent vascular events in the placebo-treated group. However, the differences in outcomes were not seen in the first few months after stroke, and the divergence between treatment groups was seen only after 1 year. In a small study, patients were given either captopril or amlodipine for treatment of hypertension beginning 1 day after stroke; moderate reductions in blood pressure were associated with improved short-term outcomes.²⁵⁹ In another small, randomized study, Eames et al²⁶⁰ found no major reduction in blood pressure among patients treated with bendrofluazide, and they concluded that this agent was not effective in treating hypertension after stroke. Large, well-designed trials are needed to clarify the management of arterial hypertension after acute stroke. A trial testing the utility of antihypertensive therapy in the setting of stroke (Controlling Hypertension and Hypotension Immediately Post-Stroke [CHHIPS]) is ongoing.²⁶¹

Because of the lack of unambiguous data, the appropriate treatment of arterial hypertension in the setting of acute ischemic stroke remains controversial. Although severe hypertension may be considered an indication for treatment, no data define the levels of arterial hypertension that mandate emergency management.²⁴⁷ However, the aforementioned data suggest that the systolic blood pressure level that would prompt treatment would be >180 mm Hg.²⁴⁰ A systolic blood pressure >185 mm Hg or a diastolic blood pressure >110 mm Hg is a contraindication to intravenous administration of rtPA.^{66,262} Still, it is not clear whether those values should be the threshold for starting emergency treatment outside the setting of administration of rtPA. Although no definitive data from controlled trials are available, in the absence of other organ dysfunction necessitating rapid reduction in blood pressure or in the setting of thrombolytic therapy, there is little scientific evidence and no clinically established benefit for rapid lowering of blood pressure among persons with acute ischemic stroke.²⁴⁷ Some data indicate that rapid and steep reductions in blood pressure

TABLE 10. Approach to Arterial Hypertension in Acute Ischemic Stroke

Indication that patient is eligible for treatment with intravenous rtPA or other acute reperfusion intervention

Blood pressure level

Systolic >185 mm Hg or diastolic >110 mm Hg

Labetalol 10 to 20 mg IV over 1 to 2 minutes, may repeat $\times 1$;

or

Nitropaste 1 to 2 inches;

or

Nicardipine infusion, 5 mg/h, titrate up by 0.25 mg/h at 5- to 15-minute intervals, maximum dose 15 mg/h; when desired blood pressure attained, reduce to 3 mg/h

If blood pressure does not decline and remains >185/110 mm Hg, do not administer rtPA

Management of blood pressure during and after treatment with rtPA or other acute reperfusion intervention

Monitor blood pressure every 15 minutes during treatment and then for another 2 hours, then every 30 minutes for 6 hours, and then every hour for 16 hours

Blood pressure level

Systolic 180 to 230 mm Hg or diastolic 105 to 120 mm Hg

Labetalol 10 mg IV over 1 to 2 minutes, may repeat every 10 to 20 minutes, maximum dose of 300 mg;

or

Labetalol 10 mg IV followed by an infusion at 2 to 8 mg/min

Systolic >230 mm Hg or diastolic 121 to 140 mm Hg

Labetalol 10 mg IV over 1 to 2 minutes, may repeat every 10 to 20 minutes, maximum dose of 300 mg;

or

Labetalol 10 mg IV followed by an infusion at 2 to 8 mg/min;

or

Nicardipine infusion, 5 mg/h, titrate up to desired effect by increasing 2.5 mg/h every 5 minutes to maximum of 15 mg/h

If blood pressure not controlled, consider sodium nitroprusside

might be harmful. Pending more data, the consensus of the panel is that emergency administration of antihypertensive agents should be withheld unless the diastolic blood pressure is >120 mm Hg or unless the systolic blood pressure is >220 mm Hg (Table 10). The panel recognizes that no data show that these values are especially dangerous and emergency treatment is needed. However, the panel remains concerned by the evidence that aggressive lowering of blood pressure among patients may cause neurological worsening, and the goal is to avoid overtreating patients with stroke until definitive data are available.

When treatment is indicated, lowering the blood pressure should be done cautiously. Some strokes may be secondary to hemodynamic factors, and a declining blood pressure may lead to neurological worsening. A reasonable goal would be to lower blood pressure by 15% to 25% within the first day.²⁶³ Because no data support the administration of any specific antihypertensive agent in the setting of acute ischemic stroke, the treating physician should select medications for lowering blood pressure on a case-by-case basis. The recommendations in Table 10 are based on consensus and reflect the goal of rapidly reducing blood pressure, but, at the same time, the potential for a rapid reversal if the drop in blood pressure

leads to neurological worsening. The selection of an agent may be influenced by other medical conditions; for example, the presence of asthma would contraindicate the administration of a β -blocker. Because of a prolonged effect and the potential for a precipitous decline in blood pressure associated with the sublingual administration of nifedipine, this agent with this route of administration is not recommended.²⁶⁴

Among patients who are candidates for treatment with intravenous rtPA, attention to management of blood pressure is critical before, during, and after the administration of the medication.²⁶³ Excessively high blood pressure is associated with an increased risk of symptomatic hemorrhagic transformation.^{66,262,265,266} Failure to meet the blood pressure parameters of previous guidelines may be one of the explanations for an increased risk of hemorrhagic complications after administration of rtPA.^{267–269} Presumably, similar risks of bleeding will be associated with elevations of blood pressure among patients receiving other acute pharmacological or mechanical interventions to improve the perfusion to the brain. The suggestion to withhold such therapies among patients with markedly elevated blood pressure is based on potential safety risks. Conversely, excessively high blood pressures could be lowered successfully with medications to permit treatment with intravenous rtPA.

Arterial hypertension is a recognized risk factor for stroke and recurrent stroke. Many patients were taking medications before their stroke or are found to have sustained hypertension after their stroke. These patients will need long-term antihypertensive treatment; the primary question is the timing of the institution of such therapy. Limited data are available to guide these decisions. On the basis of the trial of candesartan, it appears that medications can be administered with a reasonable degree of safety when started \approx 1 day after stroke.²⁵⁸ The timing of the reinstatement of treatment and the selection of medications will depend on the patient's neurological status, the underlying stroke mechanism, the patient's ability to swallow medications, and the presence of concomitant diseases. Presumably, most patients with mild to moderate strokes who are not at high risk for increased intracranial pressure may have their prestroke antihypertensive medications restarted 24 hours after their vascular event. The panel strongly endorses clinical research that will provide information about the safety and efficacy of restarting antihypertensive therapy among patients with stroke.

E. Arterial Hypotension

Persistent arterial hypotension is rare among patients with acute ischemic stroke, but it is associated with an increased likelihood of an unfavorable outcome.²⁷⁰ Castillo et al²⁴⁰ noted that the rates of neurological worsening, poor neurological outcomes, or death increased when the baseline systolic blood pressure was <100 mm Hg or the diastolic blood pressure was <70 mm Hg. The cause of hypotension should be sought; among the potential causes are aortic dissection, volume depletion, blood loss, and decreased cardiac output secondary to myocardial ischemia or cardiac arrhythmias. Patients with stroke may have depleted blood volume. Correction of hypovolemia and optimization of

cardiac output are important priorities during the first hours after stroke. Treatment includes volume replacement with normal saline and correction of cardiac arrhythmias, such as slowing a ventricular response to rapid atrial fibrillation. If these measures are ineffective, vasopressor agents such as dopamine may be used. Trials have tested the utility of volume expansion and drug-induced hypertension for treatment of acute ischemic stroke. These measures are described later in the present guideline.

F. Hypoglycemia

Because hypoglycemia may produce neurological signs that mimic ischemic stroke and because hypoglycemia itself may lead to brain injury, prompt measurement of the serum glucose concentration and rapid correction of a low serum glucose level are important.

G. Hyperglycemia

Hyperglycemia will be detected on admission in approximately one third of patients with stroke.^{271–273} Most patients have moderate elevations of glucose levels.²⁷⁴ Clinical studies demonstrate that the presence of hyperglycemia is associated with poor outcomes after ischemic stroke, including among patients treated with thrombolytic agents.^{275–279} A history of diabetes mellitus also is associated with a poorer outcome after stroke.^{280,281}

The detrimental effects of hyperglycemia are not clearly understood but include increasing tissue acidosis secondary to anaerobic glycolysis, lactic acidosis, and free radical production.^{281,282} Hyperglycemia also may affect the blood-brain barrier and the development of brain edema²⁸¹ and may be associated with an increased risk of hemorrhagic transformation of the infarction.²⁸³ Unfortunately, the contribution of hyperglycemia to poor outcomes may be affected by other factors.²⁸⁴ Elevations of blood glucose concentration may be secondary to the stress of the acute cerebrovascular event.²⁸⁵ In particular, hyperglycemia after stroke in nondiabetic patients may be a stress response.²⁸⁵ Candelise et al²⁸⁶ found that hyperglycemia is a marker of a more severe stroke. Thus, the poor outcomes among patients with hyperglycemia may in part reflect the seriousness of the vascular event itself. Recent clinical and imaging studies have highlighted the importance of hyperglycemia as a negative prognostic factor.^{271,278–280,282} Baird et al²⁸⁰ found that persistent hyperglycemia (blood glucose level >200 mg/dL) during the first 24 hours after stroke independently predicted expansion of the volume of ischemic stroke and poor neurological outcomes. These reports provide reasonable evidence that persistent elevations of blood glucose levels are associated with neurological worsening.^{281,287} These data suggest that management of hyperglycemia is an important part of acute management of patients with ischemic stroke. The outstanding issues relate to the effectiveness of management of stroke-associated hyperglycemia in improving outcomes after stroke and the level of glucose concentration that should be sought during the first 24 hours. On the basis of the aforementioned data, the panel concluded that the level of hyperglycemia that previously mandated emergency treatment in the setting of stroke was too high. The exact level of blood glucose that should

prompt interventions is not known. A reasonable approach would be to initiate treatment among patients with a blood glucose level >200 mg/dL. The management of hyperglycemia among patients with stroke likely will be influenced by the approach to treating elevated blood glucose levels among patients with other critical illnesses, including patients who have had cardiac arrest. The changes are dramatic. Several studies have looked at the utility of intensive insulin protocols in treating critically ill patients with a broad range of illnesses.^{288–293} In general, the desired level of blood glucose has been in the range of 80 to 140 mg/dL. Frequent monitoring of blood glucose levels and adjustments of insulin are required. These studies have demonstrated a reduction in death and important complications, including infections and renal failure, with aggressive management of hyperglycemia. The frequency of hypoglycemic episodes appears to be low. Physicians treating patients with severe stroke should be aware of the new regimens for treating hyperglycemia. Gray et al²⁷⁴ found that plasma glucose levels spontaneously decline in many patients. A small clinical trial tested the safety of short-term administration of glucose, insulin, and potassium to patients with moderate hyperglycemia.²⁹⁴ The intervention could be given safely, but plasma glucose levels were not significantly lower than in the control group. A subsequent report about a larger cohort treated by the same investigators found that infusions of glucose, insulin, and potassium significantly reduced blood pressure, but no differences in outcomes were noted 7 days after stroke.²⁹⁵ Bruno et al²⁹⁶ treated 24 patients with markedly elevated serum glucose levels (mean 14.7 mmol/L) within 12 hours of onset of stroke. With insulin infusions that required frequent adjustments in response to serum levels, they were able to achieve desired glucose control within 5 hours. Symptomatic hypoglycemia occurred in 5 patients. It is unclear whether the intervention affected outcomes. A British trial (United Kingdom Glucose Insulin in Stroke Trial) is testing the utility of a strategy of achieving euglycemia after stroke.²⁷⁴ Despite the lack of data to guide decisions about management, consensus exists that hyperglycemia should be controlled after stroke.²⁹⁷ A reasonable goal would be to treat those patients' elevated glucose concentrations (140 to 180 mg/dL). The approach would be similar to that prescribed for other acutely ill patients with concomitant hyperglycemia.

H. Conclusions and Recommendations

Most of the recommendations about general acute management are based on limited data. Some of the aspects of acute management may never be tested in clinical trials, whereas other aspects of treatment, such as the best strategy for treatment of hyperglycemia or arterial hypertension, likely will be clarified by ongoing or future clinical research. Pending such trials, many of the suggestions that follow are based on consensus and thus are Grade C recommendations.

Class I Recommendations

1. Airway support and ventilatory assistance are recommended for the treatment of patients with acute stroke who have decreased consciousness or who have bulbar dysfunction causing compromise of the airway (Class

I, Level of Evidence C). This recommendation has not changed from previous statements.

- 2. Hypoxic patients with stroke should receive supplemental oxygen (Class I, Level of Evidence C). This recommendation has not changed since the previous guideline.**
- 3. It is generally agreed that sources of fever should be treated and antipyretic medications should be administered to lower temperature in febrile patients with stroke (Class I, Level of Evidence C). This recommendation has not changed from previous statements. Medications such as acetaminophen can lower body temperature modestly, but the effectiveness of treating either febrile or nonfebrile patients to improve neurological outcomes is not established. Additional research on utility of emergency administration of antipyretic medications is under way.**
- 4. General agreement supports the use of cardiac monitoring to screen for atrial fibrillation and other potentially serious cardiac arrhythmias that would necessitate emergency cardiac interventions. It is generally agreed that cardiac monitoring should be performed during the first 24 hours after onset of ischemic stroke (Class I, Level of Evidence B). This recommendation has not changed from previous statements.**
- 5. The management of arterial hypertension remains controversial. Data to guide recommendations for treatment are inconclusive or conflicting. Many patients have spontaneous declines in blood pressure during the first 24 hours after onset of stroke. Until more definitive data are available, it is generally agreed that a cautious approach to the treatment of arterial hypertension should be recommended (Class I, Level of Evidence C). Patients who have other medical indications for aggressive treatment of blood pressure should be treated. This recommendation has not changed from previous statements.**
- 6. Patients who have elevated blood pressure and are otherwise eligible for treatment of rtPA may have their blood pressure lowered so that their systolic blood pressure is ≤ 185 mm Hg and their diastolic blood pressure is ≤ 110 mm Hg (Class I, Level of Evidence B) before lytic therapy is started. This recommendation has not changed from previous statements. If medications are given to lower blood pressure, the clinician should be sure that the blood pressure is stabilized at the lower level before treating with rtPA and maintained below 180/105 mm Hg for at least the first 24 hours after intravenous rtPA treatment. Because the maximum interval from stroke onset until treatment with rtPA is short, many patients with sustained hypertension above recommended levels cannot be treated with intravenous rtPA.**
- 7. Until other data become available, consensus exists that the previously described blood pressure recommendations should be followed in patients undergoing other acute interventions to recanalize occluded vessels, including intra-arterial thrombolysis (Class I, Level of Evidence C). This recommendation has been added since the previous guideline.**
- 8. It is generally agreed that patients with markedly elevated blood pressure may have their blood pressure lowered. A reasonable goal would be to lower blood pressure by $\approx 15\%$ during the first 24 hours after onset of stroke. The level of blood pressure that would**

mandate such treatment is not known, but consensus exists that medications should be withheld unless the systolic blood pressure is >220 mm Hg or the mean blood pressure is >120 mm Hg (Class I, Level of Evidence C). *This recommendation has changed from previous statements in that a potential goal for lowering blood pressure is now included.* Research testing the effects of early treatment of arterial hypertension on outcomes after stroke is under way. The panel looks forward to any data that will clarify this management decision.

9. It is generally agreed that the cause of arterial hypotension in the setting of acute stroke should be sought. Hypovolemia should be corrected with normal saline, and cardiac arrhythmias that might be reducing cardiac output should be corrected (Class I, Level of Evidence C). *This recommendation was not included in previous statements.* The utility of volume expansion and the use of medications to increase blood pressure to treat ischemic stroke are discussed elsewhere in the present guideline.
10. It is generally agreed that hypoglycemia should be treated in patients with acute ischemic stroke (Class I, Level of Evidence C). The goal is to achieve normoglycemia. Marked elevation of blood glucose levels should be avoided. *This recommendation was included in previous statements.*

Class II Recommendations

1. No data are available to guide selection of medications for the lowering of blood pressure in the setting of acute ischemic stroke. The recommended medications and doses included in Table 10 are based on general consensus (Class IIa, Level of Evidence C). *The recommendations in Table 10 have changed from the previous statements.*
2. Evidence from one clinical trial indicates that initiation of antihypertensive therapy within 24 hours of stroke is relatively safe. Thus, it is generally agreed that antihypertensive medications should be restarted at \approx 24 hours for patients who have preexisting hypertension and are neurologically stable unless a specific contraindication to restarting treatment is known (Class IIa, Level of Evidence B). *This recommendation was not included in previous statements.*
3. Evidence indicates that persistent hyperglycemia (>140 mg/dL) during the first 24 hours after stroke is associated with poor outcomes, and thus it is generally agreed that hyperglycemia should be treated in patients with acute ischemic stroke. The minimum threshold described in previous statements likely was too high, and lower serum glucose concentrations (possibly >140 to 185 mg/dL) probably should trigger administration of insulin, similar to the procedure in other acute situations accompanied by hyperglycemia (Class IIa, Level of Evidence C). *This is a change from previous statements.* Close monitoring of glucose concentrations with adjustment of insulin doses to avoid hypoglycemia is recommended. Simultaneous administration of glucose and potassium also may be appropriate. The results of ongoing research should clarify the management of hyperglycemia after stroke.

Class III Recommendations

1. Nonhypoxic patients with acute ischemic stroke do not need supplemental oxygen therapy (Class III, Level of Evidence B). *This recommendation has not changed from previous statements.*
2. Data on the utility of hyperbaric oxygen are inconclusive, and some data imply that the intervention may be harmful. Thus, with the exception of stroke secondary to air embolization, this intervention is not recommended for treatment of patients with acute ischemic stroke (Class III, Level of Evidence B). *This recommendation has changed from previous statements.*
3. Although data demonstrate the efficacy of hypothermia for improving neurological outcomes after cardiac arrest, the utility of induced hypothermia for the treatment of patients with ischemic stroke is not established. At the present time, insufficient evidence exists to recommend hypothermia for treatment of patients with acute stroke (Class III, Level of Evidence B). *This recommendation has not changed from previous statements.* Additional research on the safety and efficacy of induced hypothermia for treatment of patients with stroke is under way.

VI. Intravenous Thrombolysis

A. Recombinant Tissue Plasminogen Activator

Intravenous thrombolytic therapy for acute stroke is now generally accepted.²⁹⁸ The US Food and Drug Administration (FDA) approved the use of intravenous rtPA in 1996, partly on the basis of the results of the NINDS rtPA Stroke Study, in which 624 patients with ischemic stroke were treated with placebo or rtPA (0.9 mg/kg IV, maximum 90 mg) within 3 hours of symptom onset, with approximately one half treated within 90 minutes.⁶⁶ The study was conducted in 2 parts. In part I, the primary end point was neurological improvement at 24 hours, as indicated by complete neurological recovery or an improvement of ≥ 4 points on the NIHSS. In part II, the pivotal efficacy trial, the primary end point was a global odds ratio for a favorable outcome, defined as complete or nearly complete neurological recovery 3 months after stroke. Favorable outcomes were achieved in 31% to 50% of patients treated with rtPA, as compared with 20% to 38% of patients given placebo. The benefit was similar 1 year after stroke.²⁹⁹ The major risk of treatment was symptomatic brain hemorrhage, which occurred in 6.4% of patients treated with rtPA and 0.6% of patients given placebo. However, the death rate in the 2 treatment groups was similar at 3 months (17% versus 20%) and 1 year (24% versus 28%).^{66,299} Although the presence of edema or mass effect on baseline CT scan was associated with higher risk of symptomatic intracranial hemorrhage, follow-up study demonstrated that the presence of early ischemic changes on CT scan was not associated with adverse outcome.^{100,266} Indeed, in the Australian trial of streptokinase, early CT evidence of edema was not associated with an increased risk of hemorrhagic conversion.³⁰¹ The likelihood of favorable outcome also was affected by the severity of deficits and the patient's age. Patients with mild to moderate strokes (NIHSS score <20) and persons younger than 75 years of age had the greatest potential for a favorable response to treatment.³⁰² The chances of a complete or nearly

complete recovery among patients with severe stroke (NIHSS score of ≥ 20) improved with treatment, but overall success in this group of critically ill patients was low.³⁰² In 2 large trials, the European Cooperative Acute Stroke Study (ECASS) and ECASS-II, intravenous rtPA was not more effective than placebo in improving neurological outcomes 3 months after stroke.^{303,304} The dosage of rtPA used in ECASS was marginally higher than that used in the NINDS trials, and patients were treated up to 6 hours after stroke. Patients with CT evidence of low attenuation (edema and/or ischemia) involving more than one third of the territory of the MCA were less likely to have a good outcome after treatment with rtPA than were those who received placebo.^{98,305} However, the numbers were small, and the difference did not reach statistical significance. A post hoc analysis concluded that the patients treated within 3 hours appeared to benefit from rtPA.³⁰⁶ In the ECASS-II trial, 800 patients were assigned randomly to treatment with either rtPA (0.9 mg/kg IV) or placebo. More than one third of the patients in each group made an excellent recovery, and no significant benefit was noted from treatment. A post hoc analysis of ECASS-II showed that the likelihood of either death or dependency was lower among the patients treated with rtPA.³⁰³ The trial included vigorous methodology to avoid recruitment of patients with CT changes consistent with multilobar infarctions.⁹⁸ As a result, the strokes among the patients admitted in ECASS-II were less severe than in the other studies, and the generally more favorable prognosis among patients may have reduced the likelihood of detecting a therapeutic effect. Still, the rate of symptomatic intracranial hemorrhage was increased with rtPA treatment (8.8% versus 3.4%). An American trial tested rtPA up to 5 hours after stroke.³⁰⁷ Results were similar in that approximately one third of the patients in both treatment groups made an excellent recovery. The rate of symptomatic hemorrhage was higher in the treatment group (7% versus 1.1%). Subsequent to the approval of rtPA for treatment of patients with acute ischemic stroke, several groups reported on the utility of the treatment in a community setting.^{269,308–313} Some groups reported rates of intracranial hemorrhage and favorable outcomes that are similar to those found in the NINDS trials, but others have not. It is now clear that the risk of hemorrhage is proportional to the degree to which the NINDS protocol is not followed.^{269,314,315} Besides a risk of intracranial hemorrhage, other potential adverse experiences include systemic bleeding, myocardial rupture if the agent is given within a few days of acute myocardial infarction, and reactions such as anaphylaxis or angioedema, although these events are rare.²⁹⁸ Debate about time of initiation of rtPA treatment merits attention. The NINDS investigators reported a time-to-treatment interaction in a subgroup analysis of the NINDS rtPA Trial.⁶⁰ Treatment with rtPA initiated within 90 minutes of symptom onset was associated with an odds ratio of 2.11 (95% confidence interval, 1.33 to 3.55) for favorable outcome at 3 months as compared with placebo. In comparison, the odds ratio for good outcome at 3 months for treatment with rtPA initiated within 90 to 180 minutes was 1.69 (95% confidence interval, 1.09 to 2.62). The investigators concluded that the earlier that treatment is initiated, the better the result. A subsequent pooled analysis of all large,

multicenter, placebo-controlled trials of rtPA for acute stroke confirmed a time effect, but the upper limit of the treatment window may be as late as 5 to 6 hours.³¹⁶ Investigation of the early time epoch in the NINDS trial revealed a potential confounder in the original data: 19% of the patients treated with rtPA between 91 and 180 minutes after stroke onset had an NIHSS score of ≤ 5 compared with 4% of the placebo patients. On the basis of this observation, it has been suggested that the relative preponderance of mild strokes with a likely good outcome in the rtPA treatment group may explain the entire benefit reported for patients treated between 91 and 180 minutes. Subsequent reanalysis showed that the imbalance in patients with minor stroke did not explain the difference between treatment and placebo.³¹⁷ The adjusted odds ratio for 3-month favorable outcome (odds ratios for treatment compared with placebo) for the subgroup of patients from the NINDS rtPA Stroke Trial with NIHSS score of ≥ 5 at baseline and time from stroke onset to treatment of 91 to 180 minutes was statistically significant in favor of treatment. Indeed, when all possible subgroups were examined separately, no effect of the severity imbalance could be shown to influence the overall result that rtPA therapy positively influenced outcome. In a separate analysis by an independent group, an identical finding was reached: Baseline imbalances in the numbers of patients with mild stroke do not explain the overall study result.³¹⁸

B. Other Thrombolytic Agents

Clinical trials of streptokinase were halted prematurely because of unacceptably high rates of hemorrhage, and this agent should not be used.^{319–322} Other intravenously administered thrombolytic agents, including reteplase, urokinase, anistreplase, and staphylokinase, might have been considered for treatment of patients with acute ischemic stroke. None of these agents has been tested extensively. Tenecteplase appears promising as an effective thrombolytic with fewer bleeding complications than wild-type rtPA, but pivotal studies are under way.³²³ Desmoteplase has been tested in a pilot study; results appear promising.^{189,324}

C. Defibrogenating Enzymes

Ancrod, an enzyme derived from snake venom that degrades fibrinogen, was tested in a series of clinical studies. A preliminary trial found that ancrod treatment improved outcomes after stroke, with patients with blood fibrinogen levels < 100 mg/dL having the best responses.^{325,326} A subsequent study found a favorable benefit–risk profile for patients. Further studies of ancrod continue, given the potentially favorable combination of antithrombotic activity and mild thrombolytic effect.^{327,328}

D. Conclusions and Recommendations

Intravenous administration of rtPA is the only FDA-approved medical therapy for treatment of patients with acute ischemic stroke.³ Its use is associated with improved outcomes for a broad spectrum of patients who can be treated within 3 hours of stroke onset. Earlier treatment (ie, within 90 minutes) may be more likely to result in a favorable outcome. Later treatment, at 90 to 180 minutes, also is beneficial. Patients

TABLE 11. Characteristics of Patients With Ischemic Stroke Who Could Be Treated With rtPA

Diagnosis of ischemic stroke causing measurable neurological deficit

The neurological signs should not be clearing spontaneously.

The neurological signs should not be minor and isolated.

Caution should be exercised in treating a patient with major deficits.

The symptoms of stroke should not be suggestive of subarachnoid hemorrhage.

Onset of symptoms <3 hours before beginning treatment

No head trauma or prior stroke in previous 3 months

No myocardial infarction in the previous 3 months

No gastrointestinal or urinary tract hemorrhage in previous 21 days

No major surgery in the previous 14 days

No arterial puncture at a noncompressible site in the previous 7 days

No history of previous intracranial hemorrhage

Blood pressure not elevated (systolic <185 mm Hg and diastolic <110 mm Hg)

No evidence of active bleeding or acute trauma (fracture) on examination

Not taking an oral anticoagulant or, if anticoagulant being taken, INR \leq 1.5

If receiving heparin in previous 48 hours, aPTT must be in normal range.

Platelet count \geq 100 000 mm³

Blood glucose concentration \geq 50 mg/dL (2.7 mmol/L)

No seizure with postictal residual neurological impairments

CT does not show a multilobar infarction (hypodensity >1/3 cerebral hemisphere).

The patient or family members understand the potential risks and benefits from treatment.

INR indicates international normalized ratio; aPTT, activated partial thromboplastin time.

with major strokes (NIHSS score >22) have a very poor prognosis, but some positive treatment effect with rtPA has been documented.³²⁹ Because the risk of hemorrhage is considerable among patients with severe deficits, the decision to treat with rtPA should be made with caution. Treatment with rtPA is associated with symptomatic intracranial hemorrhage, which may be fatal. In the original NINDS trials, the risk of symptomatic bleeding was \approx 6%.¹⁰⁰ Recent community-based studies and registries report lower rates of hemorrhage.^{269,330–333} Recommendations for the management of intracranial hemorrhage after treatment with rtPA are provided in the AHA Stroke Council's updated guideline statement on management of intracerebral hemorrhage, which is being issued contemporaneously with this statement. The best methods for preventing bleeding complications are careful selection of patients and scrupulous ancillary care, especially close observation, and monitoring of the patient with early treatment of arterial hypertension. Factors that affect decisions about administration of rtPA are outlined in Table 11, and the treatment regimen for administration of rtPA is included in Table 12. Case series have suggested that thrombolysis may be used in patients with seizures at the time of presentation when evidence suggests that residual deficits are due to ischemia rather than the postictal state.^{334,335} The use of anticoagulants and antiplatelet agents should be delayed for 24 hours after treatment.

TABLE 12. Treatment of Acute Ischemic Stroke: Intravenous Administration of rtPA

Infuse 0.9 mg/kg (maximum dose 90 mg) over 60 minutes with 10% of the dose given as a bolus over 1 minute.

Admit the patient to an intensive care or stroke unit for monitoring.

Perform neurological assessments every 15 minutes during the infusion and every 30 minutes thereafter for the next 6 hours, then hourly until 24 hours after treatment.

If the patient develops severe headache, acute hypertension, nausea, or vomiting, discontinue the infusion (if rtPA is being administered) and obtain emergency CT scan.

Measure blood pressure every 15 minutes for the first 2 hours and subsequently every 30 minutes for the next 6 hours, then hourly until 24 hours after treatment.

Increase the frequency of blood pressure measurements if a systolic blood pressure is \geq 180 mm Hg or if a diastolic blood pressure is \geq 105 mm Hg; administer antihypertensive medications to maintain blood pressure at or below these levels (see Table 10).

Delay placement of nasogastric tubes, indwelling bladder catheters, or intra-arterial pressure catheters.

Obtain a follow-up CT scan at 24 h before starting anticoagulants or antiplatelet agents.

Although written consent is not necessary before administration of rtPA for treatment of stroke, a full discussion of the potential risks and benefits of treatment with rtPA with the family and the patient if possible is recommended.

Although other thrombolytic agents, including defibrinogenating drugs, are being tested, none has been established as effective or as a replacement for rtPA.

Class I Recommendations

- 1. Intravenous rtPA (0.9 mg/kg, maximum dose 90 mg) is recommended for selected patients who may be treated within 3 hours of onset of ischemic stroke (Class I, Level of Evidence A). Physicians should review the criteria outlined in Table 11 (which are modeled on those used in the NINDS trial) to determine the eligibility of the patient. A recommended regimen for observation and treatment of the patient is described in Table 12. This recommendation has not changed from previous statements.**
- 2. Besides bleeding complications, physicians should be aware of the potential side effect of angioedema that may cause partial airway obstruction (Class I, Level of Evidence C). This recommendation has been added since the previous guidelines.**

Class II Recommendations

- 1. A patient whose blood pressure can be lowered safely with antihypertensive agents may be eligible for treatment, and the physician should assess the stability of the blood pressure before starting rtPA (Class IIa, Level of Evidence B). An elevated blood pressure that requires a continuous infusion of sodium nitroprusside may not be sufficiently stable for the patient to receive rtPA. However, because time is limited, most patients with markedly elevated blood pressure cannot be managed adequately and still meet the 3-hour requirement.**

This recommendation has not changed from previous guidelines.

- 2. A patient with a seizure at the time of onset of stroke may be eligible for treatment as long as the physician is convinced that residual impairments are secondary to stroke and not a postictal phenomenon (Class IIa, Level of Evidence C). This recommendation differs from the previous statements and represents a broadening of eligibility for treatment with rtPA.**

Class III Recommendations

- 1. The intravenous administration of streptokinase for treatment of stroke is not recommended (Class III, Level of Evidence A). This recommendation has not changed from previous guidelines.**
- 2. The intravenous administration of anecrod, tenecteplase, reteplase, desmoteplase, urokinase, or other thrombolytic agents outside the setting of a clinical trial is not recommended (Class III, Level of Evidence C). This recommendation is new.**

VII. Intra-Arterial Thrombolysis

The 2003 guidelines concluded that intra-arterial administration of at least one specific thrombolytic agent, recombinant prourokinase, appears to be of some benefit in treatment of carefully selected patients with acute ischemic stroke secondary to occlusion of the MCA.² This conclusion was based on the results of a prospective, randomized, placebo-controlled phase III study testing the effectiveness of intra-arterial thrombolysis with prourokinase among patients with stroke of <6 hours' duration secondary to occlusion of the MCA.³³⁶ In the primary intent-to-treat analysis, 40% of the 121 patients treated with recombinant prourokinase and 25% of the 59 control patients had a modified Rankin Scale score of 0 to 2 at 90 days ($P=0.04$). Recanalization of the MCA was achieved in 66% of the patients treated with recombinant prourokinase and 18% of the patients in the control group ($P<0.001$). Intracranial hemorrhage with neurological deterioration within 24 hours of treatment occurred in 10% of patients treated with recombinant prourokinase and in 2% of the control group ($P=0.06$). No difference in overall death rate was seen between the 2 groups. The FDA has not approved the drug, and recombinant prourokinase is not currently available for clinical use. Extrapolation to rtPA, the widely used intravenous cerebral thrombolytic drug, and to urokinase, which is chemically similar to the prourokinase prodrug, is based on consensus and case series data. Extrapolation to other lytic agents is more speculative.

The intra-arterial approach has been promoted because a high concentration of thrombolytic agents may be delivered into the thrombus.³³⁷ Despite the uncontrolled observation that recanalization rates may be higher with intra-arterial thrombolysis than with intravenous thrombolysis,³³⁷ clinical benefit may be counterbalanced by delays to initiating treatment with the intra-arterial approach. On the basis of 1999–2001 National Hospital Discharge Survey data,³³⁸ there were 1 796 513 admissions for ischemic stroke between 1999 and 2001. Of these admissions, 1314 (0.07%) underwent intra-arterial thrombolysis, and 11 283 (0.6%) underwent intravenous thrombolysis. A second estimate is derived from the

Greater Buffalo and Erie County stroke study that suggested that intravenous or intra-arterial thrombolysis was used in 1.4% and 0.3% of 1590 patients admitted in 11 hospitals.³²⁹ Intra-arterial administration of rtPA to patients with ischemic stroke who are expected to have limited response to intravenous therapy has gained popularity. Potential reasons include severe neurological deficits (NIHSS score ≥ 10), presentation between 3 and 6 hours after symptom onset, recent history of major surgical procedures, and occlusion of major cervical and/or intracranial vessels. However, only limited data support the usefulness of intra-arterial therapy in these situations.

New evidence since the publication of the last guidelines is summarized in subsequent sections. More emphasis has been placed on deriving information from the initial angiogram, with emphasis on the site of occlusion and identification of collateral supply to the affected region. New data suggest that this information may be incorporated into a scheme to stratify patients into the expected rate of recanalization and short-term outcome after intra-arterial thrombolysis.^{337,339,340}

A small randomized, multicenter trial compared intravenous urokinase with intra-arterial urokinase within the first 6 hours of acute ischemic stroke.³⁴¹ Patients fulfilling the selection criteria were randomly assigned to receive urokinase 900 000 U via intravenous ($n=14$) or intra-arterial ($n=13$) approach. The study was terminated prematurely because 7 patients (26%) died: 4 in the intravenous group and 3 in the intra-arterial group. Although patients treated with intra-arterial therapy showed greater and earlier improvement, no significant difference was seen in primary and secondary outcomes. Recently, a cohort study was reported from Japan's Multicenter Stroke Investigator's Collaboration (J-MUSIC).³⁴² The modified Rankin Scale score at discharge was lower in the urokinase group than in the control group (mean, 2.8 in the urokinase group versus 3.3 in the control group; $P=0.03$). A favorable outcome (modified Rankin Scale score of 0 to 2) was more frequently observed in the urokinase group (51%) than in the control group (34%; $P=0.01$). A third study³⁴³ randomized 16 patients with angiographic evidence of posterior circulation vascular occlusion who presented within 24 hours of symptom onset to either intra-arterial prourokinase or conservative management. Some imbalance between groups existed, with greater severity of deficit at baseline observed in the treatment arm. Good outcomes were observed in 4 of 8 patients who received intra-arterial urokinase and in 1 of 8 patients in the control group.

It has been proposed that patients be selected for intra-arterial thrombolysis on the basis of radiological criteria. A nonrandomized study³⁴⁴ compared outcomes of 83 patients with or without a hyperdense artery sign on initial CT scan treated with intravenous or intra-arterial rtPA. An increased likelihood of favorable outcomes, indicated by a significant improvement in the discharge NIHSS score, was noted with intra-arterial rtPA treatment, irrespective of the presence or absence of hyperdense artery sign. A less favorable outcome in discharge NIHSS score was noted with intravenous rtPA in patients with a hyperdense artery sign than in those without the hyperdense artery sign. This suggests that differential response to intravenous rtPA in patients with hyperdense

artery sign³⁴⁴ on initial CT scan is not observed with intra-arterial thrombolysis.

A. Conclusions and Recommendations

Since the publication of the last guidelines, no new Class I evidence has been published. Intra-arterial administration of at least one specific thrombolytic agent appears to be of benefit in the treatment of carefully selected patients with acute ischemic stroke secondary to occlusion of the MCA. New evidence about the use of intra-arterial urokinase in patients with vertebral or basilar artery occlusion treated within 24 hours of symptom onset and patients with embolic stroke involving the anterior circulation within 4.5 hours of symptom onset suggests that intra-arterial therapy may be used. Patients who are evaluated within 6 hours of symptoms but who are ineligible to receive intravenous thrombolysis because of recent surgery or other procedures may be candidates for intra-arterial thrombolysis.^{345,346}

New criteria have been established to determine the qualifications of physicians who can perform intra-arterial thrombolysis on the basis of recent statements from professional organizations and clinical trials.

Class I Recommendations

- 1. Intra-arterial thrombolysis is an option for treatment of selected patients who have major stroke of <6 hours' duration due to occlusions of the MCA and who are not otherwise candidates for intravenous rtPA (Class I, Level of Evidence B). This recommendation has not changed since previous guidelines.**
- 2. Treatment requires the patient to be at an experienced stroke center with immediate access to cerebral angiography and qualified interventionalists. Facilities are encouraged to define criteria to credential individuals who can perform intra-arterial thrombolysis (Class I, Level of Evidence C). This recommendation has been added since previous guidelines.**

Class II Recommendation

- 1. Intra-arterial thrombolysis is reasonable in patients who have contraindications to use of intravenous thrombolysis, such as recent surgery (Class IIa, Level of Evidence C). This recommendation was not included in the previous guideline.**

Class III Recommendation

- 1. The availability of intra-arterial thrombolysis should generally not preclude the intravenous administration of rtPA in otherwise eligible patients (Class III, Level of Evidence C). This recommendation has not changed from previous guidelines.**

VIII. Anticoagulants

Physicians have used anticoagulants to treat patients with acute ischemic stroke for >50 years. These medications continue to be prescribed commonly.³⁴⁷ Despite their widespread use, the usefulness of emergency anticoagulation is the subject of debate.^{348–352} Disagreements exist about the best agent to administer, the route of administration, the use of a bolus dose to start treatment, the level of anticoagulation

required, and the duration of treatment. In a small randomized trial, Toth³⁵³ found no increase in serious bleeding complications with the use of a bolus dose to start heparin anticoagulation. A weight-based nomogram for administration of heparin after stroke has been developed.³⁵⁴ This approach seems to lessen the necessity for frequent adjustments in dose. In the past, panels of the AHA have concluded that the data about the utility of heparin in the management of stroke are either uncertain or largely negative.^{1–3,355,356} Besides the uncertainty about efficacy, the safety concern exists that urgent anticoagulation may lead to symptomatic intracranial hemorrhage. Physicians have been uncertain about the severity of neurological impairments or the initial CT findings that would contraindicate the early use of heparin.

Anticoagulants often are prescribed to patients with recent stroke in an effort to prevent early recurrent stroke and to improve neurological outcomes. The Cerebral Embolism Study Group estimated that the risk of early recurrent embolism was $\approx 12\%$ among untreated patients with embolic stroke.^{357,358} A Norwegian trial testing urgent anticoagulation among patients with recent stroke and atrial fibrillation found the risk of recurrent stroke to be $\approx 8\%$ in 1 week.³⁵⁹ Other trials testing anticoagulants in stroke have found the rates of early recurrent stroke to be much lower (in the range of 0.3%/d to 0.5%/d).^{360–362} These relatively low rates mean that detection of a therapeutic effect in prevention of early recurrent stroke by anticoagulation will be difficult.

A. Heparin

The International Stroke Trial tested 2 doses (5000 U/d or 25 000 U/d) of subcutaneously administered heparin when the medication was started within 48 hours of stroke.³⁶¹ Although the trial included randomization in its design, investigators and patients knew the nature of the treatment. Dual randomization meant that approximately one half of the patients receiving heparin also were receiving aspirin. Neither monitoring of the level of anticoagulation nor adjustment of dosages to biological responses was done. Thus, some patients may have received excessive doses of heparin, with an increased risk of bleeding complications, and others may have had inadequate dosages, with a resultant loss of effectiveness. In addition, patients enrolled in this very large trial did not need to have a brain imaging study before treatment. Although heparin was effective in lowering the risk of early recurrent stroke, an increased rate of bleeding complications negated this benefit. A subgroup analysis looking at the effects of heparin among patients with atrial fibrillation did not demonstrate a benefit from the agent.³⁶³

A Swedish study testing the utility of heparin for treatment of patients with progressing stroke did not demonstrate a benefit from the anticoagulant.³⁶⁴ Recently, 2 small European trials have tested the utility of heparin in treatment of patients with recent stroke.^{365,366} Investigators tested continuously intravenously administered heparin starting with a bolus dose with adjustments in dosage in response to activated partial thromboplastin time in a small clinical trial that enrolled patients within 12 hours of onset of stroke. The multicenter trial treated 32 patients with heparin and 35 with aspirin (control). No significant differences in outcomes, recurrent

ischemic stroke, hemorrhagic worsening, or death were noted between the 2 treatment groups. A single-center study involved the randomization of patients with acute nonlacunar hemispheric infarctions to treatment with either adjusted intravenous infusions of heparin without an initial bolus dose or saline.³⁶⁵ The trial enrolled 418 patients (208 on heparin) within 3 hours of onset of stroke. Thirteen heparin-treated patients had symptomatic hemorrhagic complications (6.2%) (7 were fatal), and symptomatic hemorrhagic events were diagnosed in 3 control patients (1.4%). Favorable outcomes at 90 days were noted in 81 of 208 patients treated with heparin (38.9%) and 60 of 210 patients (28.6%) in the control group. A meta-analysis of the studies of heparin found a benefit from administration of the medication.³⁶⁷ However, this analysis was performed before the 2 recent reports about heparin were published. Nevertheless, the results of the relatively small study by Camerlingo et al³⁶⁵ likely would be dwarfed by the data from the International Stroke Trial.

B. Low-Molecular-Weight Heparins and Danaparoid

Several trials have tested low-molecular-weight (LMW) heparins or danaparoid for treatment of patients with acute ischemic strokes. Results generally have been negative. A trial in Hong Kong tested 2 doses of subcutaneously administered nadroparin given over 10 days after stroke.³⁶⁸ Although no benefit from treatment was found at the end of the treatment period or at 3 months, those who received the larger dose of nadroparin had a significantly lower death rate at 6 months than did the control group. Another trial of nadroparin failed to find any improvement in the rate of favorable outcomes with treatment, but the rate of serious bleeding was increased with the larger of 2 doses of LMW heparin.³⁶⁹ Berge et al³⁵⁹ compared the utility of dalteparin or aspirin for prevention of early recurrent stroke or improvement in neurological outcome among patients with presumed cardioembolic stroke. Although no significant differences were noted in outcomes or the rates of recurrent strokes, the patients taking aspirin had fewer second events. The rate of bleeding complications also was higher among patients who were treated with dalteparin than among those given aspirin. A German trial compared 4 different doses of certoparin; no differences in rates of favorable outcomes were noted among the groups, but the rate of serious bleeding complications was highest among the group that received the largest dose of the LMW heparin.³⁷⁰ An aspirin-controlled trial tested 2 different doses of subcutaneously administered tinzaparin in patients with recent stroke, with no differences in favorable outcomes, rates of recurrent stroke, death, or bleeding complications.³⁷¹

A randomized, double-blind, placebo-controlled trial tested the utility of a continuous intravenous infusion of the LMW heparinoid (danaparoid) in improving outcomes after acute ischemic stroke.³⁶² The trial halted recruitment of patients with moderate to severe stroke (NIHSS scores of ≥ 15) because of an increased risk of symptomatic intracranial hemorrhages. The medication did not lessen the risk of neurological worsening or early recurrent stroke, including among patients with cardioembolic events. No improvement in the chance of having a favorable or very favorable outcome

was found at 3 months. The trial included prespecified subgroup analyses among patients with different subtypes of ischemic stroke. The only subgroup that showed benefit from treatment included patients with stroke secondary to large-artery atherosclerosis.³⁷² This finding may be supported by the results of the study by Lovett et al,³⁷³ which found that the risk of early recurrent stroke was highest among patients with severe large-artery atherosclerotic disease. A study examining the usefulness of a LMW heparin in treating patients with stroke secondary to intracranial stenotic disease has been performed in Hong Kong and Singapore, but the results have not yet been published.

Some studies have compared the utility of heparin or LMW heparins in treatment of patients with recent stroke. Woessner et al³⁷⁴ compared the usefulness of subcutaneously administered enoxaparin or adjusted-dose heparin in a multicenter trial that randomized patients with either high-grade arterial stenoses or a cardioembolic source for stroke. No significant differences were noted between the 2 regimens. Another trial investigated the efficacy of subcutaneously administered enoxaparin in comparison to heparin for prevention of thromboembolic events among patients with lower-limb paralysis after stroke.³⁷⁵ The 2 medications had equal efficacy.

C. Anticoagulants as an Adjunctive Therapy

The administration of anticoagulants or antiplatelet agents is currently contraindicated during the first 24 hours after treatment with intravenous rtPA. This restriction is based on the regimen used in the NINDS trials.⁶⁶ Arterial reocclusion may follow successful recanalization with thrombolysis.³⁷⁶ Thus, there is interest in the use of an anticoagulant that may maintain arterial patency after thrombolytic therapy. The trials of intra-arterial administration of prourokinase used heparin as part of the treatment regimen, and the control group received only heparin.^{336,377,378} In the first study, both the success of recanalization and the risk of hemorrhage were increased among the patients who received the larger of the 2 doses of adjunctive heparin. Two small studies have tested the use of intravenously administered heparin after treatment with rtPA.^{379,380} No increase in bleeding complications has been reported. Heparin also has been given in combination with abciximab with a reasonable degree of safety.³⁸¹ The experience with adjunctive anticoagulation is limited. Neither safety nor effectiveness has been established, and additional research is needed.

D. Conclusions and Recommendations

The results of the recent trials show that early administration of either heparin or a LMW heparin/danaparoid is associated with an increased risk of bleeding complications. These medications increase the risk of symptomatic hemorrhagic transformation of ischemic strokes, especially among persons with severe events. These medications are also associated with a risk of serious bleeding in other parts of the body. Although the likelihood of bleeding appears to be lower than that associated with the administration of thrombolytic agents, it is sufficiently high to require convincing evidence of efficacy to justify urgent anticoagulation. The risk of bleeding appears not to be greatly affected by the use of a

bolus dose to start treatment or by the route of administration (subcutaneous or intravenous). Monitoring of the level of anticoagulation and adjustment of the dosages in response to levels probably increase the safety of treatment.

Present data indicate that early administration of heparin or the LMW heparins/danaparoid does not lower the risk of early recurrent stroke, including among patients with cardioembolic stroke. Early administration of anticoagulants does not lessen the risk of early neurological worsening. Data are not sufficient to indicate whether anticoagulants might have efficacy among some potentially high-risk groups, such as persons with intracardiac or intra-arterial thrombi. The efficacy of urgent anticoagulation is not established for treatment of patients with vertebrobasilar disease or an arterial dissection.

Most trials have not demonstrated the efficacy of anticoagulation in improving outcomes after acute ischemic stroke. One relatively small trial found that intravenous heparin, when administered within 3 hours of onset of stroke to patients with nonlacunar stroke, may improve outcomes. In light of the generally negative data, the results of this trial may need to be replicated. Because the time window for potentially effective treatment with heparin is the same as for intravenously administered rtPA, a study may be needed to test the relative efficacy of heparin or thrombolysis.

The role of anticoagulants as an adjunctive therapy in addition to mechanical or pharmacological thrombolysis has not been defined.

The following recommendations have not changed from previous guidelines.

Class III Recommendations

- 1. Urgent anticoagulation with the goal of preventing early recurrent stroke, halting neurological worsening, or improving outcomes after acute ischemic stroke is not recommended for treatment of patients with acute ischemic stroke (Class III, Level of Evidence A). This recommendation may change if additional data demonstrate the usefulness of very early intravenous administration of anticoagulants for treatment of patients with infarctions secondary to large-artery thrombosis or cardioembolism. Urgent anticoagulation should not be used in lieu of intravenous thrombolysis for treatment of otherwise eligible patients (Class III, Level of Evidence A).**
- 2. Urgent anticoagulation is not recommended for patients with moderate to severe strokes because of an increased risk of serious intracranial hemorrhagic complications (Class III, Level of Evidence A).**
- 3. Initiation of anticoagulant therapy within 24 hours of treatment with intravenously administered rtPA is not recommended (Class III, Level of Evidence B).**

IX. Antiplatelet Agents

The 2003 guideline² recommendation that aspirin could be used after stroke was consistent with the recent Joint Guideline Statement from the AHA and the American Academy of Neurology.³⁵⁶ The administration of aspirin as an adjunctive therapy, within 24 hours of the use of thrombolytic agents, was not recommended. Aspirin was not indicated as a

substitute for other acute interventions, especially intravenous administration of rtPA, for the treatment of acute ischemic stroke.

A. Single Oral Antiplatelet Agent

Aspirin is the only oral antiplatelet agent that has been evaluated for the treatment of acute ischemic stroke. Two large trials^{360,361} each showed a nonsignificant trend in reduction in death or disability when treatment with aspirin was initiated within 48 hours of stroke. A small increase in bleeding complications was also noted. When the data from the 2 trials were combined, a modest but statistically significant benefit from aspirin was noted. The primary effect seemed to be in prevention of recurrent events. It is not clear whether aspirin limited the neurological consequences of the acute ischemic stroke itself.

The use of ticlopidine, clopidogrel, or dipyridamole in the setting of acute ischemic stroke has not been evaluated.³⁸² Initiation of treatment with clopidogrel in a daily dose of 75 mg does not cause maximal platelet inhibition for ≈ 5 days.³⁸³ This delay poses the issue of an early therapeutic effect for treatment of patients with acute stroke. A bolus dose of clopidogrel 300 mg inhibits platelet aggregation rapidly.³⁸⁴ A 300-mg loading dose of clopidogrel followed by daily doses of 75 mg/d has been recommended for treatment of patients with acute coronary syndrome (ACS) who have aspirin allergies.³⁸⁵ No data are available about the utility of this strategy in treating patients with acute ischemic stroke.^{386,387}

B. Combination of Oral Antiplatelet Agents

Although the combination of clopidogrel and aspirin is prescribed for patients with ACS, this combination has not been studied in the setting of acute ischemic stroke. No data are available about the use of other combinations of antiplatelet agents in the management of acute ischemic stroke.

C. Intravenous Antiplatelet Agents

The platelet glycoprotein IIb/IIIa inhibitors have been considered in the treatment of acute ischemic stroke because they may increase the rate of spontaneous recanalization and improve microvascular patency.^{388,389} A small case series³⁹⁰ demonstrated that intravenous abciximab administered between 3 and 24 hours after symptom onset in patients with supratentorial ischemic stroke may attenuate ischemic lesion growth as demonstrated by serial DWI. A double-blind, placebo-controlled, dose-escalation trial randomly allocated 74 patients to receive either an escalating dose of abciximab (54 patients) or placebo (20 patients) in a 3:1 ratio within 24 hours after ischemic stroke onset.^{390,391} No symptomatic intracerebral hemorrhages occurred in any group, which suggests that intravenous abciximab is relatively safe when administered within 24 hours of symptom onset in selected patients with ischemic stroke. A second randomized, double-blind, placebo-controlled phase II trial randomized 400 patients within 6 hours of ischemic stroke onset to intravenous abciximab or placebo.³⁹² The rates of symptomatic hemorrhage during the first 5 days after stroke were not significantly different between the abciximab and placebo groups (3.6% versus 1%). Treatment with abciximab showed a

nonsignificant shift in favorable outcomes defined by modified Rankin Scale scores at 3 months, after adjustment for baseline severity of stroke, age, and interval from stroke.^{391,392} A phase III, multinational, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of abciximab in patients with acute ischemic stroke has been halted because of an increased rate of bleeding. Details are not yet available.

D. Conclusions and Recommendations

No new data are available about the utility of oral antiplatelet agents (used singly or in combination) for treatment of patients with acute ischemic stroke. Currently available data demonstrate a small but statistically significant decline in risk of mortality and morbidity when aspirin is started within 48 hours after onset of stroke. It appears that the primary effects of the aspirin are due to reduction of early recurrent stroke rather than limitation of the neurological consequences of the stroke. No data are available on the utility of other antiplatelet agents, including clopidogrel, given as monotherapy or in combination with aspirin for treatment of patients with acute ischemic stroke. The relative indications for the long-term administration of antiplatelet agents to prevent recurrent stroke are beyond the scope of this statement. However, the panel recommends the administration of such agents as part of management after acute stroke.

Ongoing research is testing the usefulness of intravenously administered antiplatelet agents (glycoprotein IIb/IIIa receptor blockers) when given alone or in combination with other interventions. Preliminary evidence suggests that these agents, when used alone, have an acceptable safety profile, but considerably more research is needed to determine whether these agents have a role in the management of acute stroke in conjunction with other therapies.

Class I Recommendation

1. **The oral administration of aspirin (initial dose is 325 mg) within 24 to 48 hours after stroke onset is recommended for treatment of most patients (Class I, Level of Evidence A). This recommendation has changed in that a dose of aspirin is now included.**

Class III Recommendations

1. **Aspirin should not be considered a substitute for other acute interventions for treatment of stroke, including the intravenous administration of rtPA (Class III, Level of Evidence B). These recommendations have not changed from previous statements.**
2. **The administration of aspirin as an adjunctive therapy within 24 hours of thrombolytic therapy is not recommended (Class III, Level of Evidence A). This recommendation has not changed.**
3. **The administration of clopidogrel alone or in combination with aspirin is not recommended for the treatment of acute ischemic stroke (Class III, Level of Evidence C). This recommendation was not included in the previous statement. The panel supports research testing the usefulness of emergency administration of clopidogrel in the treatment of patients with acute stroke.**

4. **Outside the setting of clinical trials, the intravenous administration of antiplatelet agents that inhibit the glycoprotein IIb/IIIa receptor is not recommended (Class III, Level of Evidence B). This recommendation has been added since the last guideline was published.**

X. Volume Expansion, Vasodilators, and Induced Hypertension

A. Hemodilution in Acute Ischemic Stroke

It is known that patients experiencing acute ischemic stroke may have a variety of abnormalities that increase whole-blood viscosity, including leukocyte activation, red cell aggregation, and reduced red cell deformability.^{393–395} In addition, elevated fibrinogen levels, which add to plasma viscosity, have been documented. On the basis of these findings, hemodilution, with or without venesection, has been studied. The goal is to improve cerebral blood flow to hyperperfuse potentially viable brain tissue supplied by leptomeningeal collaterals in an attempt to perfuse the ischemic penumbra.^{396–400}

Volume expansion and hemodilution have been demonstrated to improve blood flow but may reduce oxygen-carrying capacity at hematocrits <30%.^{401–408} As the hematocrit is reduced, oxygen delivery increases as much as 28% to 30%; however, at levels lower than this, oxygen delivery begins to decline.⁴⁰⁹

In patients with cerebral infarction, cerebral autoregulatory mechanisms are impaired, and hemodilution has been noted to increase cerebral blood flow in the infarcted as well as the contralateral hemisphere. Oxygen-carrying molecules such as perfluorocarbons or diaspirin cross-linked hemoglobin have been shown to reduce brain infarct size in animal models but have not yet been assessed and cannot be recommended in patients.^{383,410–417}

Investigations of intravascular volume and hemodilution in patients began in the 1960s. Initial reports, from studies that were not controlled and not randomized, were encouraging and suggested clinical benefits of intravascular volume expansion. In a review of recent trials for hemodilution in stroke, a combination of plasma volume expansion with or without venesection was used.^{387,416–422} Several trials used plasma volume expansion alone, either dextran 40 or hydroxyethyl starch and albumin in one trial.^{405,423–425} In all trials, and in the Multicenter Austrian Hemodilution Stroke Trial³⁸⁷ study in particular, hemodilution did not significantly reduce deaths within the first 4 weeks but did influence deaths within 3 to 6 months. Hemodilution also had no significant influence on death, dependency, or institutionalization/long-term care. In several trials, hemodilution was associated with a tendency toward reduction in deep venous thrombosis and pulmonary embolism at 3 to 6 months. Despite volume expansion and hemodilution, the risk of significant cardiac events did not increase.

Conclusions and Recommendations

The present data indicate that intentional hemodilution, with or without venesection in clinical practice, does not reduce case fatality or improve functional outcome in survivors. The data do not support the use of hypervolemia and isovolumic

hemodilution protocols, including dextran, albumin, and hydroxyethyl starch. The only possible exception for the use of hemodilution is in stroke patients with severe polycythemia.⁴²⁶ Maintenance of a normal circulating blood volume with regulation of metabolic parameters within physiological ranges is desirable.

Class III Recommendation

1. Hemodilution with or without venesection and volume expansion is not recommended for treatment of patients with acute ischemic stroke (Class III, Level of Evidence A). This recommendation has not changed since the previous guidelines were published.

B. Vasodilators in Acute Ischemic Stroke

Methylxanthine derivatives are known vasodilators that also have other activities such as inhibition of platelet aggregation, reduction of free radical release, and inhibition of thromboxane A₂ synthesis.^{404,427–429} On the basis of these characteristics, methylxanthine derivatives, specifically pentoxifylline, propentofylline, and pentifylline, have been evaluated in the setting of acute ischemic stroke.^{430,431} In one trial, pentoxifylline and propentofylline were administered via continuous intravenous infusion over a 3-day period in patients experiencing an acute ischemic event.⁴³² Other studies continued infusions for 5 days, as in the trial by Chan and Kay in 1993, or 7 days, as in the trial of Huber et al in 1993.^{433,434}

Early case fatality, defined as within 4 weeks, was evaluated in several trials of pentoxifylline.^{432–435} The trial conducted by Chan and Kay found a large reduction in the odds of early death; however, this was not borne out in other studies. Two trials demonstrated a nonsignificant reduction in early death or deterioration.^{433,435} One trial compared the combination of pentoxifylline and aspirin with aspirin alone and found a significant decrease in short-term deaths.⁴³³ However, this trial studied early death and deterioration, and no significant reduction in these combined events was observed. The trial by Huber et al in 1993 included 30 patients after propentofylline treatment and found no difference in late case fatality.⁴³⁴ The trial by Chan and Kay administered aspirin to both patient groups with the theoretical advantage that aspirin may potentiate the antiplatelet effects of pentoxifylline, which may explain the apparent clinical effectiveness. The trial by Hsu et al demonstrated that patients with profound neurological deficit derived the greatest benefit from pentoxifylline.⁴³²

Conclusions and Recommendations

On the basis of current data, neither pentoxifylline nor pentofylline has been shown to improve outcomes after stroke.

Class III Recommendation

1. The administration of medications such as pentoxifylline is not recommended for treatment of patients with acute ischemic stroke (Class III, Level of Evidence A). This recommendation has not changed since the previous guideline was published.

C. Induced Hypertension for the Management of Acute Ischemic Stroke

In the setting of acute stroke, patients may have an ischemic penumbra of brain tissue, which may have impaired perfusion but may not be irreversibly damaged. In this situation, a local drop in cerebral blood flow occurs, and cerebral arterioles dilate in an attempt to compensate and maintain flow to the potentially salvageable ischemic tissue.⁴³⁶ The magnitude of the low perfusion and duration of the ischemia are important variables.^{437,438} It is intuitively attractive that reperfusion of this area by dilatation of leptomeningeal collaterals may be advantageous.

The optimal management of blood pressure in patients experiencing acute ischemic neurological events remains controversial.^{247,439,440} Markedly elevated blood pressure after an acute ischemic event may increase the risk of conversion from an ischemic to a hemorrhagic lesion, with life-threatening implications.⁴⁴¹ However, inducing hypertension to increase cerebral blood flow has been attractive on the basis of experimental data.⁴³⁷ Preliminary studies suggest that there may be a role for induced hypertension.^{247,442–446} Other studies by Olsen demonstrated that the ischemic penumbra has impaired autoregulation and that induction of elevated blood pressure partially restores perfusion to the penumbra, as demonstrated by single-photon emission CT imaging.^{447,448} In a study by Rordorf et al, 30 patients with acute ischemic events were treated with intravenous phenylephrine, which was titrated to improvement of neurological deficit, as demonstrated in 33% of the patients.^{445,446} In this trial, patients were entered within 12 hours of the onset of symptoms but were excluded in the presence of recent or known cardiac ischemic events, congestive heart failure, intracerebral hemorrhage, or edema related to a completed infarction. Patients were maintained hypertensive for a period of 1 to 6 days, and neurological status at discharge was improved in those who had responded to the therapy. In other reports by Hillis et al, patients were randomized to induced hypertension or conventional management.^{443,444} Serial DWI and PWI studies were performed before and during the period of induced hypertension. After 3 days of treatment, patients who were treated with induced hypertension showed an improvement in neurological examination, no change in DWI lesion volume, and reductions in PWI abnormality.

Wityk et al used induced hypertension for treatment of patients who were within 12 hours of onset of symptoms but who could not be treated with thrombolytic therapy.^{449,450} They also advocated the use of DWI and PWI as a means to demonstrate improved perfusion to monitor such patients in an intensive care setting and when intervention is undertaken to achieve a target systolic blood pressure or mean arterial pressure of 20% to 30% above baseline. Other treatment options include withdrawing previous antihypertensive therapy, augmenting intravenous fluids, or starting intravenous phenylephrine. As part of the treatment paradigm, serial neurological examinations are performed to determine whether neurological improvement occurs; patients who show no improvement in a 30- to 60-minute period are considered nonresponders, and the intervention is stopped. Patients who have responded to this mode of therapy are

maintained at that level and weaned according to neurological examination and functional imaging. Data demonstrating the safety and efficacy of this strategy are needed.

Conclusions and Recommendations

Preliminary and small clinical studies suggest that drug-induced hypertension could be used in the management of some patients with acute ischemic stroke. However, data from large clinical trials are not available. Thus, the efficacy of this treatment strategy has not been established. The administration of vasopressors may be complicated by side effects, including myocardial ischemia, in some patients with stroke. Some patients may not be able to be treated with this therapy. The safety of drug-induced hypertension for treatment of stroke in a broad spectrum of patients has not been established. Further research is needed.

Class I Recommendation

1. In exceptional cases, a physician may prescribe vasopressors to improve cerebral blood flow. If drug-induced hypertension is used, close neurological and cardiac monitoring is recommended (Class I, Level of Evidence C). This recommendation has been added since the previous guideline was published.

Class III Recommendation

1. Drug-induced hypertension, outside the setting of clinical trials, is not recommended for treatment of most patients with acute ischemic stroke (Class III, Level of Evidence B). This recommendation has been added since the previous guideline was published.

XI. Surgical Interventions

A. Carotid Endarterectomy

Little information exists about the effectiveness of surgical treatment of patients with acute ischemic stroke. Most cases of immediate operation are performed in the setting of an acute stroke after carotid endarterectomy. Emergency carotid endarterectomy generally is not performed in other settings of acute ischemic stroke because the risks of the procedure are perceived to be high. The sudden restoration of blood flow might increase the development of brain edema or lead to hemorrhagic transformation, especially among patients with major infarctions. In addition, the time required for detecting the arterial lesion and mobilizing the operating room limits the utility of surgery.

However, some surgeons report encouraging results from emergency operations for patients with severe stenosis or occlusion of the internal carotid artery existing for ≤ 24 hours.^{324,386,451–460} In general, improvement after surgery was found among patients with mild to moderate neurological impairments. Still, the data are limited, and the usefulness of urgent surgery among patients with severe neurological deficits is even less clear.

The indications for immediate carotid endarterectomy in a patient with an acute ipsilateral ischemic stroke and an intraluminal thrombus associated with an atherosclerotic plaque at the carotid bifurcation are controversial. The morbidity associated with surgery appears to be high among

patients with an intraluminal thrombus demonstrated by cerebral angiography.^{461–464} Although some groups report low rates of complications and good neurological outcomes with immediate surgery,^{461–463} others have reported better results when the patients are treated initially with anticoagulants followed by delayed operation.⁴⁶⁴

B. Other Surgical Procedures

Immediate extracranial-intracranial arterial bypass for treatment of ischemic stroke failed to improve outcomes and was associated with a high risk of intracranial hemorrhage.⁴⁶⁵ However, some surgeons have reported favorable results with emergency bypass procedures.^{466,467} In an occasional patient with an acute neurological deficit secondary to an embolus of the MCA, outcome might be improved by an emergency microsurgical embolectomy of the MCA.^{468,469} Experience with immediate surgical procedures for treatment of acute ischemic stroke in the vertebrobasilar circulation is extremely limited.

C. Conclusions and Recommendations

Data on the safety and effectiveness of carotid endarterectomy and other operations for treatment of patients with acute ischemic stroke are not sufficient to permit a recommendation. Surgical procedures may have serious risks and may not favorably alter the outcome of the patient.

XII. Endovascular Interventions

Several endovascular interventions are being evaluated for the treatment of intracranial or extracranial arterial occlusions leading to acute ischemic stroke.^{470–473} Options include emergency angioplasty and stenting, mechanical disruption of the clot, and extraction of the thrombus. In most cases, the mechanical intervention has been combined with either intravenous or intra-arterial thrombolytic therapy.

A. Angioplasty and Stenting

Limited data are available about the use of angioplasty and stenting in the emergency treatment of intracranial or extracranial lesions in patients with acute ischemic stroke.^{474–476} Angioplasty and stenting have been used to treat patients with acute stroke secondary to carotid artery dissection.⁴⁷⁷ In one series, emergency angioplasty and stenting of the internal carotid artery were performed in conjunction with intra-arterial thrombolysis in 25 patients who had acute carotid artery occlusion with secondary artery-to-artery embolism to the MCA.⁴⁷⁸ Results were compared with another group of 25 patients who were treated medically; favorable outcomes were more frequent (56% versus 26%) among patients with endovascular treatment. Jovin et al⁴⁷⁹ were successful in achieving recanalization in 23 of 25 patients who had emergency stenting of the extracranial internal carotid artery. Brekenfeld et al⁴⁸⁰ treated 350 patients with intra-arterial urokinase and noted that recanalization could be increased with angioplasty and implantation of stents. Angioplasty with or without stenting has been combined with emergency administration of thrombolytic agents in patients with occlusions in the vertebrobasilar circulation.^{481,482}

B. Mechanical Clot Disruption

Noser et al⁴⁸³ treated 16 patients with occlusion of the MCA and 16 others with occlusion of the internal carotid artery with aggressive mechanical clot disruption. In most cases, the endovascular treatment was an adjunct to thrombolysis. A Swiss study of 350 patients treated with intra-arterial pharmacological thrombolysis found that mechanical fragmentation improved the success for recanalization.⁴⁸⁰ Berlis et al⁴⁸⁴ used an endovascular photoacoustic device to speed recanalization.

C. Clot Extraction

Devices have been used to extract thrombi from occluded intracranial arteries.^{485,486} In the Mechanical Embolus Removal in Cerebral Embolism (MERCI) trial, vessels were opened with a device that removed the thrombus from an intracranial artery.⁴⁸⁷⁻⁴⁸⁹ The device was associated with rapid opening of the artery, but the efficacy in recanalization and safety results achieved with the MERCI retrieval system were similar to those achieved with intra-arterial prourokinase in the Prolyse in Acute Cerebral Thromboembolism II (PROACT II) trial.³³⁶ The rate of recanalization of the MCA in MERCI was 45%, and it was 66% in PROACT II. In MERCI, 17 patients also received thrombolytic medications when the device was unable to achieve recanalization, but the outcomes of these patients were not reported. Although the FDA has approved the use of the MERCI device for reopening intracranial arteries, its clinical utility has not been established.

D. Conclusions and Recommendations

The area of endovascular treatment of patients with acute ischemic stroke shows great promise. A number of techniques and devices are being studied. Already, the FDA has approved one device to extract a thrombus from an occluded intracranial artery. Other devices likely will be approved in the future. Emergency angioplasty also may achieve a role in management. As with the intra-arterial administration of thrombolytics, the use of these devices will be limited to those comprehensive stroke centers that have the resources and physician expertise to perform these procedures safely.

Class II Recommendations

1. **Although the MERCI device is a reasonable intervention for extraction of intra-arterial thrombi in carefully selected patients, the panel also recognizes that the utility of the device in improving outcomes after stroke is unclear (Class IIb, Level of Evidence B). This recommendation has been added since the previous guideline. The panel also recommends that the device be studied in additional clinical trials that will define its role in the emergency management of stroke. This is the first time that a panel has made a recommendation about endovascular treatment of patients with acute ischemic stroke.**
2. **The usefulness of other mechanical endovascular treatments is not established (Class IIb, Level of Evidence C). These devices should be used in the setting of clinical trials. This recommendation has not changed from previous guidelines.**

XIII. Combination Reperfusion Therapy in Acute Stroke

Initial studies of thrombolytic therapy in acute ischemic stroke involved a single pharmacological agent given either intravenously or intra-arterially. Unfortunately, neither intravenous nor intra-arterial thrombolysis with only a single pharmacological agent is an efficient way to rapidly recanalize occluded major brain arteries. Even when it works, intravenous or intra-arterial rtPA takes at least 15 to 30 minutes to reopen an occluded major vessel such as the MCA, and no evidence indicates that other available thrombolytic agents are faster. Large-vessel occlusions of the internal carotid artery or basilar artery often are resistant to intravenous or intra-arterial thrombolysis with 1 agent. Recent transcranial Doppler ultrasonography studies suggest only a 30% complete recanalization rate for MCA occlusion after administration of intravenous rtPA, a 48% partial recanalization rate, and a 27% reocclusion rate.³⁷⁶ The MCA complete recanalization rate with intra-arterial recombinant prourokinase was only 20% after 2 hours, with a 63% partial recanalization rate and a 10% reocclusion rate within the first hour of treatment.³³⁶ The low rate of complete recanalization and the high rate of reocclusion with stroke thrombolysis is not surprising when it is considered that not even aspirin is allowed for 24 hours after intravenous rtPA.

Faster and more complete recanalization should translate into better patient outcomes. To achieve this, the trend in ACS has been to use multiple pharmacological agents and, increasingly, percutaneous coronary intervention. The impetus is the more rapid and complete recanalization of occluded or stenosed coronary arteries. The standard treatment in many ACS patients includes antiplatelet therapy with aspirin, clopidogrel, glycoprotein IIb/IIIa blockers, antithrombotic therapy with heparin or LMW heparin, and direct percutaneous coronary intervention.⁴⁹⁰ In patients with ACS, Thrombolysis in Myocardial Infarction (TIMI) 14⁴⁸⁷ reported the highest TIMI 3 complete recanalization rates with reduced-dose intravenous rtPA combined with the glycoprotein IIb/IIIa antagonist abciximab. However, the rate of brain hemorrhage was increased in patients >75 years of age who received reduced-dose reteplase and abciximab in the Global Utilization of Streptokinase and tPA for Occluded Arteries (GUSTO) V trial.⁴⁸⁸

To improve the efficiency of acute stroke thrombolysis in a way that is similar to treatment of ACS, multimodal combination therapies will need to be developed. Such combination therapy should not only increase the likelihood of favorable outcomes but should also reduce the likelihood of intracranial hemorrhage. The PROACT I study demonstrated that the recanalization efficacy and safety of recombinant prourokinase was affected by the concomitant use of heparin³⁷⁷; although the large dose of anticoagulant was associated with a higher rate of recanalization, it also was complicated by more bleeding. A major stimulus to the development of stroke thrombectomy devices has been the desire to improve the speed and completeness of recanalization as compared with an intra-arterially administered drug alone (see the section on endovascular therapy). External ultrasound has also been shown to enhance intravenous rtPA

in the Combined Lysis of Thrombus in Brain ischemia Using 2 MHz Transcranial Ultrasound and Systemic tPA (CLOTBUST) study.⁴⁹¹ In CLOTBUST, complete MCA recanalization with dramatic clinical recovery occurred in 49% of patients receiving intravenous rtPA combined with transcranial ultrasound versus 30% in patients receiving intravenous rtPA only.

Another approach being evaluated is the initiation of intravenous thrombolysis in the interim period between initial evaluation and intra-arterial treatment.^{72,492} The Interventional Management of Stroke (IMS) study reported on 80 patients with an initial NIHSS score ≥ 10 treated with intravenous thrombolysis followed by intra-arterial thrombolysis.⁴⁹² Patients received intravenous rtPA (0.6 mg/kg, 60 mg maximum over 30 minutes) started within 3 hours of onset. Additional rtPA was then administered via microcatheter in 62 patients with persistent occlusion at the site of the thrombus up to a total dose of 22 mg over 2 hours of infusion or until recanalization occurred. The 80 subjects had a median baseline NIHSS score of 18. The 3-month mortality rate in treated patients (16%) was numerically lower than but not statistically different from the mortality rate observed in the placebo- (24%) and rtPA-treated subjects (21%) in the NINDS rtPA Stroke Trial. The rate of symptomatic intracerebral hemorrhage (6.3%) in IMS subjects was similar to that of rtPA-treated subjects (6.6%) but higher than the rate in placebo-treated subjects (1.0%; $P=0.018$) in the NINDS rtPA Stroke Trial. IMS subjects had a significantly better outcome at 3 months than NINDS placebo-treated subjects for all outcome measures. The new data support the previous phase I study⁷² and single-center case series⁴⁹³ supporting the safety of this approach. On the basis of the results of the phase II study, a phase III study has been planned.

The ongoing IMS II study again uses reduced-dose intravenous rtPA combined with intra-arterial rtPA but now delivered through an ultrasonic EKOS catheter in an attempt to accelerate thrombolysis. Intra-arterial administration of alteplase after intravenous administration of alteplase (0.6 mg/kg) may provide benefit in patients with initial NIHSS score ≥ 10 who present within 3 hours of symptom onset.

A. Combination of Thrombolysis and Neuroprotective Therapies

There have also been very limited studies of combination cytoprotective and reperfusion therapy in acute stroke (lubuzole,⁴⁹⁴ hypothermia,⁴⁹⁵ magnesium,³¹ clomethiazole⁴⁹⁶). Until randomized clinical efficacy trials can be completed, combination reperfusion therapies for acute stroke will remain experimental for the foreseeable future.

B. Thrombolysis and Antiplatelet Agents

Use of platelet glycoprotein IIb/IIIa inhibitors has been suggested to prevent platelet activation and reocclusion and is being evaluated in several phase I studies as adjunctive therapy to intra-arterial thrombolysis. Other clinical trials of combination plasminogen activator and glycoprotein IIb/IIIa inhibitors, some based on perfusion brain imaging, are under way. Three recently completed studies^{497–499} have suggested that intra-arterial administration of thrombolysis in combination with platelet

glycoprotein IIb/IIIa inhibitors may be safe and may potentially improve outcome. A multicenter study⁴⁹⁷ reported the results of treating patients with acute vertebralbasilar occlusion using a combination of an intravenous bolus of abciximab (0.25 mg/kg) followed by 12-hour infusion therapy (0.125 $\mu\text{g}/\text{kg}$ per minute) and intra-arterial rtPA in 47 patients. The results were compared with a retrospective cohort of 41 patients treated by intra-arterial rtPA monotherapy (median dosage, 40 mg). The rates of symptomatic intracranial hemorrhages were 13% and 12% for combination treatment and thrombolytic treatments, respectively. The combination treatment had higher rates of complete recanalization (45% versus 22%), favorable outcomes (34% versus 17%), and survival (62% versus 32%) compared with thrombolysis alone. A second study⁴⁹⁸ evaluated 26 patients with acute ischemic stroke (NIHSS score >10). Combined use of intravenous abciximab and intra-arterial urokinase thrombolysis in 10 patients was compared with intra-arterial urokinase alone in 16 patients. The recanalization rate was higher in the combined urokinase and abciximab group than in the urokinase group (90% versus 44%) with a trend of better functional outcome (50% versus 80%). No significant difference was noted in rates of symptomatic intracerebral hemorrhage (25% versus 30%). A prospective, nonrandomized, open-label trial⁵⁰⁰ was conducted to evaluate the safety of an escalating dose of reteplase in conjunction with intravenous abciximab in patients with acute ischemic stroke (3 to 6 hours after symptom onset) in 20 patients. The safety stopping rule was not activated in any of the tiers. One symptomatic intracerebral hemorrhage was observed in 1 of the 20 patients (1 U tier). Partial or complete recanalization was observed in 13 of the 20 patients. Thirteen patients demonstrated early neurological improvement, and favorable outcome at 1 month was observed in 6 patients.

C. Conclusions and Recommendations

The potential for combination interventions to restore perfusion to the brain given with or without neuroprotective therapies has great appeal. However, currently available data do not provide conclusive evidence for either the safety or efficacy of combinations of medications to improve cerebral perfusion. Data are limited with regard to the usefulness of mechanical devices to augment the effects of pharmacological thrombolysis to treat acute ischemic stroke. No data are available to demonstrate the efficacy of a neuroprotective intervention as a complement to thrombolysis or other therapies to restore perfusion.

Class III Recommendation

1. At present, combinations of interventions to restore perfusion cannot be recommended outside the setting of clinical trials (Class III, Level of Evidence B). This recommendation has been added since the previous guidelines were published.

XIV. Neuroprotective Agents

Medications that limit the cellular effects of acute ischemia or reperfusion may limit neurological injury after stroke. Potential therapeutic strategies include curbing the effects of

excitatory amino acids, such as glutamate, transmembrane fluxes of calcium, intracellular activation of proteases, apoptosis, free radical damage, inflammatory responses, and membrane repair. Although numerous interventions have shown promise in experimental studies, most clinical trials testing these therapies have produced disappointing results. In some circumstances, treated patients had poorer outcomes than did controls or the rates of adverse experiences were unacceptably high.⁵⁰¹ Although some of these clinical studies were small or may not have been well designed, others have been sufficiently large and methodologically strong to produce important information.⁵⁰² New medications and innovative clinical trial designs likely will result in future evidence that neuroprotective strategies could be helpful in treatment of stroke. These therapies could be administered alone or in combination with other interventions, including treatments to restore perfusion to the brain. One of the potential advantages of neuroprotective medications is that they could be started in the field and before completion of brain imaging studies.³¹

Nimodipine is approved for the prevention of ischemic stroke among persons with recent aneurysmal subarachnoid hemorrhage.⁵⁰³ The medication was tested in a large number of clinical trials with generally negative results.^{253,504–506} A meta-analysis of the trials performed before 1994 found no benefit from treatment.⁵⁰⁷ Subsequently, Horn et al⁵⁰⁸ treated patients within 6 hours of onset of stroke and found no benefit from nimodipine. In some cases, outcomes were poorer among patients treated with nimodipine than among controls.^{253,508} Presumably, the higher rates of poor outcomes were secondary to the antihypertensive effects of nimodipine.²⁵³ Trials of flunarizine, isradipine, and darodipine also were negative.^{509–511} Although nicardipine is used to treat elevated blood pressure in the setting of stroke, the agent has had limited testing for treatment of the stroke itself.⁵¹² A systematic review of the calcium channel–blocking agents found no evidence that these medications are effective in improving outcomes after stroke.⁵¹³

Several N-methyl-D-aspartate (NMDA) antagonists have been tested in clinical trials, with largely negative results. In several instances, the rates of serious adverse experiences were high. Although a pilot study found that selfotel might improve outcomes, subsequent clinical trials were halted prematurely because of an increased rate of unfavorable outcomes among treated patients.^{514–516} Other clinical trials tested aptiganel, but it was associated with a high rate of side effects, and no improvement in outcomes was found.^{517,518} Dextrorphan was associated with a high rate of adverse effects.⁵¹⁹ Although remacemide may lower the frequency of ischemic neurological complications associated with cardiac surgery, its effectiveness in the setting of stroke is not established.^{520,521} The NMDA antagonist AR-R15896AR was tested in a clinical trial, but side effects, including psychiatric disturbances, meant that the agent could not be tolerated by the patient.⁵²² A preliminary study of the α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist ZK 200775 showed that the medication led to declines in consciousness and possible neurological worsening. Studies of the glycine antagonist gavestinel found that the medication was relatively safe, but the likelihood of favorable outcomes

was not improved.^{523–525} The agent also was not effective in improving outcomes among patients with intracerebral hemorrhage.⁵²⁶ High doses of licostinel, an antagonist of glycine at the NMDA receptor, were associated with numerous side effects.⁵²⁷ Another glycine antagonist was associated with hepatotoxicity and likely will not be tested further.⁵²⁸ The polyamine glutamate antagonist eliprodil was tested in a clinical trial, but side effects were unacceptably high.⁵²⁹ A systematic review of the trials testing these medications found no improvements in rates of either death or favorable outcomes with treatment.⁵³⁰ Neither fosphenytoin nor sipatrigine has demonstrated effectiveness in treatment of acute stroke.^{531,532} Repinotan, a serotonin agonist, has shown some promise in preliminary studies.⁵³³

Lubeluzole was tested in several clinical trials, including one that evaluated the combination of the medication and rtPA.⁵³⁴ Although a pilot study suggested that the agent was safe and might reduce the death rate, subsequent larger clinical trials found no effects in reducing deaths or improving outcomes after stroke.^{535–537} A subsequent analysis of the trials concluded that there was no evidence for the effectiveness of lubeluzole.⁵³⁸ Trials tested the efficacy of clomethiazole, a γ -aminobutyric acid agonist, alone or in combination with rtPA.⁴⁹⁶ The medication also was used to treat patients with hemorrhagic stroke.^{539,540} Larger clinical trials failed to demonstrate efficacy of clomethiazole in improving outcomes after ischemic stroke.^{541–545} Diazepam is being tested, but the results of the trials are not available.⁵⁴⁶ Although a dose-escalation study of naloxone found the medication to be safe, no hint of efficacy was noted.⁵⁴⁷ No benefit has been reported from treatment with the opioid antagonist nalmefene, as noted in other clinical trials.^{548,549} The neuroprotective agent NXY-059 (Cerovive) has been tested in clinical trials in acute stroke.⁵⁵⁰ A recently published clinical trial showed a shift in the rate of favorable outcomes, as measured by the modified Rankin Scale, among patients treated with NXY-059.⁵⁵¹ The rate of symptomatic bleeding among patients given rtPA seemed to be reduced by the use of NXY-059. Other outcomes were not improved. The results of a second study, which have not been published but which have been announced, did not demonstrate efficacy with the use of NXY-059. A pilot study testing the combination of caffeine and alcohol when started within 6 hours of stroke found the intervention to be relatively safe.⁵⁵² Additional research on this combination is needed.

Magnesium has been tested in a series of clinical studies. Although preliminary studies showed that magnesium was well tolerated and might improve outcomes, a subsequent larger clinical trial was negative.^{553–556} However, the agent was given up to 12 hours after onset of stroke. Another study is testing the utility of early administration of magnesium in the field.³¹ A trial of tirilazad was halted prematurely when an interim analysis showed that the medication was not likely to be effective.^{557,558} A review of all trials testing tirilazad, including in the treatment of subarachnoid hemorrhage, concluded that the medication did not improve outcomes.⁵⁵⁹ A dose-escalation study suggested that ebselen might be safe and effective in improving outcomes after stroke, and another clinical trial is under way.⁵⁶⁰ A small clinical trial found that

edaravone might improve outcomes.⁵⁶¹ Neither of these medications is available in the United States.

Citicoline, an agent that appears to stabilize membranes, has been tested in several clinical studies.^{562–564} The trials did not demonstrate efficacy from treatment. A subsequent meta-analysis reported that patients with moderate to severe stroke might be helped if the medication was started within 24 hours of onset of symptoms.⁵⁶⁵ This finding should not be considered definitive but rather a rationale for further testing of the medication in this subgroup of patients. Several trials of GM1-ganglioside, which also may stabilize membranes, have not demonstrated improved outcomes with treatment.^{566–569} A systematic review of this agent did not demonstrate any benefit from treatment.⁵⁷⁰ Piracetam also has been tested in several clinical trials, with mixed results.^{571–574} Reviews of the medication also have reached differing conclusions; although the agent may be effective in some patients with ischemic stroke, there may be a trend for increased risk of death among patients treated with piracetam.^{575,576} At present, the data are not sufficiently clear to draw a conclusion about the utility of this medication.

Medications that reduce the inflammatory response to ischemia also have been evaluated. A randomized trial of enlimomab (an intercellular adhesion molecule-1 antagonist) found that the rates of poorer outcomes, including death, were increased among patients receiving the agent.⁵⁷⁷ Another trial tested a neutrophil inhibitory factor; although the medication was safe, it did not improve outcomes.⁵⁷⁸ A small study testing cerebrolysin, an agent that has potential neurotrophic and neuroprotective actions, found that the agent was safe and might improve outcomes.⁵⁷⁹ Preliminary studies of trafermin (basic fibroblast growth factor) show conflicting results. One study found that the agent was well tolerated, but another showed a higher death rate among treated patients.^{502,580} Other potential neuroprotective therapies, which are being tested, include erythropoietin, interferon- β , adenosine A₁ receptor agonists, and nitric oxide synthase inhibitors.

Hypothermia is a potent intervention that slows cerebral metabolism and protects neurons in settings of acute ischemia. Neurological outcomes after cardiac arrest appear to be improved by early institution of hypothermia.^{212,213} Hypothermia also has been used to treat patients with severe brain edema.²²⁵ This physical intervention could be combined with neuroprotective medications or therapies to restore perfusion.⁵⁸¹ Cooling may be achieved by the use of external cooling devices or endovascular approaches.^{216,219,222,582} The desired level of body temperature has not been determined. In addition, cooling may be associated with serious adverse reactions, including hypotension, cardiac arrhythmias, or infections.^{226,583} These complications appear to be associated with the degree of induced hypothermia, with the risk of side effects being correlated with prolonged hypothermia and lower temperatures. In addition, the time required to achieve the desired body temperature may be considerable, and the “therapeutic effect” of the lower temperature might not be achieved until after most of the acute cellular effects of ischemia have occurred.²¹⁸ Pilot studies suggest that cooling may be feasible and safe; it might be a therapeutic alternative for treatment of acute stroke.^{218,220} However, a recent clinical

trial found that induced hypothermia with modest lowering of temperature did not lessen the ischemic consequences of surgery for treatment of ruptured aneurysms.²¹⁵ In addition, a systematic review found no definitive evidence that either physical or chemical cooling interventions improved outcomes after acute ischemic stroke.²²⁷ Early induced hypothermia holds promise, and additional research is under way.²¹¹

Conclusions and Recommendations

Considerable experimental and clinical research is required before an intervention with identified neuroprotective effects can be recommended for treatment of patients with acute ischemic stroke. Several steps to improve research have been recommended.⁵⁸⁴ It is hoped that ongoing studies of neuroprotective interventions, including hypothermia, potentially tested alone or in combination with measures to restore perfusion, will demonstrate safety and efficacy.

Class III Recommendation

- 1. At present, no intervention with putative neuroprotective actions has been established as effective in improving outcomes after stroke, and therefore none currently can be recommended (Class III, Level of Evidence A). This recommendation has not changed from previous guidelines.**

XV. Admission to the Hospital and General Acute Treatment (After Hospitalization)

A. Admission to the Hospital

Approximately 25% of patients may have neurological worsening during the first 24 to 48 hours after stroke. It is difficult to predict which patients will deteriorate.^{277,585–588} Besides progression of the initial stroke, the potential for preventable neurological or medical complications also means that patients with stroke should be admitted to the hospital in most circumstances.^{589–593} The goals of treatment after admission to the hospital are to (1) observe for changes in the patient’s condition that might prompt initiation of medical or surgical interventions, (2) provide observation and treatment to reduce the likelihood of bleeding complications after the use of rtPA, (3) facilitate medical or surgical measures aimed at improving outcome after stroke, (4) begin measures to prevent subacute complications, (5) plan for long-term therapies to prevent recurrent stroke, and (6) start efforts to restore neurological function through rehabilitation and good supportive care.

B. Specialized Stroke Care Units

Several studies, performed mainly in Europe, demonstrate the utility of comprehensive stroke units in lessening the rates of mortality and morbidity after stroke.^{594–606} The positive effects can persist for years. The benefits from treatment in a stroke unit are comparable to the effects achieved with intravenous administration of rtPA.⁶⁰⁷ In addition, stroke unit care can be given to a broad number of patients regardless of the interval from stroke or severity of the neurological impairments, including patients who cannot be treated with thrombolytic therapy. In general, a European stroke unit includes a geographically defined facility staffed by skilled

professionals, including physicians, nurses, and rehabilitation personnel. The unit may have monitoring capabilities to permit close observation of changes in patients' neurological status or medical complications.^{608,609} European stroke units usually do not include intensive care unit-level treatment, including ventilatory assistance. Regular communications and coordinated care also are key aspects of the unit. Standardized stroke orders or integrated stroke pathways improve adherence to best practices for treatment of patients with stroke.^{610–612}

Such specialized care is included in recommendations for a CSC. It should be noted that most stroke units in the United States have much shorter lengths of stay than do the units evaluated in the European studies, and most do not incorporate comprehensive rehabilitation care.

1. General Care

Most of the individual components of general medical management after admission to the hospital have not been tested in clinical studies.^{182,590–592,613} Thus, recommendations are based on customary care and the finding from multiple randomized trials that efficient delivery of the combination of these treatments in a stroke unit yields better outcomes than does less organized delivery of these therapies in general medical wards. The patient's neurological status and vital signs should be assessed frequently during the first 24 hours after admission. Most patients are first treated with bed rest, but mobilization usually begins as soon as the patient's condition is considered stable. Some patients may have neurological worsening on movement to an upright posture. Thus, close observation should be included during the transition to sitting or standing. Early mobilization is favored because it lessens the likelihood of complications such as pneumonia, deep vein thrombosis, pulmonary embolism, and pressure sores.⁶¹³ In addition, prolonged immobility may lead to contractures, orthopedic complications, or pressure palsies.^{590,614,615} Frequent turning, the use of alternating pressure mattresses, and close surveillance of the skin help to prevent pressure sores. Measures to avoid falls are an important part of mobilization.⁶¹⁶

2. Nutrition and Hydration

Sustaining nutrition is important because dehydration or malnutrition may slow recovery.^{617,618} Dehydration is a potential cause of deep vein thrombosis after stroke. Impairments of swallowing are associated with a high risk of pneumonia.⁶¹⁹ Some patients cannot receive food or fluids because of impairments in swallowing or mental status. Patients with infarctions of the brain stem, multiple strokes, major hemispheric lesions, or depressed consciousness are at the greatest risk for aspiration. Swallowing impairments are associated with an increased risk of death.⁶²⁰ An abnormal gag reflex, impaired voluntary cough, dysphonia, incomplete oral-labial closure, a high NIHSS score, or cranial nerve palsies should alert the physician to the risk.^{621–623} A preserved gag reflex may not indicate safety with swallowing.⁶²⁴ An assessment of the ability to swallow is important before the patient is allowed to eat or drink. A water swallow test performed at the bedside is a useful screening tool, and documentation of this assessment is included as a quality-of-

care measure after stroke. A wet voice after swallowing is a predictor of a high risk for aspiration. A videofluoroscopic modified barium swallow examination may be performed if indicated.

Most patients are treated initially with intravenous fluids. Intravenous hyperalimentation is rarely necessary. When necessary, a nasogastric or nasoduodenal tube may be inserted to provide feedings and to expedite administration of medications.⁶²⁵ Some patients may not tolerate a nasogastric tube, which also is associated with risk for aspiration pneumonia. Placement of a percutaneous endoscopic gastrostomy (PEG) tube often is used to treat patients who will need prolonged tube feedings.⁶²⁶ Although this device usually requires less care, complications, including involuntary removal of the tube or peritonitis, may occur.⁶²⁷ The risk of aspiration pneumonia is not eliminated by the use of a PEG. Some evidence suggests that use of the PEG tube is superior to nasogastric tube feedings.⁶²⁸

The Feed or Ordinary Diet (FOOD) trials examined (1) the effect of administration of nutritional supplements in outcomes of patients with stroke who could swallow, (2) the effect of initiation of nasogastric feeding started within 7 days of stroke in comparison to later intervals on outcomes, and (3) the effect of PEG feedings on outcomes in comparison to nasogastric feedings.^{629,630} The studies that addressed the latter 2 questions were relatively small and, although negative, do not provide definitive data. The trial showed that supplemental nutrition was not necessary.

Bowel management to avoid constipation and fecal impaction or diarrhea also is a component of ancillary care.⁶³¹ Some feedings administered via a PEG or nasogastric tube may cause osmotic gradients that lead to diarrhea.

3. Infections

Pneumonia, which is most likely to occur in seriously affected, immobile patients and those who are unable to cough, is an important cause of death after stroke.^{590,619,632–634} Aslanyan et al⁶³³ found that the development of pneumonia was associated with an increased risk of death (hazard ratio 2.2) or unfavorable outcome (odds ratio, 3.8).⁶³³ The appearance of fever after stroke should prompt a search for pneumonia, and appropriate antibiotic therapy should be administered. Protection of the airway and suctioning may help to lower the risk of aspiration. Measures to treat nausea and vomiting also may lower the risk of aspiration pneumonia. Exercise and encouragement to take deep breaths may help to lessen the development of atelectasis. Prophylactic administration of levofloxacin was not successful in lessening the risk of pneumonia or other infections in the first days after stroke.⁶³⁵

Urinary tract infections are relatively common among patients with stroke. This complication is most likely associated with more seriously affected patients.⁶³³ Bacteremia or sepsis is a potential complication. Screening of the urine for evidence of infection should be performed whenever a patient develops a fever after stroke. Some patients, especially those with major impairments, are at high risk for urinary incontinence.⁶³⁶ To ease care and to avoid skin complications, some patients will need an indwelling bladder catheter to treat

incontinence or urinary retention. Whenever possible, prolonged use of an indwelling catheter should be avoided because of the attendant increased risk of urinary infections. Condom catheters are not satisfactory. Intermittent catheterization may be needed. Acidification of the urine also may lessen the risk of infection. Anticholinergic agents may help in recovery of bladder function. Although prophylactic administration of antibiotics usually is not done, the medications should be prescribed for patients with evidence of urinary tract infections.

C. Deep Vein Thrombosis and Pulmonary Embolism

Pulmonary embolism accounts for $\approx 10\%$ of deaths after stroke, and the complication may be detected in $\approx 1\%$ of patients who have had a stroke.⁶³⁷ Pulmonary emboli generally arise from venous thrombi that develop in a paralyzed lower extremity or pelvis. Besides being associated with a life-threatening pulmonary event, symptomatic deep vein thrombosis also slows recovery and rehabilitation after stroke. The risk of deep vein thrombosis is highest among immobilized and older patients with severe stroke.^{638–642}

The institution of measures to prevent deep vein thrombosis after stroke is a quality indicator for stroke centers in the United States.^{643,644} The options for lowering the risk of deep vein thrombosis include early mobilization, antithrombotic agents, and the use of external compression devices. The benefit of early mobilization is described above. Anticoagulants are given to prevent deep vein thrombosis and pulmonary embolism among seriously ill patients. Much of the support for the use of anticoagulants comes from clinical studies testing these agents in treating bedridden patients other than those with stroke.^{645,646} Meta-analysis demonstrated that these medications were effective among patients with stroke.⁶⁴⁷ Several clinical trials have demonstrated the utility of heparin and the LMW heparins in preventing deep vein thrombosis. There does not appear to be a significant difference in efficacy or safety between unfractionated heparin and the LMW heparins.^{648–660} The risk of serious bleeding complications seems to be relatively low.⁶⁵⁴ Long-term treatment usually involves the use of oral anticoagulants such as warfarin. Ridker et al⁶⁶¹ found that low-intensity warfarin therapy was effective in preventing recurrent venous thromboembolism. Ximelagatran also appears to be effective in lowering the risk of deep vein thrombosis, but this agent is not yet available in the United States. Aspirin also may be effective for patients who have contraindications to anticoagulants, although direct comparisons with anticoagulants are not available.^{662,663} Experience with the use of external compression of the veins in the lower extremities such as stockings or alternating pressure devices is limited.^{664–666} External compression may be useful for managing patients who cannot be treated with antithrombotic agents.^{654,655} Patients with pulmonary embolism from thrombi in the lower extremities and a contraindication for antithrombotic treatment may need the placement of a device to occlude the inferior vena cava.

1. Other Care

After stabilization of the patient's condition, rehabilitation, measures to prevent long-term complications, patient and family education, and family support may be started. Some patients may need treatment for depression. In addition, the patient should be evaluated to determine the most likely cause of stroke. Medical or surgical measures to prevent recurrent stroke should be initiated. Administration of antithrombotic agents (either antiplatelet agents or, in some cases, anticoagulants) before discharge is a quality-of-care indicator for stroke treatment in the United States. Measures to treat hyperlipidemia, diabetes mellitus, hypertension, and codeveloping heart disease also are important. Lifestyle changes include cessation of smoking and changes in diet. Changes in activity will reflect the patient's neurological impairments and overall health.

D. Conclusions and Recommendations

The management of patients after admission to the hospital remains a key component of overall treatment, and it is as important as the acutely administered therapies. The components of this aspect of treatment dovetail with the acute interventions to restore perfusion. In addition, these components of management can be given to the large number of patients who are not eligible for treatment with the acutely administered interventions. These therapies can improve outcomes by lessening complications and speeding recovery from stroke.

Class I Recommendations

- 1. The use of comprehensive specialized stroke care (stroke units) incorporating rehabilitation is recommended (Class I, Level of Evidence A). This recommendation is unchanged from the previous guideline.**
- 2. The use of standardized stroke care order sets is recommended to improve general management (Class I, Level of Evidence B). This recommendation was not in previous guidelines.**
- 3. Early mobilization of less severely affected patients and measures to prevent subacute complications of stroke are recommended (Class I, Level of Evidence C). This recommendation is unchanged from the previous guideline.**
- 4. Assessment of swallowing before starting eating or drinking is recommended (Class I, Level of Evidence B). This recommendation is new.**
- 5. Patients with suspected pneumonia or urinary tract infections should be treated with antibiotics (Class I, Level of Evidence B). This recommendation is similar to previous guidelines.**
- 6. Subcutaneous administration of anticoagulants is recommended for treatment of immobilized patients to prevent deep vein thrombosis (Class I, Level of Evidence A). The ideal timing for starting these medications is not known. This recommendation is unchanged from the previous guideline.**
- 7. Treatment of concomitant medical diseases is recommended (Class I, Level of Evidence C). This recommendation is unchanged from the previous guideline.**

- 8. Early institution of interventions to prevent recurrent stroke is recommended (Class I, Level of Evidence C). This recommendation is similar to previous guidelines.**

Class II Recommendations

- 1. Patients who cannot take food and fluids orally should receive nasogastric, nasoduodenal, or PEG feedings to maintain hydration and nutrition while undergoing efforts to restore swallowing (Class IIa, Level of Evidence B). The timing of the placement of a PEG is uncertain. This recommendation is new.**
- 2. Aspirin is a potential intervention to prevent deep vein thrombosis but is less effective than anticoagulants (Class IIa, Level of Evidence A). This recommendation has been strengthened.**
- 3. The use of intermittent external compression devices is recommended for treatment of patients who cannot receive anticoagulants (Class IIa, Level of Evidence B). This recommendation is unchanged from the previous guideline.**

Class III Recommendations

- 1. Nutritional supplements are not needed (Class III, Level of Evidence B). This recommendation is new.**
- 2. Prophylactic administration of antibiotics is not recommended (Class III, Level of Evidence B). This recommendation is new.**
- 3. If possible, the placement of indwelling bladder catheters should be avoided because of the associated risk of urinary tract infections (Class III, Level of Evidence C). Some patients may need prolonged catheter drainage of the bladder, and measures to lower risk of infection should be taken. This recommendation is similar to previous guidelines.**

XVI. Treatment of Acute Neurological Complications

The most important acute neurological complications of stroke are (1) swelling of the ischemic tissue causing mass effect; (2) hemorrhagic transformation of the infarction with or without mass effect; and, less commonly, (3) seizures. A recent study (worsening defined as a decreasing NIHSS score of ≥ 1 point) found that more than one third of patients deteriorated because of progressive stroke, approximately one third because of brain swelling, 11% because of recurrent cerebral ischemia, and 10% because of parenchymal hemorrhage.⁶⁶⁷

A. Ischemic Brain Swelling

Brain swelling, when associated with astrocytic ischemia, is due to a cytotoxic reaction mediated by multiple factors, including free radicals.⁶⁶⁸ Progressive clinical deterioration due to swelling from MCA occlusion is seen more often in women and in patients with additional vascular territorial infarctions on initial CT.⁶⁶⁹ Brain swelling typically occurs in patients who have had an occlusion of the stem of the MCA and appears ≈ 4 days after the onset.^{670–674} Dramatic early swelling has been described and attributed to reperfusion edema and possibly effects of rtPA. The term *malignant* has been affixed to brain swelling to delineate a group of patients with a large territorial infarct that swells within 24 hours,

causing brain herniation signs.⁶⁷⁵ The proportion of patients with this so-called malignant form is unknown, and its clinical profile is not well defined. Rapid deterioration from cerebellar infarcts with swelling is also more common and may be associated with sudden apnea from brain stem compression and cardiac arrhythmias. The overall risk of brain swelling in patients with anterior circulation ischemic stroke is low and is estimated to be 10% to 20%.^{376,377} The incidence in posterior circulation stroke is unknown. An imaging study may predict deterioration from swelling. Early CT scan hypodensity, defined as <12 hours after onset, of $>50\%$ of the MCA territory and the presence of hyperdense MCA signs were independent predictors of neurological deterioration.⁶⁷¹ In addition, patients with MCA infarction who developed a mass effect on CT scan as identified by compression of the frontal horn, shift of the septum pellucidum, and, later, shift of the pineal gland are at risk of worsening clinically and developing clinical signs of brain herniation.⁶⁷¹ Perfusion CT scan performed within 6 hours of symptom onset could determine which patient would deteriorate from swelling. Large hypoattenuation (defined as greater than two thirds of the MCA territory) on enhanced CT and large hypoperfusion on CT perfusion maps predicted development of “malignant MCA infarct” with high sensitivity of 91% and specificity of 94%.⁶⁷⁶

Very few clinical signs predict clinical deterioration. Patients with bilateral ptosis and involvement of the nondominant hemisphere may be at a higher risk. Multivariable analysis found that a history of hypertension, history of heart failure, presence of elevated white blood cell count, presence of $>50\%$ MCA hypodensity, and involvement of additional vascular territory increased the development of fatal brain edema.⁶⁷⁷ The need for early mechanical ventilation increases the risk of death.⁶⁷⁸

In patients with MCA infarctions who develop brain edema, increased intracranial pressure probably occurs late in the course, if at all.⁶⁷⁹ Therefore, aggressive management of intracranial pressure in patients with early developing cerebral edema is not an established goal. One of the principles in the management of brain edema after MCA infarction is to prevent further deterioration from tissue displacement and brain stem shift.

Similarly, management of cerebellar swelling should include a decompressive suboccipital craniotomy to remove the necrotic tissue. Initial management of brain swelling should include restriction of free water to avoid hypo-osmolar fluid that may worsen edema. Factors that could exacerbate swelling such as hypoxemia, hypercarbia, and hyperthermia should be corrected. The head of the bed can be elevated at 20° to 30° in an attempt to help venous drainage. Antihypertensive agents, particularly those that include cerebral vasodilatation, should be avoided.

The treatment of patients with raised intracranial pressure, present at a late stage, is directed toward standard measures that include hyperventilation, osmotic diuretics, drainage of cerebral fluid, or decompressive surgery.⁶⁸⁰ No clinical trials address the efficacy of any of these aggressive management strategies after stroke. No evidence indicates that hyperventilation, corticosteroids in conventional or large doses, furo-

semide, mannitol, or glycerol or other measures that reduce intracranial pressure improve outcome in patients with ischemic brain swelling.^{681–690} Mannitol is typically used at 0.25 to 0.5 g/kg IV administered over 20 minutes, lowers intracranial pressure, and can be given every 6 hours.⁶⁹¹ The usual maximal dose is 2 g/kg. The effect of mannitol in patients with ischemic brain swelling is unknown, but it is often used as a temporizing measure before patients undergo decompressive craniectomy. Despite intensive medical management, the death rate is estimated to be as high as 50% to 70%.^{465,466}

Decompressive surgery, including hemicraniectomy and durotomy with temporal lobe resection, remains the most attractive option for ischemic brain swelling.^{692–701} Timing of surgery is poorly defined, with some opting for early (within 24 hours) intervention.⁷⁰² Recent studies have found that decompressive craniectomy may have a less favorable outcome than suggested.⁷⁰³ More disability may be expected in older patients (>55 years of age) and in patients with dominant infarctions.⁷⁰⁴ Additional surgery, “strokectomy,” of parts of the frontal or temporal lobe may be needed in younger patients who fail to improve.⁷⁰⁵ The timing of decompressive hemicraniectomy and indications remain unclear. Several randomized, controlled clinical trials are under way in Europe.⁷⁰⁶ An alternative option to control brain swelling is moderate hypothermia, defined as 33°C to 34°C, with the use of noninvasive or invasive cooling devices; this strategy is unproven, but feasibility trials are under way.

Patients with cerebellar infarct often develop acute hydrocephalus. If hydrocephalus is present, drainage of cerebral fluid through an intraventricular catheter can rapidly lower intracranial pressure; however, a concern about upward herniation of cerebellar tissue remains.^{707–710} Suboccipital craniotomy is the treatment to relieve both hydrocephalus and brain stem compression caused by large cerebellar infarctions.^{703,698,710–716}

B. Hemorrhagic Transformation

Considerable information exists about the natural rate of early hemorrhagic transformation of ischemic stroke.^{717–723} Some studies suggest that almost all infarctions have some element of petechial hemorrhage. With the use of CT, one prospective study estimated that ≈5% of infarctions spontaneously developed symptomatic hemorrhagic transformations from frank hematomas.⁷²⁴ The location, size, and cause of stroke can influence the development of this complication. Further information about the influence of hemorrhagic transformation outcome in stroke is needed. Small asymptomatic petechiae are much less important than hematomas, which can be associated with neurological decline. The use of all anti-thrombotics, but especially anticoagulants and thrombolytic agents, increases the likelihood of serious hemorrhagic transformation.^{279,725–727} The early use of aspirin is also associated with a small increase in the risk of clinical detectable hemorrhage.

Management of patients with hemorrhagic infarction depends on the amount of bleeding and its symptoms and may include clot evacuation in deteriorating patients. A recent study found that hemorrhagic transformation in stroke patients was detected in one third of patients admitted to acute

rehabilitation, but functional outcome was not significantly different from that of patients who did not have hemorrhagic transformation on the first CT scan.⁷²⁸ Hemorrhagic conversion in patients with cerebellar infarct significantly increased the risk of deterioration.⁷²⁹ Recently, it has been suggested that gadolinium enhancement on T1-weighted MR images is predictive of hemorrhagic transformation, but this finding is unconfirmed.⁷³⁰

C. Seizures

The reported frequency of seizures during the first days of stroke ranges from 2% to 23% depending on study designs.^{704,731–734} The true risk of seizures appears to be toward the lower end of the estimate. Seizures are more likely to occur within 24 hours of stroke and are usually partial, with or without secondary generalization. Recurrent seizures develop in ≈20% to 80% of patients; however, recent estimates have found the rate of early postischemic stroke seizures to range from 2% to 33%. Late seizures vary from 3% to 67%.^{735,736} The risk of late seizures is higher in patients with preexisting dementia.⁷³⁷ Status epilepticus is uncommon.⁷³⁸ No data are available on the utility of prophylactic administration of anticonvulsants after stroke. Few data are available on the efficacy of anticonvulsants in the treatment of stroke patients who have experienced seizures. Thus, recommendations are based on the established management of seizures that may complicate any neurological illness.

D. Conclusions and Recommendations

Considerable research is needed on the prevention and treatment of neurological complications of acute ischemic stroke, including seizures, hemorrhagic transformation of the infarction, and brain edema. The latter, which is a leading cause of death after a major ischemic stroke, is a pressing issue. At present, neither medical nor surgical interventions have been established as effective in controlling brain edema, preventing the neurological consequences of increased intracranial pressure or herniation, or improving outcomes after stroke. Although several medical interventions are used traditionally to control edema and although surgical procedures may be a life-saving measure, it appears that earlier interventions may be associated with better clinical outcomes than waiting for the patient to have signs of profound neurological dysfunction, such as herniation. Until additional data are available, the recommendations that follow are based on general consensus or limited information.

Class I Recommendations

1. Patients with major infarctions affecting the cerebral hemisphere or cerebellum are at high risk for complicating brain edema and increased intracranial pressure. Measures to lessen the risk of edema and close monitoring of the patient for signs of neurological worsening during the first days after stroke are recommended (Class I, Level of Evidence B). This recommendation has not changed since the previous guidelines. Because many hospitals may not have neurosurgical expertise, transfer of patients at risk for malignant

brain edema to an institution that has such expertise should be considered. *This recommendation is new.*

2. Patients with acute hydrocephalus secondary to an ischemic stroke most commonly affecting the cerebellum can be treated with placement of a ventricular drain (Class I, Level of Evidence B). *This recommendation has not changed since the previous guidelines.*
3. Decompressive surgical evacuation of a space-occupying cerebellar infarction is a potentially life-saving measure, and clinical recovery may be very good (Class I, Level of Evidence B). Although data from clinical trials are not available, it is recommended for patients with major cerebellar infarction. *This recommendation has not changed since the previous guidelines.*
4. Recurrent seizures after stroke should be treated in a manner similar to other acute neurological conditions (Class I, Level of Evidence B). *This recommendation has not changed since the previous guidelines.*

Class II Recommendations

1. Although aggressive medical measures, including osmotherapy, have been recommended for treatment of deteriorating patients with malignant brain edema after large cerebral infarction, these measures are unproven (Class IIa, Level of Evidence C). Hyperventilation is a short-lived intervention. Medical measures may delay decompressive surgery. *This recommendation has not changed since the previous guidelines.*
2. Decompressive surgery for malignant edema of the cerebral hemisphere may be life-saving, but the impact of morbidity is unknown. Both the age of the patient and the side of the infarction (dominant versus non-dominant hemisphere) may affect decisions about surgery. Although the surgery may be recommended for treatment of seriously affected patients, the physician should advise the patient's family about the potential outcomes, including survival with severe disability (Class IIa, Level of Evidence B). *This recommendation has been modified.*
3. No specific recommendation is made for treatment of patients with asymptomatic hemorrhagic transformation after ischemic stroke (Class IIb, Level of Evidence C). *This recommendation is new.* Treatment of symptomatic hemorrhagic transformation is addressed in the intracerebral hemorrhage management guideline being issued contemporaneously with this statement. Measures to lessen the likelihood of hemorrhagic complications of thrombolytic agents or other inter-

ventions to restore or improve perfusion such as careful control of arterial blood pressure are recommended.

Class III Recommendations

1. Because of lack of evidence of efficacy and the potential to increase the risk of infectious complications, corticosteroids (in conventional or large doses) are not recommended for treatment of cerebral edema and increased intracranial pressure complicating ischemic stroke (Class III, Level of Evidence A). *This recommendation has not changed since the previous guidelines.*
2. Prophylactic administration of anticonvulsants to patients with stroke but who have not had seizures is not recommended (Class III, Level of Evidence C). *This recommendation has not changed since the previous guidelines.*

E. Palliative Care

Unfortunately, some patients with stroke have a fatal brain injury. These critically ill persons have profound neurological impairments such as a persistent vegetative state or evidence of unstable vital signs. Other patients with stroke have serious preexisting medical or neurological illnesses, such as dementia, that have caused severe impairments, and the new cerebrovascular event may add more disability. Despite the interventions that are described in this outline, the prognosis of such patients often is very poor. Many people would not want to survive if a devastating stroke would lead to a persistent vegetative state or other condition of devastating incapacity.

An increasing number of patients have advanced directive statements that provide instructions about emergency treatment in a situation such as a massive stroke. Physicians should honor those directives. In other circumstances, such directives may not be available, and the patient's neurological status usually precludes decision making. Occasionally, a guardian with medical power of attorney can make the decision. Otherwise, the physician should involve family members. The physician should provide clear information about the nature of the stroke, the prognosis, and the treatment options. The family should be given the opportunity to select or withhold medical interventions. In such situation, the medical care may emphasize measures to keep the patient comfortable and to support the family during the terminal aspects of the stroke.

Disclosures

Writing Group Disclosures

Writing Group Member	Employment	Research Grant	Other Research Support	Speakers' Bureau/Honoraria	Ownership Interest	Consultant/Advisory Board	Other
Harold P. Adams, Jr	University of Iowa Carver College of Medicine	Boehringer Ingelheim†; Centocor (Johnson & Johnson)†; Eli Lilly†; Merck†; NMT Medical†; Sanofi†; Bristol-Myers Squibb†; GlaxoSmithKline*	AstraZeneca†; Merck*	Bayer*	None	American Board of Psychiatry and Neurology†	None
Gregory del Zoppo	Scripps Research Institute	None	None	None	None	Boehringer Ingelheim (overseas product for fibrinolysis)*	None
Mark J. Alberts	Northwestern University Medical School	Boehringer Ingelheim*; Bristol-Myers Squibb*; Sanofi-Synthelabo*	None	AstraZeneca*; Boehringer Ingelheim*; Bristol-Myers Squibb†; Sanofi-Synthelabo†	None	AstraZeneca*; Boehringer Ingelheim*; Bristol-Myers Squibb†; Sanofi-Synthelabo†	None
Deepak L. Bhatt	Cleveland Clinic Foundation	Bristol-Myers Squibb†; Eisai†; Ethicon†; Sanofi-Aventis†; The Medicines Company†	None	AstraZeneca*; Bristol-Myers Squibb*; Cardax*; Centocor*; Daiichi-Sankyo*; Eisai*; Eli Lilly*; GlaxoSmithKline*; Millenium*; Otsuka*; ParinGenix*; PDL*; Sanofi-Aventis*; Schering-Plough*; The Medicines Company*; tns Healthcare*	None	AstraZeneca*; Bristol-Myers Squibb*; Cardax*; Centocor*; Daiichi-Sankyo*; Eisai*; Eli Lilly*; GlaxoSmithKline*; Millenium*; Otsuka*; ParinGenix*; PDL*; Sanofi-Aventis*; Schering-Plough*; The Medicines Company*; tns Healthcare*	Provided expert testimony regarding antithrombotic therapy
Lawrence Brass	Yale University	Bristol-Myers Squibb*; Sanofi-Synthelabo*	None	Bristol-Myers Squibb*; Sanofi-Synthelabo*; Solvay Pharmaceuticals*; Wyeth*	None	AstraZeneca*; Bristol-Myers Squibb*; Merck*; ONO Pharmaceuticals*; Sanofi-Synthelabo*; Solvay Pharmaceuticals*; Wyeth*	None
Anthony Furlan	Cleveland Clinic Foundation	Bristol-Myers Squibb†; Sanofi†; Possis*	None	None	None	Paion*	None
Robert L. Grubb	Washington University	None	None	None	None	None	None
Randall T. Higashida	University of California at San Francisco Medical Center	Concentric Medical*	None	None	None	Concentric Medical*	None
Edward C. Jauch	University of Cincinnati College of Medicine	Biosite*	None	Boehringer Ingelheim*	None	AstraZeneca*; Biosite*; Genentech*; Johnson & Johnson*; Novo Nordisk*	None
Chelsea Kidwell	Washington Hospital Center Stroke Center	None	None	None	None	Bristol-Myers Squibb*; GlaxoSmithKline*; Millenium Pharmaceuticals*; S. Daichi Arbio Pharmaceuticals*; Sanofi*	None
Patrick D. Lyden	University of California at San Diego Stroke Center	AstraZeneca*; Bayer*; Merck*; Yamanouchi*	None	None	None	Merck*; Mitsubishi*	None
Lewis B. Morgenstern	University of Michigan	None	None	AstraZeneca*; Novo Nordisk*	None	Merck*	None
Adnan I. Qureshi	University of Minnesota, Minneapolis	Centocor Therapeutic†; ESP Pharma*	None	Bristol-Myers Squibb*; Sanofi Pharmaceuticals*	None	Pfizer*; Protein Design Laboratories*	None
Robert H. Rosenwasser	Thomas Jefferson University	None	None	None	None	None	None
Phillip A. Scott	University of Michigan	None	None	None	None	AstraZeneca*	None
Eelco F.M. Wijdicks	Mayo Clinic	None	None	None	None	None	None

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire that all members of the writing group are required to complete and submit. A relationship is considered to be "Significant" if (1) the person receives \$10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (2) the person owns 5% or more of the voting stock or share of the entity, or owns \$10 000 or more of the fair market value of the entity. A relationship is considered to be "Modest" if it is less than "Significant" under the preceding definition.

*Modest.
†Significant

Reviewer Disclosures

Reviewer	Employment	Research Grant	Other Research Support	Speakers' Bureau/Honoraria	Expert Witness	Ownership Interest	Consultant/Advisory Board	Other
S. Claiborne Johnston	University of California at San Francisco	Sanofi Aventis/Bristol-Myers Squibb†	None	None	None	None	Boehringer Ingelheim for Secondary Stroke Prevention Trials†	None
Ralph Sacco	Columbia University	NINDS grants for stroke research†	None	None	None	None	None	None
Stanley Tuhrim	Mount Sinai Medical Center	None	None	None	None	None	None	None

This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire that all reviewers are required to complete and submit. A relationship is considered to be "Significant" if (1) the person receives \$10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (2) the person owns 5% or more of the voting stock or share of the entity, or owns \$10 000 or more of the fair market value of the entity. A relationship is considered to be "Modest" if it is less than "Significant" under the preceding definition.

†Significant.

References

- Adams HP Jr, Brott TG, Crowell RM, Furlan AJ, Gomez CR, Grotta J, Helgason CM, Marler JR, Woolson RF, Zivin JA. Guidelines for the management of patients with acute ischemic stroke: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. *Circulation*. 1994;90:1588–1601.
- Adams HP Jr, Adams RJ, Brott T, del Zoppo GJ, Furlan A, Goldstein LB, Grubb RL, Higashida R, Kidwell C, Kwiatkowski TG, Marler JR, Hademenos GJ. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. *Stroke*. 2003;34:1056–1083.
- Adams H, Adams R, Del Zoppo G, Goldstein LB. Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update: a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. *Stroke*. 2005;36:916–923.
- Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Schwamm LH, Tomsick T. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention. *Stroke*. 2006;37:577–617.
- Williams JE, Rosamond WD, Morris DL. Stroke symptom attribution and time to emergency department arrival: the delay in accessing stroke healthcare study. *Acad Emerg Med*. 2000;7:93–96.
- Wein TH, Staub L, Felberg R, Hickenbottom SL, Chan W, Grotta JC, Demchuk AM, Groff J, Bartholomew LK, Morgenstern LB. Activation of emergency medical services for acute stroke in a nonurban population: the T.L.L. Temple Foundation Stroke Project. *Stroke*. 2000;31:1925–1928.
- Handschu R, Poppe R, Rauss J, Neundorfer B, Erguth F. Emergency calls in acute stroke. *Stroke*. 2003;34:1005–1009.
- Rosnagel K, Jungehulsing GJ, Nolte CH, Muller-Nordhorn J, Roll S, Wegscheider K, Villringer A, Willich SN. Out-of-hospital delays in patients with acute stroke. *Ann Emerg Med*. 2004;44:476–483.
- Schroeder EB, Rosamond WD, Morris DL, Evenson KR, Hinn AR. Determinants of use of emergency medical services in a population with stroke symptoms: the Second Delay in Accessing Stroke Healthcare (DASH II) Study. *Stroke*. 2000;31:2591–2596.
- Morris DL, Rosamond WD, Hinn AR, Gorton RA. Time delays in accessing stroke care in the emergency department. *Acad Emerg Med*. 1999;6:218–223.
- Porteous GH, Corry MD, Smith WS. Emergency medical services dispatcher identification of stroke and transient ischemic attack. *Prehosp Emerg Care*. 1999;3:211–216.
- Morris DL, Rosamond W, Madden K, Schultz C, Hamilton S. Pre-hospital and emergency department delays after acute stroke: the Genentech Stroke Presentation Survey. *Stroke*. 2000;31:2585–2590.
- Lacy CR, Suh DC, Bueno M, Kostis JB. Delay in presentation and evaluation for acute stroke: Stroke Time Registry for Outcomes Knowledge and Epidemiology (S.T.R.O.K.E.). *Stroke*. 2001;32:63–69.
- Arora S, Broderick JP, Frankel M, Frankel M, Heinrich JP, Hickenbottom S, Karp H, LaBresh KA, Malarcher A, Mensah G, Moomaw CJ, Schwamm L, Weiss P; Paul Coverdell Prototype Registries Writing Group. Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry. *Stroke*. 2005;36:1232–1240.
- Zweifler RM, Mendizabal JE, Cunningham S, Shah AK, Rothrock JF. Hospital presentation after stroke in a community sample: the Mobile Stroke Project. *South Med J*. 2002;95:1263–1268.
- California Acute Stroke Pilot Registry (CASPR) Investigators. Prioritizing interventions to improve rates of thrombolysis for ischemic stroke. *Neurology*. 2005;64:654–659.
- Williams LS, Bruno A, Rouch D, Marriott DJ. Stroke patients' knowledge of stroke: influence on time to presentation. *Stroke*. 1997;28:912–915.
- Barsan WG, Brott TG, Broderick JP, Haley EC, Levy DE, Marler JR. Time of hospital presentation in patients with acute stroke. *Arch Intern Med*. 1993;153:2558–2561.
- Wester P, Radberg J, Lundgren B, Peltonen M; Seek-Medical-Attention-in-Time Study Group. Factors associated with delayed admission to hospital and in-hospital delays in acute stroke and TIA: a prospective, multicenter study. *Stroke*. 1999;30:40–48.
- Menon SC, Pandey DK, Morgenstern LB. Critical factors determining access to acute stroke care. *Neurology*. 1998;51:427–432.
- Morgenstern LB, Bartholomew LK, Grotta JC, Staub L, King M, Chan W. Sustained benefit of a community and professional intervention to increase acute stroke therapy. *Arch Intern Med*. 2003;163:2198–2202.
- Morgenstern LB, Staub L, Chan W, Wein TH, Bartholomew LK, King M, Felberg RA, Burgin WS, Groff J, Hickenbottom SL, Saldin K, Demchuk AM, Kalra A, Dhingra A, Grotta JC. Improving delivery of acute stroke therapy: the TLL Temple Foundation Stroke Project. *Stroke*. 2002;33:160–166.
- Pepe PE, Zachariah BS, Sayre MR, Floccare D; Chain of Recovery Writing Group. Ensuring the chain of recovery for stroke in your community. *Acad Emerg Med*. 1998;5:352–358.
- Kothari R, Barsan W, Brott T, Broderick J, Ashbrock S. Frequency and accuracy of prehospital diagnosis of acute stroke. *Stroke*. 1995;26:937–941.
- 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2005;112(suppl 1):IV-1–IV-203.
- Kidwell CS, Starkman S, Eckstein M, Weems K, Saver JL. Identifying stroke in the field: prospective validation of the Los Angeles Prehospital Stroke Screen (LAPSS). *Stroke*. 2000;31:71–76.
- Kothari RU, Pancioli A, Liu T, Brott T, Broderick J. Cincinnati Pre-hospital Stroke Scale: reproducibility and validity. *Ann Emerg Med*. 1999;33:373–378.
- Suyama J, Crocco T. Prehospital care of the stroke patient. *Emerg Med Clin North Am*. 2002;20:537–552.

29. Abarbanell NR. Is prehospital blood glucose measurement necessary in suspected cerebrovascular accident patients? *Am J Emerg Med.* 2005;23:823–827.
30. Virkkunen I, Yli-Hankala A, Silfvast T. Induction of therapeutic hypothermia after cardiac arrest in prehospital patients using ice-cold Ringer's solution: a pilot study. *Resuscitation.* 2004;62:299–302.
31. Saver JL, Kidwell C, Eckstein M, Starkman S; FAST-MAG Pilot Trial Investigators. Prehospital neuroprotective therapy for acute stroke: results of the Field Administration of Stroke Therapy-Magnesium (FAST-MAG) pilot trial. *Stroke.* 2004;35:e106–e108.
32. Crocco T, Gullett T, Davis SM, Flores N, Sauerbeck L, Jauch E, Threlkeld B, Pio B, Ottaway M, Pancioli A, Chenier T. Feasibility of neuroprotective agent administration by prehospital personnel in an urban setting. *Stroke.* 2003;34:1918–1922.
33. Silliman SL, Quinn B, Huggett V, Merino JG. Use of a field-to-stroke center helicopter transport program to extend thrombolytic therapy to rural residents. *Stroke.* 2003;34:729–733.
34. Chalela JA, Kasner SE, Jauch EC, Pancioli AM. Safety of air medical transportation after tissue plasminogen activator administration in acute ischemic stroke. *Stroke.* 1999;30:2366–2368.
35. Conroy MB, Rodriguez SU, Kimmel SE, Kasner SE. Helicopter transfer offers a potential benefit to patients with acute stroke. *Stroke.* 1999;30:2580–2584.
36. Silbergleit R, Burney RE, Draper J, Nelson K. Outcome of patients after air medical transport for management of nontraumatic acute intracranial bleeding. *Prehospital Disaster Med.* 1994;9:252–256.
37. Silbergleit R, Scott PA, Lowell MJ, Silbergleit R. Cost-effectiveness of helicopter transport of stroke patients for thrombolysis. *Acad Emerg Med.* 2003;10:966–972.
38. Rymer MM, Thurtchley DE; Stroke Team at the Mid America Brain and Stroke Institute. Organizing regional networks to increase acute stroke intervention. *Neurol Res.* 2005;27(suppl 1):S9–S16.
39. Hess DC, Wang S, Hamilton W, Lee S, Pardue C, Waller JL, Gross H, Nichols F, Hall C, Adams RJ. REACH: clinical feasibility of a rural telestroke network. *Stroke.* 2005;36:2018–2020.
40. Audebert HJ, Kukla C, Clarmann von Claranau S, Kuhn J, Vatankhah B, Schenkel J, Ickenstein GW, Haberl RL, Horn M; TEMPiS Group. Telemedicine for safe and extended use of thrombolysis in stroke: the Telemedic Pilot Project for Integrative Stroke Care (TEMPiS) in Bavaria. *Stroke.* 2005;36:287–291.
41. Fisher M. Developing and implementing future stroke therapies: the potential of telemedicine. *Ann Neurol.* 2005;58:666–671.
42. Shafqat S, Kvedar JC, Guanci MM, Chang Y, Schwamm LH. Role for telemedicine in acute stroke: feasibility and reliability of remote administration of the NIH Stroke Scale. *Stroke.* 1999;30:2141–2145.
43. Handschu R, Littmann R, Reulbach U, Gaul C, Heckmann JG, Neundorfer B, Scibor M. Telemedicine in emergency evaluation of acute stroke: interrater agreement in remote video examination with a novel multimedia system. *Stroke.* 2003;34:2842–2846.
44. Alberts MJ, Hademenos G, Latchaw RE, Jagoda A, Marler JR, Mayberg MR, Starke RD, Todd HW, Viste KM, Girgus M, Shephard T, Emr M, Shwayder P, Walker MD; Brain Attack Coalition. Recommendations for the establishment of primary stroke centers. *JAMA.* 2000;283:3102–3109.
45. Alberts MJ, Latchaw RE, Selman WR, Shephard T, Hadley MN, Brass LM, Koroshetz W, Marler JR, Booss J, Zorowitz RD, Croft JB, Magnis E, Mulligan D, Jagoda A, O'Connor R, Cawley CM, Connors JJ, Rose-DeRenzy JA, Emr M, Warren M, Walker MD; Brain Attack Coalition. Recommendations for comprehensive stroke centers: a consensus statement from the Brain Attack Coalition. *Stroke.* 2005;36:1597–1616.
46. Lattimore SU, Chalela J, Davis L, DeGraba T, Ezzeddine M, Haymore J, Nyquist P, Baird AE, Hallenbeck J, Warach S; NINDS Suburban Hospital Stroke Center. Impact of establishing a primary stroke center at a community hospital on the use of thrombolytic therapy: the NINDS Suburban Hospital Stroke Center experience. *Stroke.* 2003;34:e55–e57.
47. Douglas VC, Tong DC, Gillum LA, Zhao S, Brass LM, Dostal J, Johnston SC. Do the Brain Attack Coalition's criteria for stroke centers improve care for ischemic stroke? *Neurology.* 2005;64:422–427.
48. Wojner-Alexandrov AW, Alexandrov AV, Rodriguez D, Persse D, Grotta JC. Houston Paramedic and Emergency Stroke Treatment and Outcomes Study (HoPSTO). *Stroke.* 2005;36:1512–1518.
49. Gropen TI, Gagliano PJ, Blake CA, Blake CA, Sacco RL, Kwiatkowski T, Richmond NJ, Leifer D, Libman R, Azhar S, Daley MB; NYSDOH Stroke Center Designation Project Workgroup. Quality improvement in acute stroke: the New York State Stroke Center Designation Project. *Neurology.* 2006;67:88–93.
50. Audebert HJ, Schenkel J, Heuschmann PU, Bogdahn U, Haberl RL; Telemedic Pilot Project for Integrative Stroke Care Group. Effects of the implementation of a telemedical stroke network: the Telemedic Pilot Project for Integrative Stroke Care (TEMPiS) in Bavaria, Germany. *Lancet Neurol.* 2006;5:742–748.
51. Birbeck GL, Zingmond DS, Cui X, Vickrey BG. Multispecialty stroke services in California hospitals are associated with reduced mortality. *Neurology.* 2006;66:1527–1532.
52. Rymer MM, Thurtchley D, Summers D; America Brain and Stroke Institute Stroke Team. Expanded modes of tissue plasminogen activator delivery in a comprehensive stroke center increases regional acute stroke interventions. *Stroke.* 2003;34:e58–e60.
53. Frey JL, Jahnke HK, Goslar PW, Partovi S, Flaster MS. tPA by telephone: extending the benefits of a comprehensive stroke center. *Neurology.* 2005;64:154–156.
54. Gillum LA, Johnston SC. Characteristics of academic medical centers and ischemic stroke outcomes. *Stroke.* 2001;32:2137–2142.
55. Dion JE. Management of ischemic stroke in the next decade: stroke centers of excellence. *J Vasc Interv Radiol.* 2004;5(pt 2):S133–S141.
56. Silverman IE, Beland DK, Bohannon RW, Ohki SK, Spiegel GR. Expanding the range of therapies for acute ischemic stroke: the early experience of the Regional Stroke Center at Hartford Hospital. *Conn Med.* 2004;68:419–429.
57. Adams R, Acker J, Alberts M, Andrews L, Atkinson R, Fenelon K, Furlan A, Girgus M, Horton K, Hughes R, Koroshetz W, Latchaw R, Magnis E, Mayberg M, Pancioli A, Robertson RM, Shephard T, Smith R, Smith SC Jr, Smith S, Stranne SK, Kenton EJ 3rd, Bashe G, Chavez A, Goldstein L, Hodosh R, Keitel C, Kelly-Hayes M, Leonard A, Morgenstern L, Wood JO; Advisory Working Group on Stroke Center Identification Options of the American Stroke Association. Recommendations for improving the quality of care through stroke centers and systems: an examination of stroke center identification options: multi-disciplinary consensus recommendations from the Advisory Working Group on Stroke Center Identification Options of the American Stroke Association. *Stroke.* 2002;33:e1–e7.
58. Kidwell CS, Shephard T, Tonn S, Lawyer B, Murdock M, Koroshetz W, Alberts M, Hademenos GJ, Saver JL. Establishment of primary stroke centers: a survey of physician attitudes and hospital resources. *Neurology.* 2003;60:1452–1456.
59. Schwamm LH, Pancioli A, Acker JE 3rd, Goldstein LB, Zorowitz RD, Shephard TJ, Moyer P, Gorman M, Johnston SC, Duncan PW, Gorelick P, Frank J, Stranne SK, Smith R, Federspiel W, Horton KB, Magnis E, Adams RJ; American Stroke Association's Task Force on the Development of Stroke Systems. Recommendations for the establishment of stroke systems of care: recommendations from the American Stroke Association's Task Force on the Development of Stroke Systems. *Stroke.* 2005;36:690–703.
60. Marler JR, Tilley BC, Lu M, Brott TG, Lyden PC, Grotta JC, Broderick JP, Levine SR, Frankel MP, Horowitz SH, Haley EC Jr, Lewandowski CA, Kwiatkowski TP. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. *Neurology.* 2000;55:1649–1655.
61. Marler JR, Jones PW, Emr M. Proceedings of a national symposium on rapid identification and treatment of acute stroke. Washington, DC; December 12–13, 1996.
62. Asimos AW, Norton HJ, Price MF, Cheek WM. Therapeutic yield and outcomes of a community teaching hospital code stroke protocol. *Acad Emerg Med.* 2004;11:361–370.
63. Belvis R, Cocho D, Marti-Fabregas J, Pagonabarraga J, Aleu A, Garcia-Bargo MD, Pons J, Coma E, Garcia-Alfranca F, Jimenez-Fabrega X, Marti-Vilalta JL. Benefits of a prehospital stroke code system: feasibility and efficacy in the first year of clinical practice in Barcelona, Spain. *Cerebrovasc Dis.* 2005;19:96–101.
64. Bray JE, Martin J, Cooper G, Barger B, Bernard S, Bladin C. An interventional study to improve paramedic diagnosis of stroke. *Prehosp Emerg Care.* 2005;9:297–302.
65. Kidwell CS, Alger JR, Di Salle F, Starkman S, Villablanca P, Bentson J, Saver JL. Diffusion MRI in patients with transient ischemic attacks. *Stroke.* 1999;30:1174–1180.
66. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. *N Engl J Med.* 1995;333:1581–1587.

67. Nor AM, Davis J, Sen B, Shipsey D, Louw SJ, Dyker AG, Davis M, Ford GA. The Recognition of Stroke in the Emergency Room (ROSIER) scale: development and validation of a stroke recognition instrument. *Lancet Neurol*. 2005;4:727-734.
68. Goldstein LB, Samsa GP. Reliability of the National Institutes of Health Stroke Scale: extension to non-neurologists in the context of a clinical trial. *Stroke*. 1997;28:307-310.
69. Cote R, Hachinski VC, Shurvell BL, Norris JW, Wolfson C. The Canadian Neurological Scale: a preliminary study in acute stroke. *Stroke*. 1986;17:731-737.
70. Krieger DW. Should a hospital without a neurologist use t-PA to treat stroke? *Cleve Clin J Med*. 1999;66:585-586.
71. Frankel MR, Morgenstern LB, Kwiatkowski T, Lu M, Tilley BC, Broderick JP, Libman R, Levine SR, Brott T. Predicting prognosis after stroke: a placebo group analysis from the National Institute of Neurological Disorders and Stroke rt-PA Stroke Trial. *Neurology*. 2000;55:952-959.
72. Lewandowski CA, Frankel M, Tomsick TA, Broderick J, Frey J, Clark W, Starkman S, Grotta J, Spilker J, Khoury J, Brott T. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. *Stroke*. 1999;30:2598-2605.
73. Kothari RU, Brott T, Broderick JP, Hamilton CA. Emergency physicians: accuracy in the diagnosis of stroke. *Stroke*. 1995;26:2238-2241.
74. Morgenstern LB, Lisabeth LD, Moccozi AC, Smith MA, Longwell PJ, McFarling DA, Risser JM. A population-based study of acute stroke and TIA diagnosis. *Neurology*. 2004;62:895-900.
75. Goldstein LB, Simel DL. Is this patient having a stroke? *JAMA*. 2005;293:2391-2402.
76. Christensen H, Fogh Christensen A, Boysen G. Abnormalities on ECG and telemetry predict stroke outcome at 3 months. *J Neurol Sci*. 2005;234:99-103.
77. Oppenheimer SM, Hachinski VC. The cardiac consequences of stroke. *Neurol Clin*. 1992;10:167-176.
78. Oppenheimer SM. Neurogenic cardiac effects of cerebrovascular disease. *Curr Opin Neurol*. 1994;7:20-24.
79. Dimant J, Grob D. Electrocardiographic changes and myocardial damage in patients with acute cerebrovascular accidents. *Stroke*. 1977;8:448-455.
80. Norris JW, Froggatt GM, Hachinski VC. Cardiac arrhythmias in acute stroke. *Stroke*. 1978;9:392-396.
81. Mikolich JR, Jacobs WC, Fletcher GF. Cardiac arrhythmias in patients with acute cerebrovascular accidents. *JAMA*. 1981;246:1314-1317.
82. Vingerhoets F, Bogousslavsky J, Regli F, Van Melle G. Atrial fibrillation after acute stroke. *Stroke*. 1993;24:26-30.
83. Sagar G, Riley P, Vohrah A. Is admission chest radiography of any clinical value in acute stroke patients? *Clin Radiol*. 1996;51:499-502.
84. Bladin CF, Alexandrov AV, Bellavance A, Bornstein N, Chambers B, Cote R, Lebrun L, Pirisi A, Norris JW. Seizures after stroke: a prospective multicenter study. *Arch Neurol*. 2000;57:1617-1622.
85. Kidwell CS, Villablanca JP, Saver JL. Advances in neuroimaging of acute stroke. *Curr Atheroscler Rep*. 2000;2:126-135.
86. Kang DW, Chalela JA, Dunn W, Warach S; NIH-Suburban Stroke Center Investigators. MRI screening before standard tissue plasminogen activator therapy is feasible and safe. *Stroke*. 2005;36:1939-1943.
87. Hjort N, Butcher K, Davis SM, Kidwell CS, Koroshetz WJ, Rother J, Schellinger PD, Warach S, Ostergaard L; UCLA Thrombolysis Investigators. Magnetic resonance imaging criteria for thrombolysis in acute cerebral infarct. *Stroke*. 2005;36:388-397.
88. Kidwell CS, Chalela JA, Saver JL, Starkman S, Hill MD, Demchuk AM, Butman JA, Patronas N, Alger JR, Latour LL, Luby ML, Baird AE, Leary MC, Tremwel M, Ovbiagele B, Fredieu A, Suzuki S, Villablanca JP, Davis S, Dunn B, Todd JW, Ezzeddine MA, Haymore J, Lynch JK, Davis L, Warach S. Comparison of MRI and CT for detection of acute intracerebral hemorrhage. *JAMA*. 2004;292:1823-1830.
89. Rother J, Schellinger PD, Gass A, Siebler M, Villringer A, Fiebach JB, Fiehler J, Jansen O, Kucinski T, Schoder V, Szabo K, Junge-Hulsing GJ, Hennerici M, Zeumer H, Sartor K, Weiller C, Hacke W; Kompetenznetzwerk Schlaganfall Study Group. Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke <6 hours. *Stroke*. 2002;33:2438-2445.
90. Schellinger PD, Jansen O, Fiebach JB, Pohlers O, Ryssel H, Heiland S, Steiner T, Hacke W, Sartor K. Feasibility and practicality of MR imaging of stroke in the management of hyperacute cerebral ischemia. *AJNR Am J Neuroradiol*. 2000;21:1184-1189.
91. Keir SL, Wardlaw JM. Systematic review of diffusion and perfusion imaging in acute ischemic stroke. *Stroke*. 2000;31:2723-2731.
92. Zivin JA. Perfusion-weighted imaging/diffusion-weighted imaging mismatch on MRI can now be used to select patients for recombinant tissue plasminogen activator beyond 3 hours: con. *Stroke*. 2005;36:1105-1106.
93. Powers WJ. Testing a test: a report card for DWI in acute stroke. *Neurology*. 2000;54:1549-1551.
94. Adams HP Jr, Brott TG, Furlan AJ, Gomez CR, Grotta J, Helgason CM, Kwiatkowski T, Lyden PD, Marler JR, Torner J, Feinberg W, Mayberg M, Thies W. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke: a statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. *Circulation*. 1996;94:1167-1174.
95. Mullins ME, Schaefer PW, Sorensen AG, Halpern EF, Ay H, He J, Koroshetz WJ, Gonzalez RG. CT and conventional and diffusion-weighted MR imaging in acute stroke: study in 691 patients at presentation to the emergency department. *Radiology*. 2002;224:353-360.
96. Moulin T, Cattin F, Crepin-Leblond T, Halpern EF, Ay H, He J, Koroshetz WJ, Gonzalez RG. Early CT signs in acute middle cerebral artery infarction: predictive value for subsequent infarct locations and outcome. *Neurology*. 1996;47:366-375.
97. von Kummer R, Nolte PN, Schnitger H, Halpern EF, Ay H, He J, Koroshetz WJ, Gonzalez RG. Detectability of cerebral hemisphere ischaemic infarcts by CT within 6 h of stroke. *Neuroradiology*. 1996;38:31-33.
98. von Kummer R, Allen KL, Holle R, Bozzao L, Bastianello S, Manelfe C, Bluhmki E, Ringleb P, Meier DH, Hacke W. Acute stroke: usefulness of early CT findings before thrombolytic therapy. *Radiology*. 1997;205:327-333.
99. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). *JAMA*. 1995;274:1017-1025.
100. Patel SC, Levine SR, Tilley BC, Grotta JC, Lu M, Frankel M, Haley EC Jr, Brott TG, Broderick JP, Horowitz S, Lyden PD, Lewandowski CA, Marler JR, Welch KM; National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. *JAMA*. 2001;286:2830-2838.
101. Larrue V, von Kummer R, del Zoppo G, Bluhmki E. Hemorrhagic transformation in acute ischemic stroke: potential contributing factors in the European Cooperative Acute Stroke Study. *Stroke*. 1997;28:957-960.
102. Schriger DL, Kalafut M, Starkman S, Krueger M, Saver JL. Cranial computed tomography interpretation in acute stroke: physician accuracy in determining eligibility for thrombolytic therapy. *JAMA*. 1998;279:1293-1297.
103. Marks MP, Holmgren EB, Fox AJ, Patel S, von Kummer R, Froehlich J. Evaluation of early computed tomographic findings in acute ischemic stroke. *Stroke*. 1999;30:389-392.
104. Wardlaw JM, Dorman PJ, Lewis SC, Patel S, von Kummer R, Froehlich J. Can stroke physicians and neuroradiologists identify signs of early cerebral infarction on CT? *J Neurol Neurosurg Psychiatry*. 1999;67:651-653.
105. Grotta JC, Chiu D, Lu M, Patel S, Levine SR, Tilley BC, Brott TG, Haley EC Jr, Lyden PD, Kothari R, Frankel M, Lewandowski CA, Libman R, Kwiatkowski T, Broderick JP, Marler JR, Corrigan J, Huff S, Mitsias P, Talati S, Tanne D. Agreement and variability in the interpretation of early CT changes in stroke patients qualifying for intravenous rtPA therapy. *Stroke*. 1999;30:1528-1533.
106. Kalafut MA, Schriger DL, Saver JL, Starkman S. Detection of early CT signs of >1/3 middle cerebral artery infarctions: interrater reliability and sensitivity of CT interpretation by physicians involved in acute stroke care. *Stroke*. 2000;31:1667-1671.
107. Barber PA, Demchuk AM, Zhang J, Buchan AM; ASPECTS Study Group. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy: Alberta Stroke Programme Early CT Score. *Lancet*. 2000;355:1670-1674.
108. Demchuk AM, Hill MD, Barber PA, Silver B, Patel SC, Levine SR; NINDS rtPA Stroke Study Group, NIH. Importance of early ischemic

- computed tomography changes using ASPECTS in NINDS rtPA Stroke Study. *Stroke*. 2005;36:2110–2115.
109. Wardlaw JM, Mielke O. Early signs of brain infarction at CT: observer reliability and outcome after thrombolytic treatment—systematic review. *Radiology*. 2005;235:444–453.
 110. Ezzeddine MA, Lev MH, McDonald CT, Rordorf G, Oliveira-Filho J, Aksoy FG, Farkas J, Segal AZ, Schwamm LH, Gonzalez RG, Koroshetz WJ. CT angiography with whole brain perfused blood volume imaging: added clinical value in the assessment of acute stroke. *Stroke*. 2002;33:959–966.
 111. Kloska SP, Nabavi DG, Gaus C, Nam EM, Klotz E, Ringelstein EB, Heindel W. Acute stroke assessment with CT: do we need multimodal evaluation? *Radiology*. 2004;233:79–86.
 112. Wintermark M, Fischbein NJ, Smith WS, Ko NU, Quist M, Dillon WP. Accuracy of dynamic perfusion CT with deconvolution in detecting acute hemispheric stroke. *AJNR Am J Neuroradiol*. 2005;26:104–112.
 113. Schramm P, Schellinger PD, Klotz E, Kallenberg K, Fiebach JB, Kulkens S, Heiland S, Knauth M, Sartor K. Comparison of perfusion computed tomography and computed tomography angiography source images with perfusion-weighted imaging and diffusion-weighted imaging in patients with acute stroke of less than 6 hours' duration. *Stroke*. 2004;35:1652–1658.
 114. Klotz E, Konig M. Perfusion measurements of the brain: using dynamic CT for the quantitative assessment of cerebral ischemia in acute stroke. *Eur J Radiol*. 1999;30:170–184.
 115. Wintermark M, Reichhart M, Thiran JP, Maeder P, Chalaron M, Schnyder P, Bogousslavsky J, Meuli R. Prognostic accuracy of cerebral blood flow measurement by perfusion computed tomography, at the time of emergency room admission, in acute stroke patients. *Ann Neurol*. 2002;51:417–432.
 116. Lev MH, Farkas J, Rodriguez VR, Schwamm LH, Hunter GJ, Putman CM, Rordorf GA, Buonanno FS, Budzik R, Koroshetz WJ, Gonzalez RG. CT angiography in the rapid triage of patients with hyperacute stroke to intraarterial thrombolysis: accuracy in the detection of large vessel thrombus. *J Comput Assist Tomogr*. 2001;25:520–528.
 117. Esteban JM, Cervera V. Perfusion CT and angio CT in the assessment of acute stroke. *Neuroradiology*. 2004;46:705–715.
 118. Wildermuth S, Knauth M, Brandt T, Winter R, Sartor K, Hacke W. Role of CT angiography in patient selection for thrombolytic therapy in acute hemispheric stroke. *Stroke*. 1998;29:935–938.
 119. Shrier DA, Tanaka H, Numaguchi Y, Konno S, Patel U, Shibata D. CT angiography in the evaluation of acute stroke. *AJNR Am J Neuroradiol*. 1997;18:1011–1020.
 120. Verro P, Tanenbaum LN, Borden NM, Sen S, Eshkar N. CT angiography in acute ischemic stroke: preliminary results. *Stroke*. 2002;33:276–278.
 121. Mohr JP, Biller J, Hilal SK, Yuh WT, Tatemichi TK, Hedges S, Tali E, Nguyen H, Mun I, Adams HP Jr, et al. Magnetic resonance versus computed tomographic imaging in acute stroke. *Stroke*. 1995;26:807–812.
 122. Warach S, Gaa J, Siewert B, Wielopolski P, Edelman RR. Acute human stroke studied by whole brain echo planar diffusion-weighted magnetic resonance imaging. *Ann Neurol*. 1995;37:231–241.
 123. Warach S, Chien D, Li W, Ronthal M, Edelman RR. Fast magnetic resonance diffusion-weighted imaging of acute human stroke [published correction appears in *Neurology*. 1992;1742:2192]. *Neurology*. 1992;42:1717–1723.
 124. Lutsep HL, Albers GW, DeCrespigny A, Kamat GN, Marks MP, Moseley ME. Clinical utility of diffusion-weighted magnetic resonance imaging in the assessment of ischemic stroke. *Ann Neurol*. 1997;41:574–580.
 125. Barber PA, Darby DG, Desmond PM, Yang Q, Gerraty RP, Jolley D, Donnan GA, Tress BM, Davis SM. Prediction of stroke outcome with echoplanar perfusion- and diffusion-weighted MRI. *Neurology*. 1998;51:418–426.
 126. Lee LJ, Kidwell CS, Alger J, Starkman S, Saver JL. Impact on stroke subtype diagnosis of early diffusion-weighted magnetic resonance imaging and magnetic resonance angiography. *Stroke*. 2000;31:1081–1089.
 127. Lovblad KO, Laubach HJ, Baird AE, Curtin F, Schlaug G, Edelman RR, Warach S. Clinical experience with diffusion-weighted MR in patients with acute stroke. *AJNR Am J Neuroradiol*. 1998;19:1061–1066.
 128. Ay H, Buonanno FS, Rordorf G, Schaefer PW, Schwamm LH, Wu O, Gonzalez RG, Yamada K, Sorensen GA, Koroshetz WJ. Normal diffusion-weighted MRI during stroke-like deficits. *Neurology*. 1999;52:1784–1792.
 129. Barber PA, Darby DG, Desmond PM, Gerraty RP, Yang Q, Li T, Jolley D, Donnan GA, Tress BM, Davis SM. Identification of major ischemic change: diffusion-weighted imaging versus computed tomography. *Stroke*. 1999;30:2059–2065.
 130. van Everdingen KJ, van der Grond J, Kappelle LJ, Ramos LM, Mali WP. Diffusion-weighted magnetic resonance imaging in acute stroke. *Stroke*. 1998;29:1783–1790.
 131. Gonzalez RG, Schaefer PW, Buonanno FS, Schwamm LH, Budzik RF, Rordorf G, Wang B, Sorensen AG, Koroshetz WJ. Diffusion-weighted MR imaging: diagnostic accuracy in patients imaged within 6 hours of stroke symptom onset. *Radiology*. 1999;210:155–162.
 132. Lovblad KO, Baird AE, Schlaug G, Benfield A, Siewert B, Voetsch B, Connor A, Burzynski C, Edelman RR, Warach S. Ischemic lesion volumes in acute stroke by diffusion-weighted magnetic resonance imaging correlate with clinical outcome. *Ann Neurol*. 1997;42:164–170.
 133. Tong DC, Yenari MA, Albers GW, O'Brien M, Marks MP, Moseley ME. Correlation of perfusion- and diffusion-weighted MRI with NIHSS score in acute (<6.5 hour) ischemic stroke. *Neurology*. 1998;50:864–870.
 134. Kidwell CS, Alger JR, Saver JL. Beyond mismatch: evolving paradigms in imaging the ischemic penumbra with multimodal magnetic resonance imaging. *Stroke*. 2003;34:2729–2735.
 135. Sobesky J, Zaro Weber O, Lehnhardt FG, Hesselmann V, Neveling M, Jacobs A, Heiss WD. Does the mismatch match the penumbra? Magnetic resonance imaging and positron emission tomography in early ischemic stroke. *Stroke*. 2005;36:980–985.
 136. Jansen O, Schellinger P, Fiebach J, Hacke W, Sartor K. Early recanalisation in acute ischaemic stroke saves tissue at risk defined by MRI. *Lancet*. 1999;353:2036–2037.
 137. Wu O, Koroshetz WJ, Ostergaard L, Buonanno FS, Copen WA, Gonzalez RG, Rordorf G, Rosen BR, Schwamm LH, Weisskoff RM, Sorensen AG. Predicting tissue outcome in acute human cerebral ischemia using combined diffusion- and perfusion-weighted MR imaging. *Stroke*. 2001;32:933–942.
 138. Jacobs MA, Mitsias P, Soltanian-Zadeh H, Santhakumar S, Ghanei A, Hammond R, Peck DJ, Chopp M, Patel S. Multiparametric MRI tissue characterization in clinical stroke with correlation to clinical outcome: part 2. *Stroke*. 2001;32:950–957.
 139. Kidwell CS, Alger JR, Saver JL, et al. MR signatures of infarction vs. salvageable penumbra in acute human stroke: a preliminary model [abstract]. *Stroke*. 2000;31:285.
 140. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, Soehngen M, Warach S; DIAS Study Group. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. *Stroke*. 2005;36:66–73.
 141. Fiebach JB, Schellinger PD, Gass A, Kucinski T, Siebler M, Villringer A, Olkers P, Hirsch JG, Heiland S, Wilde P, Jansen O, Rother J, Hacke W, Sartor K; Kompetenznetzwerk Schlaganfall B5. Stroke magnetic resonance imaging is accurate in hyperacute intracerebral hemorrhage: a multicenter study on the validity of stroke imaging. *Stroke*. 2004;35:502–506.
 142. Kidwell CS, Saver JL, Villablanca JP, Duckwiler G, Fredieu A, Gough K, Leary MC, Starkman S, Gobin YP, Jahan R, Vespa P, Liebeskind DS, Alger JR, Vinuela F. Magnetic resonance imaging detection of microbleeds before thrombolysis: an emerging application. *Stroke*. 2002;33:95–98.
 143. Wong KS, Chan YL, Liu JY, Gao S, Lam WW. Asymptomatic microbleeds as a risk factor for aspirin-associated intracerebral hemorrhages. *Neurology*. 2003;60:511–513.
 144. Chalela JA, Kang DW, Warach S. Multiple cerebral microbleeds: MRI marker of a diffuse hemorrhage-prone state. *J Neuroimaging*. 2004;14:54–57.
 145. Kakuda W, Thijs VN, Lansberg MG, Bammer R, Wechsler L, Kemp S, Moseley ME, Marks MP, Albers GW; DEFUSE Investigators. Clinical importance of microbleeds in patients receiving IV thrombolysis. *Neurology*. 2005;65:1175–1178.
 146. Qureshi AI, Isa A, Cinnamon J, Fountain J, Ottenlips JR, Braimah J, Frankel MR. Magnetic resonance angiography in patients with brain infarction. *J Neuroimaging*. 1998;8:65–70.
 147. Scarabino T, Carriero A, Giannatempo GM, Marano R, De Matthaeis P, Bonomo L, Salvolini U. Contrast-enhanced MR angiography (CE MRA)

- in the study of the carotid stenosis: comparison with digital subtraction angiography (DSA). *J Neuroradiol.* 1999;26:87–91.
148. Fiebach JB, Schellinger PD, Jansen O, Meyer M, Wilde P, Bender J, Schramm P, Juttler E, Oehler J, Hartmann M, Hahnel S, Knauth M, Hacke W, Sartor K. CT and diffusion-weighted MR imaging in randomized order: diffusion-weighted imaging results in higher accuracy and lower interrater variability in the diagnosis of hyperacute ischemic stroke. *Stroke.* 2002;33:2206–2210.
 149. Urbach H, Flacke S, Keller E, Textor J, Berlís A, Hartmann A, Reul J, Solymosi L, Schild HH. Detectability and detection rate of acute cerebral hemisphere infarcts on CT and diffusion-weighted MRI. *Neuroradiology.* 2000;42:722–727.
 150. Lansberg MG, Albers GW, Beaulieu C, Marks MP. Comparison of diffusion-weighted MRI and CT in acute stroke. *Neurology.* 2000;54:1557–1561.
 151. Baird AE, Lovblad KO, Schlaug G, Edelman RR, Warach S. Multiple acute stroke syndrome: marker of embolic disease? *Neurology.* 2000;54:674–678.
 152. Seifert T, Enzinger C, Storch MK, Pichler G, Niederkorn K, Fazekas F. Acute small subcortical infarctions on diffusion weighted MRI: clinical presentation and aetiology. *J Neurol Neurosurg Psychiatry.* 2005;76:1520–1524.
 153. Caso V, Budak K, Georgiadis D, Schuknecht B, Baumgartner RW. Clinical significance of detection of multiple acute brain infarcts on diffusion weighted magnetic resonance imaging. *J Neurol Neurosurg Psychiatry.* 2005;76:514–518.
 154. Wessels T, Rottger C, Jauss M, Kaps M, Traupe H, Stolz E. Identification of embolic stroke patterns by diffusion-weighted MRI in clinically defined lacunar stroke syndromes. *Stroke.* 2005;36:757–761.
 155. Smajlovic D, Sinanovic O. Sensitivity of the neuroimaging techniques in ischemic stroke. *Med Arh.* 2004;58:282–284.
 156. Arauz A, Murillo L, Cantu C, Barinagarrementeria F, Higuera J. Prospective study of single and multiple lacunar infarcts using magnetic resonance imaging: risk factors, recurrence, and outcome in 175 consecutive cases. *Stroke.* 2003;34:2453–2458.
 157. Gerraty RP, Parsons MW, Barber PA, Darby DG, Desmond PM, Tress BM, Davis SM. Examining the lacunar hypothesis with diffusion and perfusion magnetic resonance imaging. *Stroke.* 2002;33:2019–2024.
 158. Takahashi K, Kobayashi S, Matui R, Yamaguchi S, Yamashita K. The differences of clinical parameters between small multiple ischemic lesions and single lesion detected by diffusion-weighted MRI. *Acta Neurol Scand.* 2002;106:24–29.
 159. Wityk RJ, Goldsborough MA, Hillis A, Beauchamp N, Barker PB, Borowicz LM Jr, McKhann GM. Diffusion- and perfusion-weighted brain magnetic resonance imaging in patients with neurologic complications after cardiac surgery. *Arch Neurol.* 2001;58:571–576.
 160. Stapf C, Hofmeister C, Hartmann A, Marx P, Mast H. Predictive value of clinical lacunar syndromes for lacunar infarcts on magnetic resonance brain imaging. *Acta Neurol Scand.* 2000;101:13–18.
 161. Ay H, Oliveira-Filho J, Buonanno FS, Ezzeddine M, Schaefer PW, Rordorf G, Schwamm LH, Gonzalez RG, Koroshetz WJ. Diffusion-weighted imaging identifies a subset of lacunar infarction associated with embolic source. *Stroke.* 1999;30:2644–2650.
 162. Etgen T, Graf von Einsiedel H, Rottinger M, Winbeck K, Conrad B, Sander D. Detection of acute brainstem infarction by using DWI/MRI. *Eur Neurol.* 2004;52:145–150.
 163. Saur D, Kucinski T, Grzyska U, Eckert B, Eggers C, Niesen W, Schoder V, Zeumer H, Weiller C, Rother J. Sensitivity and interrater agreement of CT and diffusion-weighted MR imaging in hyperacute stroke. *AJNR Am J Neuroradiol.* 2003;24:878–885.
 164. Keir SL, Wardlaw JM, Bastin ME, Dennis MS. In which patients is diffusion-weighted magnetic resonance imaging most useful in routine stroke care? *J Neuroimaging.* 2004;14:118–122.
 165. Wen HM, Lam WW, Rainer T, Fan YH, Leung TW, Chan YL, Wong KS. Multiple acute cerebral infarcts on diffusion-weighted imaging and risk of recurrent stroke. *Neurology.* 2004;63:1317–1319.
 166. Oliveira-Filho J, Ay H, Schaefer PW, Buonanno FS, Chang Y, Gonzalez RG, Koroshetz WJ. Diffusion-weighted magnetic resonance imaging identifies the “clinically relevant” small-penetrator infarcts. *Arch Neurol.* 2000;57:1009–1014.
 167. Marks MP, de Crespigny A, Lentz D, Enzmann DR, Albers GW, Moseley ME. Acute and chronic stroke: navigated spin-echo diffusion-weighted MR imaging. *Radiology.* 1996;199:403–408.
 168. Baron JC, Bousser MG, Rey A, Guillard A, Comar D, Castaigne P. Reversal of focal “misery-perfusion syndrome” by extra-intracranial arterial bypass in hemodynamic cerebral ischemia: a case study with 150 positron emission tomography. *Stroke.* 1981;12:454–459.
 169. Furlan M, Marchal G, Viader F, Derlon JM, Baron JC. Spontaneous neurological recovery after stroke and the fate of the ischemic penumbra. *Ann Neurol.* 1996;40:216–226.
 170. Heiss WD, Huber M, Fink GR, Herholz K, Pietrzyk U, Wagner R, Wienhard K. Progressive derangement of periinfarct viable tissue in ischemic stroke. *J Cereb Blood Flow Metab.* 1992;12:193–203.
 171. Heiss WD, Grond M, Thiel A, Ghaemi M, Sobesky J, Rudolf J, Bauer B, Wienhard K. Permanent cortical damage detected by flumazenil positron emission tomography in acute stroke. *Stroke.* 1998;29:454–461.
 172. Read SJ, Hirano T, Abbott DF, Sachinidis JI, Tochon-Danguy HJ, Chan JG, Egan GF, Scott AM, Bladin CF, McKay WJ, Donnan GA. Identifying hypoxic tissue after acute ischemic stroke using PET and 18F-fluoromisonidazole. *Neurology.* 1998;51:1617–1621.
 173. Yonas H, Gur D, Claassen D, Wolfson SK Jr, Moosy J. Stable xenon-enhanced CT measurement of cerebral blood flow in reversible focal ischemia in baboons. *J Neurosurg.* 1990;73:266–273.
 174. Ueda T, Sakaki S, Yuh WT, Nochide I, Ohta S. Outcome in acute stroke with successful intra-arterial thrombolysis and predictive value of initial single-photon emission-computed tomography. *J Cereb Blood Flow Metab.* 1999;19:99–108.
 175. Grotta JC, Alexandrov AV. tPA-associated reperfusion after acute stroke demonstrated by SPECT. *Stroke.* 1998;29:429–432.
 176. Berrouschot J, Barthel H, von Kummer R, Nochide I, Ohta S. 99m technetium-ethyl-cysteinate-dimer single-photon emission CT can predict fatal ischemic brain edema. *Stroke.* 1998;29:2556–2562.
 177. Christou I, Alexandrov AV, Burgin WS, Wojner AW, Felberg RA, Malkoff M, Grotta JC. Timing of recanalization after tissue plasminogen activator therapy determined by transcranial Doppler correlates with clinical recovery from ischemic stroke. *Stroke.* 2000;31:1812–1816.
 178. Demchuk AM, Burgin WS, Christou I, Felberg RA, Barber PA, Hill MD, Alexandrov AV. Thrombolysis in brain ischemia (TIBI) transcranial Doppler flow grades predict clinical severity, early recovery, and mortality in patients treated with intravenous tissue plasminogen activator. *Stroke.* 2001;32:89–93.
 179. Alexandrov AV, Wojner AW, Grotta JC; CLOTBUST Investigators. CLOTBUST: design of a randomized trial of ultrasound-enhanced thrombolysis for acute ischemic stroke. *J Neuroimaging.* 2004;14:108–112.
 180. Albers GW, Hart RG, Lutsep HL, Newell DW, Sacco RL. Addendum to the supplement to the guidelines for the management of transient ischemic attacks. *Stroke.* 2000;31:1001.
 181. Wolf PA, Clagett GP, Easton JD, Goldstein LB, Gorelick PB, Kelly-Hayes M, Sacco RL, Whisnant JP. Preventing ischemic stroke in patients with prior stroke and transient ischemic attack: a statement for healthcare professionals from the Stroke Council of the American Heart Association. *Stroke.* 1999;30:1991–1994.
 182. Hacke W, Krieger D, Hirschberg M. General principles in the treatment of acute ischemic stroke. *Cerebrovasc Dis.* 1991;1(suppl 1):93–99.
 183. Krieger D, Hacke W. The intensive care of the stroke patient. In: Barnett HJM, Mohr JP, Stein BM, Yatsu FM, eds. *Stroke: Pathophysiology, Diagnosis and Management.* 3rd ed. New York, NY: Churchill Livingstone; 1998.
 184. Milhaud D, Popp J, Thouvenot E, Heroum C, Bonafe A. Mechanical ventilation in ischemic stroke. *J Stroke Cerebrovasc Dis.* 2004;13:183–188.
 185. Grotta J, Pasteur W, Khwaja G, Hamel T, Fisher M, Ramirez A. Elective intubation for neurologic deterioration after stroke. *Neurology.* 1995;45:640–644.
 186. Bushnell CD, Phillips-Bute BG, Laskowitz DT, Lynch JR, Chilukuri V, Borel CO. Survival and outcome after endotracheal intubation for acute stroke. *Neurology.* 1999;52:1374–1381.
 187. Katzan IL, Cebul RD, Husak SH, Lynch JR, Chilukuri V, Borel CO. The effect of pneumonia on mortality among patients hospitalized for acute stroke. *Neurology.* 2003;60:620–625.
 188. Adams HP Jr. Management of patients with acute ischaemic stroke. *Drugs.* 1997;54(suppl 3):60–69; discussion 69–70.
 189. Nachtmann A, Siebler M, Rose G, Lynch JR, Chilukuri V, Borel CO. Cheyne-Stokes respiration in ischemic stroke. *Neurology.* 1995;45:820–821.
 190. Singhal AB, Benner T, Roccatagliata L, Koroshetz WJ, Schaefer PW, Lo EH, Buonanno FS, Gonzalez RG, Sorensen AG. A pilot study of

- normobaric oxygen therapy in acute ischemic stroke. *Stroke*. 2005;36:797–802.
191. Ronning OM, Guldvog B. Should stroke victims routinely receive supplemental oxygen? A quasi-randomized controlled trial. *Stroke*. 1999;30:2033–2037.
 192. Treib J, Grauer MT, Woessner R, Morgenthaler M. Treatment of stroke on an intensive stroke unit: a novel concept. *Intensive Care Med*. 2000;26:1598–1611.
 193. Bitterman H, Melamed Y. Delayed hyperbaric treatment of cerebral air embolism. *Isr J Med Sci*. 1993;29:22–26.
 194. Nighoghossian N, Trouillas P. Hyperbaric oxygen in the treatment of acute ischemic stroke: an unsettled issue. *J Neurol Sci*. 1997;150:27–31.
 195. Nighoghossian N, Trouillas P, Adeleine P, Salord F. Hyperbaric oxygen in the treatment of acute ischemic stroke: a double-blind pilot study. *Stroke*. 1995;26:1369–1372.
 196. Rusyniak DE, Kirk MA, May JD, Kao LW, Brizendine EJ, Welch JL, Cordell WH, Alonso RJ. Hyperbaric Oxygen in Acute Ischemic Stroke Trial Pilot Study. Hyperbaric oxygen therapy in acute ischemic stroke: results of the Hyperbaric Oxygen in Acute Ischemic Stroke Trial Pilot Study. *Stroke*. 2003;34:571–574.
 197. Alternative Therapy Evaluation Committee for the Insurance Corporation of British Columbia. A review of the scientific evidence on the treatment of traumatic brain injuries and strokes with hyperbaric oxygen. *Brain Inj*. 2003;17:225–236.
 198. Azzimondi G, Bassein L, Nonino F, Fiorani L, Vignatelli L, Re G, D'Alessandro R. Fever in acute stroke worsens prognosis: a prospective study. *Stroke*. 1995;26:2040–2043.
 199. Reith J, Jorgensen HS, Pedersen PM, Nakayama H, Raaschou HO, Jeppesen LL, Olsen TS. Body temperature in acute stroke: relation to stroke severity, infarct size, mortality, and outcome. *Lancet*. 1996;347:422–425.
 200. Castillo J, Davalos A, Marrugat J, Noya M. Timing for fever-related brain damage in acute ischemic stroke. *Stroke*. 1998;29:2455–2460.
 201. Ginsberg MD, Busto R. Combating hyperthermia in acute stroke: a significant clinical concern. *Stroke*. 1998;29:529–534.
 202. Hajat C, Hajat S, Sharma P. Effects of poststroke pyrexia on stroke outcome: a meta-analysis of studies in patients. *Stroke*. 2000;31:410–414.
 203. Wang Y, Lim LL, Levi C, Heller RF, Fisher J. Influence of admission body temperature on stroke mortality. *Stroke*. 2000;31:404–409.
 204. Kammersgaard LP, Jorgensen HS, Rungby JA, Reith J, Nakayama H, Weber UJ, Houth J, Olsen TS. Admission body temperature predicts long-term mortality after acute stroke: the Copenhagen Stroke Study. *Stroke*. 2002;33:1759–1762.
 205. Zaremba J. Hyperthermia in ischemic stroke. *Med Sci Monit*. 2004;10:RA148–RA153.
 206. Jorgensen HS, Reith J, Nakayama H, Kammersgaard LP, Raaschou HO, Olsen TS. What determines good recovery in patients with the most severe strokes? The Copenhagen Stroke Study. *Stroke*. 1999;30:2008–2012.
 207. Sulter G, Elting JW, Maurits N, Luyckx GJ, De Keyser J. Acetylsalicylic acid and acetaminophen to combat elevated body temperature in acute ischemic stroke. *Cerebrovasc Dis*. 2004;17:118–122.
 208. Kasner SE, Wein T, Piriyaawat P, Villar-Cordova CE, Chalela JA, Krieger DW, Morgenstern LB, Kimmel SE, Grotta JC. Acetaminophen for altering body temperature in acute stroke: a randomized clinical trial. *Stroke*. 2002;33:130–134.
 209. Dippel DW, van Breda EJ, van Gemert HM, van der Worp HB, Meijer RJ, Kappelle LJ, Koudstaal PJ. Effect of paracetamol (acetaminophen) on body temperature in acute ischemic stroke: a double-blind, randomized phase II clinical trial. *Stroke*. 2001;32:1607–1612.
 210. Dippel DW, van Breda EJ, van der Worp HB, van Gemert HM, Meijer RJ, Kappelle LJ, Koudstaal PJ, PISA Investigators. Effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute ischemic stroke: PISA, a phase II double-blind, randomized, placebo-controlled trial [ISRCTN98608690]. *BMC Cardiovasc Disord*. 2003;3:2.
 211. Hammer MD, Krieger DW. Hypothermia for acute ischemic stroke: not just another neuroprotectant. *Neurologist*. 2003;9:280–289.
 212. Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, Smith K. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. *N Engl J Med*. 2002;346:557–563.
 213. Bernard SA, Buist M. Induced hypothermia in critical care medicine: a review. *Crit Care Med*. 2003;31:2041–2051.
 214. The Hypothermia After Cardiac Arrest Study Group. Mild hypothermia to improve the neurologic outcome after cardiac arrest. *N Engl J Med*. 2002;346:2041–2051.
 215. Todd MM, Hindman BJ, Clarke WR, Torner JC; Intraoperative Hypothermia for Aneurysm Surgery Trial (IHAST) Investigators. Mild intraoperative hypothermia during surgery for intracranial aneurysm. *N Engl J Med*. 2005;352:135–145.
 216. Schwab S, Schwarz S, Aschoff A, Keller E, Hacke W. Moderate hypothermia and brain temperature in patients with severe middle cerebral artery infarction. *Acta Neurochir Suppl*. 1998;71:131–134.
 217. Schwab S, Schwarz S, Spranger M, Keller E, Bertram M, Hacke W. Moderate hypothermia in the treatment of patients with severe middle cerebral artery infarction. *Stroke*. 1998;29:2461–2466.
 218. Kammersgaard LP, Rasmussen BH, Jorgensen HS, Reith J, Weber U, Olsen TS. Feasibility and safety of inducing modest hypothermia in awake patients with acute stroke through surface cooling: a case-control study: the Copenhagen Stroke Study. *Stroke*. 2000;31:2251–2256.
 219. Georgiadis D, Schwarz S, Kollmar R, Schwab S. Endovascular cooling for moderate hypothermia in patients with acute stroke: first results of a novel approach. *Stroke*. 2001;32:2550–2553.
 220. Krieger DW, De Georgia MA, Abou-Chebl A, Andrefsky JC, Sila CA, Katzan IL, Mayberg MR, Furlan AJ. Cooling for Acute Ischemic Brain Damage (COOL AID): an open pilot study of induced hypothermia in acute ischemic stroke. *Stroke*. 2001;32:1847–1854.
 221. Wang H, Olivero W, Lanzino G, Elkins W, Rose J, Honings D, Rodde M, Burnham J, Wang D. Rapid and selective cerebral hypothermia achieved using a cooling helmet. *J Neurosurg*. 2004;100:272–277.
 222. Slotboom J, Kiefer C, Brekenfeld C, Ozdoba C, Remonda L, Nedelchev K, Arnold M, Mattle H, Schroth G. Locally induced hypothermia for treatment of acute ischaemic stroke: a physical feasibility study. *Neuroradiology*. 2004;46:923–934.
 223. Marion DW. Controlled normothermia in neurologic intensive care. *Crit Care Med*. 2004;32(suppl):S43–S45.
 224. Milhaud D, Thouvenot E, Heroum C, Escuret E. Prolonged moderate hypothermia in massive hemispheric infarction: clinical experience. *J Neurosurg Anesthesiol*. 2005;17:49–53.
 225. Georgiadis D, Schwarz S, Aschoff A, Schwab S. Hemicraniectomy and moderate hypothermia in patients with severe ischemic stroke. *Stroke*. 2002;33:1584–1588.
 226. Olsen TS, Weber UJ, Kammersgaard LP. Therapeutic hypothermia for acute stroke. *Lancet Neurol*. 2003;2:410–416.
 227. Correia M, Silva M, Veloso M. Cooling therapy for acute stroke. *Cochrane Database Syst Rev*. 2000;(2):CD001247.
 228. Kocan MJ. Cardiovascular effects of acute stroke. *Prog Cardiovasc Nurs*. 1999;14:61–67.
 229. Kolin A, Norris JW. Myocardial damage from acute cerebral lesions. *Stroke*. 1984;15:990–993.
 230. Korpelainen JT, Sotaniemi KA, Makikallio A, Huikuri HV, Myllyla VV. Dynamic behavior of heart rate in ischemic stroke. *Stroke*. 1999;30:1008–1013.
 231. Korpelainen JT, Sotaniemi KA, Huikuri HV, Myllyla VV. Abnormal heart rate variability as a manifestation of autonomic dysfunction in hemispheric brain infarction. *Stroke*. 1996;27:2059–2063.
 232. Lane RD, Wallace JD, Petrosky PP, Schwartz GE, Gradman AH. Supraventricular tachycardia in patients with right hemisphere strokes. *Stroke*. 1992;23:362–366.
 233. Tokgozlu SL, Batur MK, Topuoglu MA, Saribas O, Kes S, Oto A. Effects of stroke localization on cardiac autonomic balance and sudden death. *Stroke*. 1999;30:1307–1311.
 234. Orlandi G, Fanucchi S, Strata G, Pataleo L, Landucci Pellegrini L, Prontera C, Martini A, Murri L. Transient autonomic nervous system dysfunction during hyperacute stroke. *Acta Neurol Scand*. 2000;102:317–321.
 235. Afsar N, Fak AS, Metzger JT, Van Melle G, Kappenberger L, Bogousslavsky J. Acute stroke increases QT dispersion in patients without known cardiac diseases. *Arch Neurol*. 2003;60:346–350.
 236. McDermott MM, Lefevre F, Arron M, Martin GJ, Biller J. ST segment depression detected by continuous electrocardiography in patients with acute ischemic stroke or transient ischemic attack. *Stroke*. 1994;25:1820–1824.
 237. Chua HC, Sen S, Cosgriff RF, Gerstenblith G, Beauchamp NJ Jr, Oppenheimer SM. Neurogenic ST depression in stroke. *Clin Neurol Neurosurg*. 1999;101:44–48.

238. Britton M, de Faire U, Helmers C, Miah K, Ryding C, Wester PO. Arrhythmias in patients with acute cerebrovascular disease. *Acta Med Scand*. 1979;205:425–428.
239. Robinson T, Waddington A, Ward-Close S, Taub N, Potter J. The predictive role of 24-hour compared to causal blood pressure levels on outcome following acute stroke. *Cerebrovasc Dis*. 1997;7:264–272.
240. Castillo J, Leira R, Garcia MM, Serena J, Blanco M, Davalos A. Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome. *Stroke*. 2004;35:520–526.
241. Phillips SJ. Pathophysiology and management of hypertension in acute ischemic stroke. *Hypertension*. 1994;23:131–136.
242. Johnston KC, Mayer SA. Blood pressure reduction in ischemic stroke: a two-edged sword? *Neurology*. 2003;61:1030–1031.
243. Vemmos KN, Spengos K, Tsvigoulis G, Zakopoulos N, Manios E, Kotsis V, Daffertshofer M, Vassilopoulos D. Factors influencing acute blood pressure values in stroke subtypes. *J Hum Hypertens*. 2004;18:253–259.
244. Aslanyan S, Fazekas F, Weir CJ, Horner S, Lees KR; GAIN International Steering Committee and Investigators. Effect of blood pressure during the acute period of ischemic stroke on stroke outcome: a tertiary analysis of the GAIN International Trial. *Stroke*. 2003;34:2420–2425.
245. Aslanyan S, Weir CJ, Lees KR; GAIN International Steering Committee and Investigators. Elevated pulse pressure during the acute period of ischemic stroke is associated with poor stroke outcome. *Stroke*. 2004;35:e153–e155.
246. Kaplan NM. Management of hypertensive emergencies. *Lancet*. 1994;344:1335–1338.
247. Powers WJ. Acute hypertension after stroke: the scientific basis for treatment decisions. *Neurology*. 1993;43(pt 1):461–467.
248. Goldstein LB. Blood pressure management in patients with acute ischemic stroke. *Hypertension*. 2004;43:137–141.
249. Verstappen A, Thijs V. What do we (not) know about the management of blood pressure in acute stroke? *Curr Neurol Neurosci Rep*. 2004;4:505–509.
250. Chalmers J. The management of blood pressure in acute stroke. *Lancet Neurol*. 2003;2:593.
251. Hillis AE. Systemic blood pressure and stroke outcome and recurrence. *Curr Atheroscler Rep*. 2004;6:274–280.
252. Ahmed N, Wahlgren NG. Effects of blood pressure lowering in the acute phase of total anterior circulation infarcts and other stroke subtypes. *Cerebrovasc Dis*. 2003;15:235–243.
253. Wahlgren NG, MacMahon DG, DeKeyser J, Indredavik B, Ryman T. Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke. *Cerebrovasc Dis*. 1994;4:204–210.
254. Fogelholm R, Palomaki H, Erila T, Rissanen A, Kaste M. Blood pressure, nimodipine, and outcome of ischemic stroke. *Acta Neurol Scand*. 2004;109:200–204.
255. Oliveira-Filho J, Silva SC, Trabuco CC, Pedreira BB, Sousa EU, Bacellar A. Detrimental effect of blood pressure reduction in the first 24 hours of acute stroke onset. *Neurology*. 2003;61:1047–1051.
256. Bath P. High blood pressure as risk factor and prognostic predictor in acute ischaemic stroke: when and how to treat it? *Cerebrovasc Dis*. 2004;17(suppl 1):51–57.
257. Chalmers J. Trials on blood pressure-lowering and secondary stroke prevention. *Am J Cardiol*. 2003;91:3G–8G.
258. Schrader J, Luders S, Kulschewski A, Berger J, Zidek W, Treib J, Einhaupl K, Diener HC, Dominiak P; Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. *Stroke*. 2003;34:1699–1703.
259. Rodriguez-Garcia JL, Botia E, de La Sierra A, Villanueva MA, Gonzalez-Spinola J. Significance of elevated blood pressure and its management on the short-term outcome of patients with acute ischemic stroke. *Am J Hypertens*. 2005;18:379–384.
260. Eames PJ, Robinson TG, Panerai RB, Potter JF. Bendrofluzide fails to reduce elevated blood pressure levels in the immediate post-stroke period. *Cerebrovasc Dis*. 2005;19:253–259.
261. Potter J, Robinson T, Ford G, James M, Jenkins D, Mistri A, Bulpitt C, Drummond A, Jagger C, Knight J, Markus H, Beevers G, Dewey M, Lees K, Moore A, Paul S; The CHHIPS Trial Group. CHHIPS (Controlling Hypertension and Hypotension Immediately Post-Stroke) Pilot Trial: rationale and design. *J Hypertens*. 2005;23:649–655.
262. Brott T, Lu M, Kothari R, Fagan SC, Frankel M, Grotta JC, Broderick J, Kwiatkowski T, Lewandowski C, Haley EC, Marler JR, Tilley BC. Hypertension and its treatment in the NINDS rt-PA Stroke Trial. *Stroke*. 1998;29:1504–1509.
263. Grossman E, Ironi AN, Messerli FH. Comparative tolerability profile of hypertensive crisis treatments. *Drug Saf*. 1998;19:99–122.
264. Grossman E, Messerli FH, Grodzicki T, Kowey P. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? *JAMA*. 1996;276:1328–1331.
265. Patel SC, Mody A. Cerebral hemorrhagic complications of thrombolytic therapy. *Prog Cardiovasc Dis*. 1999;42:217–233.
266. The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. *Stroke*. 1997;28:2109–2118.
267. Lopez-Yunez AM, Bruno A, Williams LS, Yilmaz E, Zurru C, Biller J. Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage. *Stroke*. 2001;32:12–16.
268. Katzan IL, Furlan AJ, Lloyd LE, Frank JI, Harper DL, Hinchey JA, Hammel JP, Qu A, Sila CA. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. *JAMA*. 2000;283:1151–1158.
269. Katzan IL, Hammer MD, Furlan AJ, Hixson ED, Nadzam DM; Cleveland Clinic Health System Stroke Quality Improvement Team. Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update. *Stroke*. 2003;34:799–800.
270. Leonardi-Bee J, Bath PM, Phillips SJ, Sandercock PA; IST Collaborative Group. Blood pressure and clinical outcomes in the International Stroke Trial. *Stroke*. 2002;33:1315–1320.
271. Williams LS, Rotich J, Qi R, Fineberg N, Espay A, Bruno A, Fineberg SE, Tierney WR. Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke. *Neurology*. 2002;59:67–71.
272. Scott JF, Robinson GM, French JM, O'Connell JE, Alberti KG, Gray CS. Prevalence of admission hyperglycaemia across clinical subtypes of acute stroke. *Lancet*. 1999;353:376–377.
273. Baird TA, Parsons MW, Barber PA, Butcher KS, Desmond PM, Tress BM, Colman PG, Jerums G, Chambers BR, Davis SM. The influence of diabetes mellitus and hyperglycaemia on stroke incidence and outcome. *J Clin Neurosci*. 2002;9:618–626.
274. Gray CS, Hildreth AJ, Alberti GK, O'Connell JE; GIST Collaboration. Poststroke hyperglycemia: natural history and immediate management. *Stroke*. 2004;35:122–126.
275. Bruno A, Biller J, Adams HP Jr, Clarke WR, Woolson RF, Williams LS, Hansen MD; Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Acute blood glucose level and outcome from ischemic stroke. *Neurology*. 1999;52:280–284.
276. Bruno A, Levine SR, Frankel MR, Brott TG, Lin Y, Tilley BC, Lyden PD, Broderick JP, Kwiatkowski TG, Fineberg SE; NINDS rt-PA Stroke Study Group. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. *Neurology*. 2002;59:669–674.
277. Davalos A, Castillo J. Potential mechanisms of worsening. *Cerebrovasc Dis*. 1997;7(suppl 5):19–24.
278. Alvarez-Sabin J, Molina CA, Ribo M, Arenillas JF, Montaner J, Huertas R, Santamarina E, Rubiera M. Impact of admission hyperglycemia on stroke outcome after thrombolysis: risk stratification in relation to time to reperfusion. *Stroke*. 2004;35:2493–2498.
279. Leigh R, Zaidat OO, Suri MF, Lynch G, Sundararajan S, Sunshine JL, Tarr R, Selman W, Landis DM, Suarez JI. Predictors of hyperacute clinical worsening in ischemic stroke patients receiving thrombolytic therapy. *Stroke*. 2004;35:1903–1907.
280. Baird TA, Parsons MW, Phan T, Butcher KS, Desmond PM, Tress BM, Colman PG, Chambers BR, Davis SM. Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. *Stroke*. 2003;34:2208–2214.
281. Lindsberg PJ, Roine RO. Hyperglycemia in acute stroke. *Stroke*. 2004;35:363–364.
282. Parsons MW, Barber PA, Desmond PM, Baird TA, Darby DG, Byrnes G, Tress BM, Davis SM. Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study. *Ann Neurol*. 2002;52:20–28.
283. Kase CS, Furlan AJ, Wechsler LR, Higashida RT, Rowley HA, Hart RG, Molinari GF, Frederick LS, Roberts HC, Gebel JM, Sila CA, Schulz GA, Roberts RS, Gent M. Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trial. *Neurology*. 2001;57:1603–1610.

284. Weir CJ, Murray GD, Dyker AG, Lees KR. Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow up study. *BMJ*. 1997;314:1303–1306.
285. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. *Stroke*. 2001;32:2426–2432.
286. Candelise L, Landi G, Orazio EN, Boccardi E. Prognostic significance of hyperglycemia in acute stroke. *Arch Neurol*. 1985;42:661–663.
287. Kagansky N, Levy S, Knobler H. The role of hyperglycemia in acute stroke. *Arch Neurol*. 2001;58:1209–1212.
288. Goldberg PA, Sakharova OV, Barrett PW, Falko LN, Roussel MG, Bak L, Blake-Holmes D, Marieb NJ, Inzucchi SE. Improving glycemic control in the cardiothoracic intensive care unit: clinical experience in two hospital settings. *J Cardiothorac Vasc Anesth*. 2004;18:690–697.
289. Chant C, Wilson G, Friedrich JO. Validation of an insulin infusion nomogram for intensive glucose control in critically ill patients. *Pharmacotherapy*. 2005;25:352–359.
290. Kanji S, Singh A, Tierney M, Meggison H, McIntyre L, Hebert PC. Standardization of intravenous insulin therapy improves the efficiency and safety of blood glucose control in critically ill adults. *Intensive Care Med*. 2004;30:804–810.
291. Finney SJ, Zekveld C, Elia A, Evans TW. Glucose control and mortality in critically ill patients. *JAMA*. 2003;290:2041–2047.
292. Pittas AG, Siegel RD, Lau J. Insulin therapy for critically ill hospitalized patients: a meta-analysis of randomized controlled trials. *Arch Intern Med*. 2004;164:2005–2011.
293. Van den Bergh G, Wouters PJ, Bouillon R, Weekers F, Verwaest C, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P. Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. *Crit Care Med*. 2003;31:359–366.
294. Scott JF, Robinson GM, French JM, O'Connell JE, Alberti KG, Gray CS. Glucose potassium insulin infusions in the treatment of acute stroke patients with mild to moderate hyperglycemia: the Glucose Insulin in Stroke Trial (GIST). *Stroke*. 1999;30:793–799.
295. Scott JF, Robinson GM, French JM, O'Connell JE, Alberti KG, Gray CS. Blood pressure response to glucose potassium insulin therapy in patients with acute stroke with mild to moderate hyperglycemia. *J Neurol Neurosurg Psychiatry*. 2001;70:401–404.
296. Bruno A, Saha C, Williams LS, Shankar R. IV insulin during acute cerebral infarction in diabetic patients. *Neurology*. 2004;62:1441–1442.
297. Levetan CS. Effect of hyperglycemia on stroke outcomes. *Endocr Pract*. 2004;10(suppl 2):34–39.
298. Lyden PD. *Thrombolytic Therapy for Acute Stroke*. 2nd ed. Totowa, NJ: Humana Press; 2005.
299. Kwiatkowski TG, Libman RB, Frankel M, Tilley BC, Morgenstern LB, Lu M, Broderick JP, Lewandowski CA, Marler JR, Levine SR, Brott T; National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. Effects of tissue plasminogen activator for acute ischemic stroke at one year. *N Engl J Med*. 1999;340:1781–1787.
300. Deleted in proof.
301. Gilligan A, Markus R, Read S, Srikanth V, Hirano T, Fitt G, Arends M, Chambers BR, Davis SM, Donnan GA; Australian Streptokinase Trial Investigators. Baseline blood pressure but not early computed tomography changes predicts major hemorrhage after streptokinase in acute ischemic stroke. *Stroke*. 2002;33:2236–2242.
302. The NINDS t-PA Stroke Study Group. Generalized efficacy of t-PA for acute stroke: subgroup analysis of the NINDS t-PA Stroke Trial. *Stroke*. 1997;28:2119–2125.
303. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P; Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). *Lancet*. 1998;352:1245–1251.
304. Kaste M, Hacke W, Fieschi C, et al. Results of the European Cooperative Acute Stroke Study (ECASS). *Cerebrovasc Dis*. 1995;5:225.
305. von Kummer R, Hacke W. Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke. *Stroke*. 1992;23:646–652.
306. Steiner T, Bluhmki E, Kaste M, Toni D, Trouillas P, von Kummer R, Hacke W; ECASS Study Group. The ECASS 3-hour cohort: secondary analysis of ECASS data by time stratification: European Cooperative Acute Stroke Study. *Cerebrovasc Dis*. 1998;8:198–203.
307. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS Study: a randomized controlled trial: Alteplase Thrombolysis for Acute Noninterventive Therapy in Ischemic Stroke. *JAMA*. 1999;282:2019–2026.
308. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. *JAMA*. 2000;283:1145–1150.
309. Grond M, Stenzel C, Schmulling S, Rudolf J, Neveling M, Lechleuthner A, Schneweis S, Heiss WD. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. *Stroke*. 1998;29:1544–1549.
310. Derex L, Hermier M, Adeleine P, Pialat JB, Wiart M, Berthezene Y, Phillippeau F, Honnorat J, Froment JC, Trouillas P, Nighoghossian N. Clinical and imaging predictors of intracerebral haemorrhage in stroke patients treated with intravenous tissue plasminogen activator. *J Neurol Neurosurg Psychiatry*. 2005;76:70–75.
311. Trouillas P, Nighoghossian N, Getenet JC, Riche G, Neuschwander P, Froment JC, Turjman F, Jin JX, Malicier D, Fournier G, Gabry AL, Ledoux X, Derex L, Berthezene Y, Adeleine P, Xie J, Ffrench P, Dechavanne M. Open trial of intravenous tissue plasminogen activator in acute carotid territory stroke: correlations of outcome with clinical and radiological data. *Stroke*. 1996;27:882–890.
312. Tanne D, Verro P, Mansbach H, et al. Overview and summary of phase IV data on use of t-PA for acute ischemic stroke. *Stroke Interventionalist*. 1998;1:3.
313. Tanne D, Bates V, Verro P, Kasner SE, Binder JR, Patel SC, Mansbach HH, Daley S, Schultz LR, Karanjia PN, Scott P, Dayno JM, Vereczkey-Porter K, Benesch C, Book D, Coplin WM, Dulli D, Levine SR; t-PA Stroke Survey Group. Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey. *Neurology*. 1999;53:424–427.
314. Katzan IL, Hammer MD, Hixson ED, Furlan AJ, Abou-Chebl A, Nadzam DM; Cleveland Clinic Health System Stroke Quality Improvement Team. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. *Arch Neurol*. 2004;61:346–350.
315. Graham GD. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. *Stroke*. 2003;34:2847–2850.
316. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S; ATLANTIS Trials Investigators, ECASS Trials Investigators, NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. *Lancet*. 2004;363:768–774.
317. Kwiatkowski T, Libman R, Tilley BC, Lewandowski C, Grotta JC, Lyden P, Levine SR, Brott T; National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study. *Ann Emerg Med*. 2005;45:377–384.
318. Wardlaw JM, Lindley RI, Lewis S. Thrombolysis for acute ischemic stroke: still a treatment for the few by the few. *West J Med*. 2002;176:198–199.
319. Donnan GA, Hommel M, Davis SM, McNeil JJ, Steering Committees of the ASK and MAST-E Trials, Australian Streptokinase Trial. Streptokinase in acute ischaemic stroke. *Lancet*. 1995;346:56.
320. Hommel M, Boissel JP, Cornu C, Boutitie F, Lees KR, Besson G, Leys D, Amarenco P, Bogaert M; MAST Study Group. Termination of trial of streptokinase in severe acute ischaemic stroke. *Lancet*. 1995;345:57.
321. The Multicenter Acute Stroke Trial—Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. *N Engl J Med*. 1996;335:145–150.
322. Multicentre Acute Stroke Trial—Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. *Lancet*. 1995;346:1509–1514.
323. Haley EC Jr, Lyden PD, Johnston KC, Hemmen TM; TNK in Stroke Investigators. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. *Stroke*. 2005;36:607–612.
324. Walters BB, Ojemann RG, Heros RC. Emergency carotid endarterectomy. *J Neurosurg*. 1987;66:817–823.
325. Sherman DG, Atkinson RP, Chippendale T, Levin KA, Ng K, Futrell N, Hsu CY, Levy DE. Intravenous anecrod for treatment for acute ischemic

- stroke: the STAT study: a randomized controlled trial: Stroke Treatment with Ancrod Trial. *JAMA*. 2000;283:2395–2403.
326. The Ancrod Stroke Study Investigators. Ancrod for the treatment of acute ischemic brain infarction. *Stroke*. 1994;25:1755–1759.
 327. Liu M, Counsell C, Zhao XL, Wardlaw J. Fibrinogen depleting agents for acute ischaemic stroke. *Cochrane Database Syst Rev*. 2003;(3): CD000091.
 328. Sherman DG. Antithrombotic and hypofibrinogenetic therapy in acute ischemic stroke: what is the next step? *Cerebrovasc Dis*. 2004;17(suppl 1):138–143.
 329. Qureshi AI, Kirmani JF, Sayed MA, Safdar A, Ahmed S, Ferguson R, Hershey LA, Qazi KJ; Buffalo Metropolitan Area and Erie County Stroke Study Group. Time to hospital arrival, use of thrombolytics, and in-hospital outcomes in ischemic stroke. *Neurology*. 2005;64: 2115–2120.
 330. Dick AP, Straka J. IV tPA for acute ischemic stroke: results of the first 101 patients in a community practice. *Neurologist*. 2005;11:305–308.
 331. Nadeau JO, Shi S, Fang J, Kapral MK, Richards JA, Silver FL, Hill MD; Investigators for the Registry of the Canadian Stroke Network. TPA use for stroke in the Registry of the Canadian Stroke Network. *Can J Neurol Sci*. 2005;32:433–439.
 332. Grotta JC, Burgin WS, El-Mitwalli A, Long M, Campbell M, Morgenstern LB, Malkoff M, Alexandrov AV. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. *Arch Neurol*. 2001;58:2009–2013.
 333. Merino JG, Silver B, Wong E, Foell B, Demaerschalk B, Tamayo A, Poncha F, Hachinski V; Southwestern Ontario Stroke Program. Extending tissue plasminogen activator use to community and rural stroke patients. *Stroke*. 2002;33:141–146.
 334. Sylaja PN, Dzialowski I, Krol A, Roy J, Federico P, Demchuk AM; Calgary Stroke Program. Role of CT angiography in thrombolysis decision-making for patients with presumed seizure at stroke onset. *Stroke*. 2006;37:915–917.
 335. Selim M, Kumar S, Fink J, Schlaug G, Caplan LR, Linfante I. Seizure at stroke onset: should it be an absolute contraindication to thrombolysis? *Cerebrovasc Dis*. 2002;14:54–57.
 336. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F. Intra-arterial prourokinase for acute ischemic stroke: the PROACT II study: a randomized controlled trial: Prolyse in Acute Cerebral Thromboembolism. *JAMA*. 1999;282:2003–2011.
 337. Qureshi AI. Endovascular treatment of cerebrovascular diseases and intracranial neoplasms. *Lancet*. 2004;363:804–813.
 338. Qureshi AI, Suri MF, Nasar A, He W, Kirmani JF, Divani AA, Prestigiacomo CJ, Low RB. Thrombolysis for ischemic stroke in the United States: data from National Hospital Discharge Survey 1999–2001. *Neurosurgery*. 2005;57:647–654.
 339. Qureshi AI. New grading system for angiographic evaluation of arterial occlusions and recanalization response to intra-arterial thrombolysis in acute ischemic stroke. *Neurosurgery*. 2002;50:1405–1414; discussion 1414–1415.
 340. Mohammad Y, Xavier AR, Christoforidis G, Bourekas E, Slivka A. Qureshi grading scheme for angiographic occlusions strongly correlates with the initial severity and in-hospital outcome of acute ischemic stroke. *J Neuroimaging*. 2004;14:235–241.
 341. Ducrocq X, Bracard S, Taillandier L, Anxionnat R, Lacour JC, Guillemin F, Debouverie M, Bollaert PE. Comparison of intravenous and intra-arterial urokinase thrombolysis for acute ischaemic stroke. *J Neuroradiol*. 2005;32:26–32.
 342. Inoue T, Kimura K, Minematsu K, Yamaguchi T; Japan Multicenter Stroke Investigator's Collaboration. A case-control analysis of intra-arterial urokinase thrombolysis in acute cardioembolic stroke. *Cerebrovasc Dis*. 2005;19:225–228.
 343. Macleod MR, Davis SM, Mitchell PJ, Gerraty RP, Fitt G, Hankey GJ, Stewart-Wynne EG, Rosen D, McNeil JJ, Bladin CF, Chambers BR, Herkes GK, Young D, Donnan GA. Results of a multicentre, randomised controlled trial of intra-arterial urokinase in the treatment of acute posterior circulation ischaemic stroke. *Cerebrovasc Dis*. 2005;20: 12–17.
 344. Agarwal P, Kumar S, Hariharan S, Eshkar N, Verro P, Cohen B, Sen S. Hyperdense middle cerebral artery sign: can it be used to select intra-arterial versus intravenous thrombolysis in acute ischemic stroke? *Cerebrovasc Dis*. 2004;17:182–190.
 345. Chalela JA, Katzan I, Liebeskind DS, Rasmussen P, Zaidat O, Suarez JJ, Chiu D, Klucznick RP, Jauch E, Cucchiara BL, Saver J, Kasner SE. Safety of intra-arterial thrombolysis in the postoperative period. *Stroke*. 2001;32:1365–1369.
 346. Choi JH, Bateman BT, Mangla S, Marshall RS, Prabhakaran S, Chong J, Mohr JP, Mast H, Pile-Spellman J. Endovascular recanalization therapy in acute ischemic stroke. *Stroke*. 2006;37:419–424.
 347. Al-Sadat A, Sunbuli M, Chaturvedi S. Use of intravenous heparin by North American neurologists: do the data matter? *Stroke*. 2002;33: 1574–1577.
 348. Adams HP Jr. Emergency use of anticoagulation for treatment of patients with ischemic stroke. *Stroke*. 2002;33:856–861.
 349. Caplan LR. Resolved: heparin may be useful in selected patients with brain ischemia. *Stroke*. 2003;34:230–231.
 350. Donnan GA, Davis SM. Heparin in stroke: not for most, but the controversy lingers. *Stroke*. 2003;34:232–233.
 351. Moonis M, Fisher M. Considering the role of heparin and low-molecular-weight heparins in acute ischemic stroke. *Stroke*. 2002;33: 1927–1933.
 352. Sandercock P. Full heparin anticoagulation should not be used in acute ischemic stroke. *Stroke*. 2003;34:231–232.
 353. Toth C. The use of a bolus of intravenous heparin while initiating heparin therapy in anticoagulation following transient ischemic attack or stroke does not lead to increased morbidity or mortality. *Blood Coagul Fibrinolysis*. 2003;14:463–468.
 354. Toth C, Voll C. Validation of a weight-based nomogram for the use of intravenous heparin in transient ischemic attack or stroke. *Stroke*. 2002; 33:670–674.
 355. Coull BM, Williams LS, Goldstein LB, Meschia JF, Heitzman D, Chaturvedi S, Johnston KC, Starkman S, Morgenstern LB, Wilterdink JL, Levine SR, Saver JL; American Academy of Neurology; American Stroke Association. Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). *Neurology*. 2002;59:13–22.
 356. Coull BM, Williams LS, Goldstein LB, Meschia JF, Heitzman D, Chaturvedi S, Johnston KC, Starkman S, Morgenstern LB, Wilterdink JL, Levine SR, Saver JL; Joint Stroke Guideline Development Committee of the American Academy of Neurology; American Stroke Association. Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). *Stroke*. 2002;33: 1934–1942.
 357. Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke: brain hemorrhage and management options. *Stroke*. 1984;15: 779–789.
 358. Cerebral Embolism Study Group. Cardioembolic stroke, early anticoagulation, and brain hemorrhage. *Arch Intern Med*. 1987;147:636–640.
 359. Berge E, Abdelnoor M, Nakstad PH, Sandset PM; HAEST Study Group. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study: Heparin in Acute Embolic Stroke Trial. *Lancet*. 2000;355:1205–1210.
 360. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. *Lancet*. 1997;349:1641–1649.
 361. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. *Lancet*. 1997;349:1569–1581.
 362. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. *JAMA*. 1998;279:1265–1272.
 363. Saxena R, Lewis S, Berge E, Sandercock PA, Koudstaal PJ. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial. *Stroke*. 2001;32:2333–2337.
 364. Roden-Jullig A, Britton M. Effectiveness of heparin treatment for progressing ischaemic stroke: before and after study. *J Intern Med*. 2000; 248:287–291.
 365. Camerlingo M, Salvi P, Belloni G, Gamba T, Cesana BM, Mamoli A. Intravenous heparin started within the first 3 hours after onset of symptoms as a treatment for acute nonlacunar hemispheric cerebral infarctions. *Stroke*. 2005;36:2415–2420.

366. Chamorro A, Busse O, Obach V, Toni D, Sandercock P, Reverter JC, Cervera A, Torres F, Davalos A; RAPID Investigators. The rapid anti-coagulation prevents ischemic damage study in acute stroke: final results from the writing committee. *Cerebrovasc Dis*. 2005;19:402–404.
367. Gubitz G, Counsell C, Sandercock P, Signorini D. Anticoagulants for acute ischaemic stroke. *Cochrane Database Syst Rev*. 2000;(2): CD000024.
368. Kay R, Wong KS, Yu YL, Chan YW, Tsoi TH, Ahuja AT, Chan FL, Fong KY, Law CB, Wong A. Low-molecular-weight heparin for the treatment of acute ischemic stroke. *N Engl J Med*. 1995;333:1588–1593.
369. Chamorro A. Heparin in acute ischemic stroke: the case for a new clinical trial. *Cerebrovasc Dis*. 1999;9(suppl 3):16–23.
370. Diener HC, Ringelstein EB, von Kummer R, Langohr HD, Bewermeyer H, Landgraf H, Hennerici M, Welzel D, Grave M, Brom J, Weidinger G; Therapy of Patients With Acute Stroke (TOPAS) Investigators. Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the TOPAS trial. *Stroke*. 2001;32:22–29.
371. Bath PM, Lindstrom E, Boysen G, De Deyn P, Friis P, Leys D, Martila R, Olsson J, O'Neill D, Orgogozo J, Ringelstein B, van der Sande J, Turpie AG. Tinzaparin in Acute Ischaemic Stroke (TAIST): a randomised aspirin-controlled trial. *Lancet*. 2001;358:702–710.
372. Adams HP Jr, Bendixen BH, Leira E, Chang KC, Davis PH, Woolson RF, Clarke WR, Hansen MD. Antithrombotic treatment of ischemic stroke among patients with occlusion or severe stenosis of the internal carotid artery: a report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). *Neurology*. 1999;53:122–125.
373. Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. *Neurology*. 2004;62:569–573.
374. Woessner R, Grauer M, Bianchi O, Mueller M, Moersdorf S, Berlit P, Goertler M, Grotemeyer KH, Sliwka U, Stoll M, Treib J. Treatment with Anticoagulants in Cerebral Events (TRACE). *Thromb Haemost*. 2004;91:690–693.
375. Hillbom M, Eriola T, Sotaniemi K, Tatlisumak T, Sarna S, Kaste M. Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study. *Acta Neurol Scand*. 2002;106:84–92.
376. Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. *Neurology*. 2002;59:862–867.
377. del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M; PROACT Investigators. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke: Prolyse in Acute Cerebral Thromboembolism. *Stroke*. 1998;29:4–11.
378. Furlan AJ, Kanoti G. When is thrombolysis justified in patients with acute ischemic stroke? A bioethical perspective. *Stroke*. 1997;28:214–218.
379. Grond M, Rudolf J, Neveling M, Stenzel C, Heiss W-D. Risk of immediate heparin after rt-PA therapy in acute ischemic stroke. *Cerebrovasc Dis*. 1997;7:318–323.
380. Schmulling S, Rudolf J, Strotmann-Tack T, Grond M, Schneewis S, Sobesky J, Thiel A, Heiss WD. Acetylsalicylic acid pretreatment, concomitant heparin therapy and the risk of early intracranial hemorrhage following systemic thrombolysis for acute ischemic stroke. *Cerebrovasc Dis*. 2003;16:183–190.
381. Mandava P, Lick SD, Rahman MA, Langsjoen H, Reddy KV, Nelson J, Kent TA. Initial safety experience of abciximab and heparin for acute ischemic stroke. *Cerebrovasc Dis*. 2005;19:276–278.
382. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*. 2004;126(suppl):483S–512S.
383. Qureshi AI, Luft AR, Sharma M, Guterman LR, Hopkins LN. Prevention and treatment of thromboembolic and ischemic complications associated with endovascular procedures, part I: pathophysiological and pharmacological features. *Neurosurgery*. 2000;46:1344–1359.
384. Gurbel PA, Cummings CC, Bell CR, Alford AB, Meister AF, Serebrany VL; Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. *Am Heart J*. 2003;145:239–247.
385. Harrington RA, Becker RC, Ezekowitz M, Meade TW, O'Connor CM, Vorchheimer DA, Guyatt GH. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*. 2004;126(suppl):513S–548S.
386. McCormick PW, Spetzler RF, Bailes JE, Zabramski JM, Frey JL. Thromboendarterectomy of the symptomatic occluded internal carotid artery. *J Neurosurg*. 1992;76:752–758.
387. Aichner FT, Fazekas F, Brainin M, Polz W, Mamoli B, Zeiler K. Hypervolemic hemodilution in acute ischemic stroke: the Multicenter Austrian Hemodilution Stroke Trial (MAHST). *Stroke*. 1998;29:743–749.
388. Lapchak PA, Araujo DM. Therapeutic potential of platelet glycoprotein IIb/IIIa receptor antagonists in the management of ischemic stroke. *Am J Cardiovasc Drugs*. 2003;3:87–94.
389. Janardhan V, Qureshi AI. Mechanisms of ischemic brain injury. *Curr Cardiol Rep*. 2004;6:117–123.
390. Mitsias PD, Lu M, Silver B, Morris D, Ewing JR, Daley S, Lewandowski C, Katramados A, Papamitsakis NI, Ebadian HB, Zhao Q, Soltanian-Zadeh H, Hearshen D, Patel SC, Chopp M. MRI-guided, open trial of abciximab for ischemic stroke within a 3- to 24-hour window. *Neurology*. 2005;65:612–615.
391. The Abciximab in Ischemic Stroke Investigators. Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled, dose-escalation study. *Stroke*. 2000;31:601–609.
392. Abciximab Emergent Stroke Treatment Trial Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. *Stroke*. 2005;36:880–890.
393. Kiyohara Y, Ueda K, Hasuo Y, Fujii I, Yanai T, Wada J, Kawano H, Shikata T, Omae T, Fujishima M. Hematocrit as a risk factor of cerebral infarction: long-term prospective population survey in a Japanese rural community. *Stroke*. 1986;17:687–692.
394. Harrison MJ. Influence of haematocrit in the cerebral circulation. *Cerebrovasc Brain Metab Rev*. 1989;1:55–67.
395. Harrison MJ. Protection against ischaemia: the basis of acute stroke therapy. *Curr Opin Neurol Neurosurg*. 1992;5:33–38.
396. Belayev L, Busto R, Zhao W, Clemens JA, Ginsberg MD. Effect of delayed albumin hemodilution on infarction volume and brain edema after transient middle cerebral artery occlusion in rats. *J Neurosurg*. 1997;87:595–601.
397. Belayev L, Liu Y, Zhao W, Busto R, Ginsberg MD. Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. *Stroke*. 2001;32:553–560.
398. Belayev L, Pinard E, Nallet H, Seylaz J, Liu Y, Riyamongkol P, Zhao W, Busto R, Ginsberg MD. Albumin therapy of transient focal cerebral ischemia: in vivo analysis of dynamic microvascular responses. *Stroke*. 2002;33:1077–1084.
399. Liu Y, Belayev L, Zhao W, Busto R, Belayev A, Ginsberg MD. Neuroprotective effect of treatment with human albumin in permanent focal cerebral ischemia: histopathology and cortical perfusion studies. *Eur J Pharmacol*. 2001;428:193–201.
400. Handschu R, Garling A, Heuschmann PU, Kolominsky-Rabas PL, Erbguth F, Neundorfer B. Acute stroke management in the local general hospital. *Stroke*. 2001;32:866–870.
401. Vorstrup S, Andersen A, Juhler M, Brun B, Boysen G. Hemodilution increases cerebral blood flow in acute ischemic stroke. *Stroke*. 1989;20:884–889.
402. Hartmann A, Dettmers C, Beyenburg S. Effect of hemodilution on regional cerebral blood flow. *Acta Neurol Scand Suppl*. 1989;127:36–48.
403. Hartmann A, Dettmers C, Lagreze H, Tsuda Y. Blood flow and clinical course in patients with ischemic stroke without cerebrospecific therapy. *Acta Neurochir Suppl (Wien)*. 1993;57:130–135.
404. Hartmann A, Rommel T, Dettmers C, Tsuda Y, Lagreze H, Broich K. Hemodilution in cerebral infarcts. *Arzneimittelforschung*. 1991;41:348–351.
405. Hartmann A, Tsuda Y, Lagreze H. Effect of hypervolaemic hemodilution of regional cerebral blood flow in patients with acute ischaemic stroke: a controlled study with hydroxyethylstarch. *J Neurol*. 1987;235:34–38.
406. Wood JH, Polyzoidis KS, Kee DB Jr, Tsuda Y, Lagreze H, Broich K. Augmentation of cerebral blood flow induced by hemodilution in stroke patients after superficial temporal-middle cerebral arterial bypass operation. *Neurosurgery*. 1984;15:535–539.
407. Wood JH, Simeone FA, Fink EA, Golden MA. Hypervolemic hemodilution in experimental focal cerebral ischemia: elevation of cardiac

- output, regional cortical blood flow, and ICP after intravascular volume expansion with low molecular weight dextran. *J Neurosurg.* 1983;59:500–509.
408. Wood JH, Simeone FA, Kron RE, Snyder LL. Experimental hypervolemic hemodilution: physiological correlations of cortical blood flow, cardiac output, and intracranial pressure with fresh blood viscosity and plasma volume. *Neurosurgery.* 1984;14:709–723.
 409. Chien S. Haemorrheology in disease: pathophysiological significance and therapeutic implications. *Clin Hemorheol.* 1981;419–442.
 410. Aronowski J, Strong R, Grotta JC. Combined neuroprotection and reperfusion therapy for stroke: effect of lubeluzole and diaspirin cross-linked hemoglobin in experimental focal ischemia. *Stroke.* 1996;27:1571–1576; discussion 1576–1577.
 411. Kline RA, Negendank W, McCoy L, Berguer R. Beneficial effects of isovolemic hemodilution using a perfluorocarbon emulsion in a stroke model. *Am J Surg.* 1991;162:103–106.
 412. Kline RA, Negendank W, McCoy LE. Treatment of cerebral ischemia with Dextran-40 or Fluosol DA 20%. *Biomater Artif Cells Immobilization Biotechnol.* 1992;20:979–983.
 413. Standl T. Artificial oxygen carriers as red blood cell substitutes: perfluorocarbons and cell-free hemoglobin. *Infusionsther Transfusionsmed.* 2000;27:128–137.
 414. Standl T. Hemoglobin-based erythrocyte transfusion substitutes. *Expert Opin Biol Ther.* 2001;1:831–843.
 415. Yamashita K, Yamaguchi S, Kobayashi S. Effect of perfluorochemicals on experimental cerebral ischemia [in Japanese]. *No To Shinkei.* 1989;41:1205–1210.
 416. Scandinavian Stroke Study Group. Multicenter trial of hemodilution in acute ischemic stroke: results of subgroup analyses. *Stroke.* 1988;19:464–471.
 417. Frei A, Cottier C, Wunderlich P, Ludin E. Glycerol and dextran combined in the therapy of acute stroke: a placebo-controlled, double-blind trial with a planned interim analysis. *Stroke.* 1987;18:373–379.
 418. Scandinavian Stroke Study Group. Multicenter trial of hemodilution in ischemic stroke: background and study protocol. *Stroke.* 1985;16:885–890.
 419. Hemodilution in acute stroke. *Stroke.* 1986;17:332.
 420. Scandinavian Stroke Study Group. Multicenter trial of hemodilution in acute ischemic stroke, I: results in the total patient population. *Stroke.* 1987;18:691–699.
 421. Italian Acute Stroke Study Group. The Italian hemodilution trial in acute stroke. *Stroke.* 1987;18:670–676.
 422. The Hemodilution in Stroke Study Group. Hypervolemic hemodilution treatment of acute stroke: results of a randomized multicenter trial using pentastarch. *Stroke.* 1989;20:317–323.
 423. Schneider R. Current status of hemodilution therapy [in German]. *Acta Med Austriaca.* 1991;18(suppl 1):37–40.
 424. Schneider R, Hacke W, Kiesewetter H, Jung F. Hemodilution in acute ischemic insults: comparative study on the clinical and hemorheologic effectiveness of 10% HES 200/0.5 and 10% dextran 40 [in German]. *Fortschr Med.* 1985;103:1031–1034.
 425. Schneider R, Kutzim P. Hemodilution [in German]. *Fortschr Neurol Psychiatr.* 1988;56:361–372.
 426. Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. *Lancet.* 1978;2:1219–1222.
 427. Andine P, Rudolphi KA, Fredholm BB, Hagberg H. Effect of propentofylline (HWA 285) on extracellular purines and excitatory amino acids in CA1 of rat hippocampus during transient ischaemia. *Br J Pharmacol.* 1990;100:814–818.
 428. Miyashita K, Nakajima T, Ishikawa A, Miyatake T. An adenosine uptake blocker, propentofylline, reduces glutamate release in gerbil hippocampus following transient forebrain ischemia. *Neurochem Res.* 1992;17:147–150.
 429. Ward A, Clissold SP. Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. *Drugs.* 1987;34:50–97.
 430. Bluhm RE, Molnar J, Cohen MM. The effect of pentoxifylline on the energy metabolism of ischemic gerbil brain. *Clin Neuropharmacol.* 1985;8:280–285.
 431. DeLeo J, Schubert P, Kreutzberg GW. Protection against ischemic brain damage using propentofylline in gerbils. *Stroke.* 1988;19:1535–1539.
 432. Hsu CY, Norris JW, Hogan EL, Bladin P, Dinsdale HB, Yatsu FM, Earnest MP, Scheinberg P, Caplan LR, Karp HR. Pentoxifylline in acute nonhemorrhagic stroke: a randomized, placebo-controlled double-blind trial. *Stroke.* 1988;19:716–722.
 433. Chan YW, Kay CS. Pentoxifylline in the treatment of acute ischaemic stroke: a reappraisal in Chinese stroke patients. *Clin Exp Neurol.* 1993;30:110–116.
 434. Huber M, Kittner B, Hojer C, Fink GR, Neveling M, Heiss WD. Effect of propentofylline on regional cerebral glucose metabolism in acute ischemic stroke. *J Cereb Blood Flow Metab.* 1993;13:526–530.
 435. Wong WJ, HH, Lo YK, Chu FL. A control trial of pentoxifylline plus glycerine in the treatment of acute ischemic stroke. In: *Abstracts of the 7th Asian Congress of Neurology*; September 1987. 45.
 436. Heiss WD, Graf R. The ischemic penumbra. *Curr Opin Neurol.* 1994;7:11–19.
 437. Astrup J, Siesjo BK, Symon L. Thresholds in cerebral ischemia: the ischemic penumbra. *Stroke.* 1981;12:723–725.
 438. Heiss WD, Sobesky J, Hesselmann V. Identifying thresholds for penumbra and irreversible tissue damage. *Stroke.* 2004;35(suppl 1):2671–2674.
 439. Bath PM, Bath FJ, Asplund K. Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke. *Cochrane Database Syst Rev.* 2000;(2):CD000162.
 440. Powers WJ, Zazulia AR, Videen TO, Adams RE, Yundt KD, Aiyagari V, Grubb RL Jr, Diringer MN. Autoregulation of cerebral blood flow surrounding acute (6 to 22 hours) intracerebral hemorrhage. *Neurology.* 2001;57:18–24.
 441. Caplan LR. Worsening in ischemic stroke patients: is it time for a new strategy? *Stroke.* 2002;33:1443–1445.
 442. Bath FJ, Bath P. What is the correct management of blood pressure in acute stroke: the Blood Pressure in Acute Stroke Collaboration. *Cerebrovasc Dis.* 1997;7:205–213.
 443. Hillis AE, Barker PB, Beauchamp NJ, Winters BD, Mirski M, Wityk RJ. Restoring blood pressure reperfused Wernicke's area and improved language. *Neurology.* 2001;56:670–672.
 444. Hillis AE, Ulatowski JA, Barker PB, Torbey M, Ziai W, Beauchamp NJ, Oh S, Wityk RJ. A pilot randomized trial of induced blood pressure elevation: effects on function and focal perfusion in acute and subacute stroke. *Cerebrovasc Dis.* 2003;16:236–246.
 445. Rordorf G, Cramer SC, Efid JT, Schwamm LH, Buonanno F, Koroshetz WJ. Pharmacological elevation of blood pressure in acute stroke: clinical effects and safety. *Stroke.* 1997;28:2133–2138.
 446. Rordorf G, Koroshetz WJ, Ezzeddine MA, Segal AZ, Buonanno FS. A pilot study of drug-induced hypertension for treatment of acute stroke. *Neurology.* 2001;56:1210–1213.
 447. Olsen TS. Regional cerebral blood flow after occlusion of the middle cerebral artery. *Acta Neurol Scand.* 1986;73:321–337.
 448. Olsen TS, Larsen B, Herning M, Skriver EB, Lassen NA. Blood flow and vascular reactivity in collaterally perfused brain tissue: evidence of an ischemic penumbra in patients with acute stroke. *Stroke.* 1983;14:332–341.
 449. Wityk RJ, Restrepo L. Hypoperfusion and its augmentation in patients with brain ischemia. *Curr Treat Options Cardiovasc Med.* 2003;5:193–199.
 450. Wityk RJ, Stern BJ. Ischemic stroke: today and tomorrow. *Crit Care Med.* 1994;22:1278–1293.
 451. Meyer FB, Sundt TM Jr, Piepgras DG, Sandok BA, Forbes G. Emergency carotid endarterectomy for patients with acute carotid occlusion and profound neurological deficits. *Ann Surg.* 1986;203:82–89.
 452. Schneider C, Johansen K, Konigstein R, Metzner C, Oettinger W. Emergency carotid thromboendarterectomy: safe and effective. *World J Surg.* 1999;23:1163–1167.
 453. Kasper GC, Wladis AR, Lohr JM, Roedersheimer LR, Reed RL, Miller TJ, Welling RE. Carotid thromboendarterectomy for recent total occlusion of the internal carotid artery. *J Vasc Surg.* 2001;33:242–249; discussion 249–250.
 454. Gertler JP, Blankensteijn JD, Brewster DC, Moncure AC, Cambria RP, LaMuraglia GM, Darling RC Jr, Abbott WM. Carotid endarterectomy for unstable and compelling neurologic conditions: do results justify an aggressive approach? *J Vasc Surg.* 1994;19:32–40; discussion 40–42.
 455. Eckstein HH, Schumacher H, Dorfler A, Forsting M, Jansen O, Ringleb P, Allenberg JR. Carotid endarterectomy and intracranial thrombolysis: simultaneous and staged procedures in ischemic stroke. *J Vasc Surg.* 1999;29:459–471.

456. Eckstein HH, Schumacher H, Klemm K, Laubach H, Kraus T, Ringleb P, Dorfler A, Weigand M, Bardenheuer H, Allenberg JR. Emergency carotid endarterectomy. *Cerebrovasc Dis*. 1999;9:270–281.
457. Eckstein HH, Schumacher H, Laubach H, Ringleb P, Forsting M, Dorfler A, Bardenheuer H, Allenberg JR. Early carotid endarterectomy after non-disabling ischaemic stroke: adequate therapeutical option in selected patients. *Eur J Vasc Endovasc Surg*. 1998;15:423–428.
458. Gay JL, Curtil A, Buffiere S, Favre JP, Barral X. Urgent carotid artery repair: retrospective study of 21 cases. *Ann Vasc Surg*. 2002;16:401–406.
459. Huber R, Muller BT, Seitz RJ, Siebler M, Modder U, Sandmann W. Carotid surgery in acute symptomatic patients. *Eur J Vasc Endovasc Surg*. 2003;25:60–67.
460. Sbarigia E, Toni D, Speziale F, Falcou A, Sacchetti ML, Panico MA, Fiorelli M, Argentino C, Ducasse E, Fiorani P. Emergency and early carotid endarterectomy in patients with acute ischemic stroke selected with a predefined protocol: a prospective pilot study. *Int Angiol*. 2003;22:426–430.
461. Sundt TM, Sandok BA, Whisnant JP. Carotid endarterectomy: complications and preoperative assessment of risk. *Mayo Clin Proc*. 1975;50:301–306.
462. Biller J, Adams HP Jr, Boarini D, Godersky JC, Smoker WR, Kongable G. Intraluminal clot of the carotid artery: a clinical-angiographic correlation of nine patients and literature review. *Surg Neurol*. 1986;25:467–477.
463. Heros RC. Carotid endarterectomy in patients with intraluminal thrombus. *Stroke*. 1988;19:667–668.
464. Buchan A, Gates P, Pelz D, Barnett HJ. Intraluminal thrombus in the cerebral circulation: implications for surgical management. *Stroke*. 1988;19:681–687.
465. Crowell RM. STA-MCA bypass for acute focal cerebral ischemia. In: Schmiedek P, ed. *Microsurgery for Stroke*. New York, NY: Springer Verlag; 1977:244–250.
466. Yoshimoto Y, Kwak S. Superficial temporal artery–middle cerebral artery anastomosis for acute cerebral ischemia: the effect of small augmentation of blood flow. *Acta Neurochir (Wien)*. 1995;137:128–137, discussion 137.
467. Kakinuma K, Ezuka I, Takai N, Yamamoto K, Sasaki O. The simple indicator for revascularization of acute middle cerebral artery occlusion using angiogram and ultra-early embolectomy. *Surg Neurol*. 1999;51:332–341.
468. Meyer FB, Piepgras DG, Sundt TM Jr, Yanagihara T. Emergency embolectomy for acute occlusion of the middle cerebral artery. *J Neurosurg*. 1985;62:639–647.
469. Linskey ME, Sekhar LN, Hecht ST. Emergency embolectomy for embolic occlusion of the middle cerebral artery after internal carotid artery balloon test occlusion: case report. *J Neurosurg*. 1992;77:134–138.
470. Harrigan MR, Guterman LR. Endovascular treatment of acute stroke. *Neurosurg Clin N Am*. 2005;16:433–444, xi.
471. Molina CA, Saver JL. Extending reperfusion therapy for acute ischemic stroke: emerging pharmacological, mechanical, and imaging strategies. *Stroke*. 2005;36:2311–2320.
472. Nesbit GM, Luh G, Tien R, Barnwell SL. New and future endovascular treatment strategies for acute ischemic stroke. *J Vasc Interv Radiol*. 2004;15(pt 2):S103–S110.
473. Leary MC, Saver JL, Gobin YP, Jahan R, Duckwiler GR, Vinuela F, Kidwell CS, Frazee J, Starkman S. Beyond tissue plasminogen activator: mechanical intervention in acute stroke. *Ann Emerg Med*. 2003;41:838–846.
474. Hayashi K, Kitagawa N, Takahata H, Morikawa M, Yoshioka T, Shabani HK, Kitange G, Ochi M, Kaminogo M, Shibata S. Endovascular treatment for cervical carotid artery stenosis presenting with progressing stroke: three case reports. *Surg Neurol*. 2002;58:148–154; discussion 154.
475. Du Mesnil De Rochemont R, Sitzer M, Neumann-Haefelin T, Harmjanz A, Berkefeld J. Endovascular recanalization of acute atherothrombotic carotid artery occlusion holds up progressive stroke. *Neuroradiology*. 2004;46:583–586.
476. Gupta R, Schumacher HC, Mangla S, Meyers PM, Duong H, Khandji AG, Marshall RS, Mohr JP, Pile-Spellman J. Urgent endovascular revascularization for symptomatic intracranial atherosclerotic stenosis. *Neurology*. 2003;61:1729–1735.
477. Cohen JE, Leker RR, Gotkine M, Gomori M, Ben-Hur T. Emergent stenting to treat patients with carotid artery dissection: clinically and radiologically directed therapeutic decision making. *Stroke*. 2003;34:e254–e257.
478. Nedeltchev K, Brekenfeld C, Remonda L, Ozdoba C, Do DD, Arnold M, Mattle HP, Schroth G. Internal carotid artery stent implantation in 25 patients with acute stroke: preliminary results. *Radiology*. 2005;237:1029–1037.
479. Jovin TG, Gupta R, Uchino K, Jungreis CA, Wechsler LR, Hammer MD, Tayal A, Horowitz MB. Emergent stenting of extracranial internal carotid artery occlusion in acute stroke has a high revascularization rate. *Stroke*. 2005;36:2426–2430.
480. Brekenfeld C, Remonda L, Nedeltchev K, v Bredow F, Ozdoba C, Wiest R, Arnold M, Mattle HP, Schroth G. Endovascular neuroradiological treatment of acute ischemic stroke: techniques and results in 350 patients. *Neurol Res*. 2005;27(suppl 1):S29–S35.
481. Kirton A, Wong JH, Mah J, Ross BC, Kennedy J, Bell K, Hill MD. Successful endovascular therapy for acute basilar thrombosis in an adolescent. *Pediatrics*. 2003;112(pt 1):e248–e251.
482. Lin DD, Gailloud P, Beauchamp NJ, Aldrich EM, Wityk RJ, Murphy KJ. Combined stent placement and thrombolysis in acute vertebrobasilar ischemic stroke. *AJNR Am J Neuroradiol*. 2003;24:1827–1833.
483. Noser EA, Shaltoni HM, Hall CE, Alexandrov AV, Garami Z, Cacayorin ED, Song JK, Grotta JC, Campbell MS 3rd. Aggressive mechanical clot disruption: a safe adjunct to thrombolytic therapy in acute stroke? *Stroke*. 2005;36:292–296.
484. Berlis A, Lutsep H, Barnwell S, Norbush A, Wechsler L, Jungreis CA, Woolfenden A, Redekop G, Hartmann M, Schumacher M. Mechanical thrombolysis in acute ischemic stroke with endovascular photoacoustic recanalization. *Stroke*. 2004;35:1112–1116.
485. Yu W, Binder D, Foster-Barber A, Malek R, Smith WS, Higashida RT. Endovascular embolectomy of acute basilar artery occlusion. *Neurology*. 2003;61:1421–1423.
486. Schumacher HC, Meyers PM, Yavagal DR, Harel NY, Elkind MS, Mohr JP, Pile-Spellman J. Endovascular mechanical thrombectomy of an occluded superior division branch of the left MCA for acute cardioembolic stroke. *Cardiovasc Intervent Radiol*. 2003;26:305–308.
487. Antman EM, Giugliano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS, Vahanian A, Adgey AA, Menown I, Rupprecht HJ, Van der Wieken R, Ducas J, Scherer J, Anderson K, Van de Werf F, Braunwald E; The TIMI 14 Investigators. Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial. *Circulation*. 1999;99:2720–2732.
488. Lincoff AM, Califf RM, Van de Werf F, Willerson JT, White HD, Armstrong PW, Guetta V, Gibler WB, Hochman JS, Bode C, Vahanian A, Steg PG, Ardissino D, Savonitto S, Bar F, Sadowski Z, Betriu A, Booth JE, Wolski K, Waller M, Topol EJ; Global Use of Strategies To Open Coronary Arteries Investigators (GUSTO). Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. *JAMA*. 2002;288:2130–2135.
489. Smith WS, Sung G, Starkman S, Saver JL, Kidwell CS, Gobin YP, Lutsep HL, Nesbit GM, Grobelny T, Rymer MM, Silverman IE, Higashida RT, Budzik RF, Marks MP; MERCI Trial Investigators. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. *Stroke*. 2005;36:1432–1438.
490. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Canadian Cardiovascular Society. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). *Circulation*. 2004;110:e82–e292.
491. Alexandrov AV, Molina CA, Grotta JC, Garami Z, Ford SR, Alvarez-Sabin J, Montaner J, Saqqur M, Demchuk AM, Moya LA, Hill MD, Wojner AW; CLOTBUST Investigators. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. *N Engl J Med*. 2004;351:2170–2178.
492. The IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. *Stroke*. 2004;35:904–911.

493. Ernst R, Pancioli A, Tomsick T, Kissela B, Woo D, Kanter D, Jauch E, Carrozzella J, Spilker J, Broderick J. Combined intravenous and intra-arterial recombinant tissue plasminogen activator in acute ischemic stroke. *Stroke*. 2000;31:2552–2557.
494. Grotta J. Combination therapy with lubezole and t-PA in the treatment of acute ischemic stroke. Paper presented at: American Heart Association's 23rd International Joint Conference on Stroke; Anaheim, Calif; February, 1998.
495. De Georgia MA, Krieger DW, Abou-Chebl A, Devlin TG, Jauss M, Davis SM, Koroshetz WJ, Rordorf G, Warach S. Cooling for Acute Ischemic Brain Damage (COOL AID): a feasibility trial of endovascular cooling. *Neurology*. 2004;63:312–317.
496. Lyden P, Jacoby M, Schim J, Albers G, Mazzeo P, Ashwood T, Nordlund A, Odergren T. The Clomethiazole Acute Stroke Study in tissue-type plasminogen activator-treated stroke (CLASS-T): final results. *Neurology*. 2001;57:1199–1205.
497. Eckert B, Koch C, Thomalla G, Kucinski T, Grzyska U, Roether J, Alfke K, Jansen O, Zeumer H. Aggressive therapy with intravenous abciximab and intra-arterial rtPA and additional PTA/stenting improves clinical outcome in acute vertebralbasilar occlusion: combined local fibrinolysis and intravenous abciximab in acute vertebralbasilar stroke treatment (FAST): results of a multicenter study. *Stroke*. 2005;36:1160–1165.
498. Lee DH, Jo KD, Kim HG, Choi SJ, Jung SM, Ryu DS, Park MS. Local intraarterial urokinase thrombolysis of acute ischemic stroke with or without intravenous abciximab: a pilot study. *J Vasc Interv Radiol*. 2002;13:769–774.
499. Qureshi AI, Harris-Lane P, Kirmani JF, Janjua N, Divani AA, Mohammad YM, Suarez JI, Montgomery MO. Intra-arterial reteplase and intravenous abciximab in patients with acute ischemic stroke: an open-label, dose-ranging, phase I study. *Neurosurgery*. 2006;59:789–796; discussion 796–797.
500. Qureshi AI, Suri MF, Ali Z, Ringer AJ, Boulos AS, Nakada MT, Alberico RA, Martin LB, Guterman LR, Hopkins LN. Intraarterial reteplase and intravenous abciximab for treatment of acute ischemic stroke: a preliminary feasibility and safety study in a non-human primate model. *Neuroradiology*. 2005;47:845–854.
501. Lutsep HL, Clark WM. Neuroprotection in acute ischaemic stroke: current status and future potential. *Drugs R D*. 1999;1:3–8.
502. Wahlgren NG, Ahmed N. Neuroprotection in cerebral ischaemia: facts and fancies—the need for new approaches. *Cerebrovasc Dis*. 2004;17(suppl 1):153–166.
503. Mayberg MR, Batjer HH, Dacey R, Diringer M, Haley EC, Heros RC, Sternau LL, Torner J, Adams HP Jr, Feinberg W, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. *Stroke*. 1994;25:2315–2328.
504. Kaste M, Fogelholm R, Eriola T, Palomaki H, Murros K, Rissanen A, Sarna S. A randomized, double-blind, placebo-controlled trial of nimodipine in acute ischemic hemispheric stroke. *Stroke*. 1994;25:1348–1353.
505. Bogousslavsky J, Regli F, Zumstein V, Kobberling W. Double-blind study of nimodipine in non-severe stroke. *Eur Neurol*. 1990;30:23–26.
506. The American Nimodipine Study Group. Clinical trial of nimodipine in acute ischemic stroke [published correction appears in *Stroke*. 1992;23:615]. *Stroke*. 1992;23:3–8.
507. Mohr JP, Orgogozo JM, Harrison MJG, Hennerici M, Wahlgren NG, Gelmers JH, Martinez-Vila E, Dyck J, Tetteborn D. Meta-analysis of oral nimodipine trials in acute ischemic stroke. *Cerebrovasc Dis*. 1994;4:197–203.
508. Horn J, de Haan RJ, Vermeulen M, Limburg M. Very Early Nimodipine Use in Stroke (VENUS): a randomized, double-blind, placebo-controlled trial. *Stroke*. 2001;32:461–465.
509. Franke CL, Palm R, Dalby M, Schoonderwaldt HC, Hantson L, Eriksson B, Lang-Jenssen L, Smakman J. Flunarizine in Stroke Treatment (FIST): a double-blind, placebo-controlled trial in Scandinavia and the Netherlands. *Acta Neurol Scand*. 1996;93:56–60.
510. Azcona A, Lataste X. Isradipine in patients with acute ischaemic cerebral infarction: an overview of the ASCLEPIOS Programme. *Drugs*. 1990;40(suppl 2):52–57.
511. Oczkowski WJ, Hachinski VC, Bogousslavsky J, Barnett HJ, Carruthers SG. A double-blind, randomized trial of PY108-068 in acute ischemic cerebral infarction. *Stroke*. 1989;20:604–608.
512. Rosenbaum D, Zabramski J, Frey J, Yatsu F, Marler J, Spetzler R, Grotta J. Early treatment of ischemic stroke with a calcium antagonist. *Stroke*. 1991;22:437–441.
513. Horn J, Limburg M. Calcium antagonists for acute ischemic stroke. *Cochrane Database Syst Rev*. 2000;(2):CD001928.
514. Grotta J, Clark W, Coull B, Pettigrew LC, Mackay B, Goldstein LB, Meissner I, Murphy D, LaRue L. Safety and tolerability of the glutamate antagonist CGS 19755 (selfotel) in patients with acute ischemic stroke: results of a phase IIa randomized trial. *Stroke*. 1995;26:602–605.
515. Morris GF, Bullock R, Marshall SB, Marmarou A, Maas A, Marshall LF; the Selfotel Investigators. Failure of the competitive N-methyl-D-aspartate antagonist selfotel (CGS 19755) in the treatment of severe head injury: results of two phase III clinical trials. *J Neurosurg*. 1999;91:737–743.
516. Davis SM, Lees KR, Albers GW, Diener HC, Markabi S, Karlsson G, Norris J. Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. *Stroke*. 2000;31:347–354.
517. Albers GW, Goldstein LB, Hall D, Lesko LM; Aptiganel Acute Stroke Investigators. Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial. *JAMA*. 2001;286:2673–2682.
518. Dyker AG, Edwards KR, Fayad PB, Hormes JT, Lees KR. Safety and tolerability study of aptiganel hydrochloride in patients with an acute ischemic stroke. *Stroke*. 1999;30:2038–2042.
519. Albers GW, Atkinson RP, Kelley RE, Rosenbaum DM; Dextrorphan Study Group. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. *Stroke*. 1995;26:254–258.
520. Arrowsmith JE, Harrison MJ, Newman SP, Stygall J, Timberlake N, Pugsley WB. Neuroprotection of the brain during cardiopulmonary bypass: a randomized trial of remacemide during coronary artery bypass in 171 patients. *Stroke*. 1998;29:2357–2362.
521. Dyker AG, Lees KR. Remacemide hydrochloride: a double-blind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke. *Stroke*. 1999;30:1796–1801.
522. Diener HC, AlKhedr A, Busse O, Hacke W, Zingmark PH, Jonsson N, Basun H; Study Group. Treatment of acute ischaemic stroke with the low-affinity, use-dependent NMDA antagonist AR-R15896AR: a safety and tolerability study. *J Neurol*. 2002;249:561–568.
523. Lees KR, Asplund K, Carolei A, Davis SM, Diener HC, Kaste M, Orgogozo JM, Whitehead J; GAIN International Investigators. Glycine Antagonist (gavestinel) in Neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. *Lancet*. 2000;355:1949–1954.
524. Lees KR, Lavelle JF, Cunha L, Diener HC, Sanders EA, Tack P, Wester P; GAIN Phase II European Study Group. Glycine antagonist (GV150526) in acute stroke: a multicentre, double-blind placebo-controlled phase II trial. *Cerebrovasc Dis*. 2001;11:20–29.
525. Sacco RL, DeRosa JT, Haley EC Jr, Levin B, Ordonneau P, Phillips SJ, Rundek T, Snipes RG, Thompson JL; Glycine Antagonist in Neuroprotection Americas Investigators. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial. *JAMA*. 2001;285:1719–1728.
526. Haley EC Jr, Thompson JL, Levin B, Davis S, Lees KR, Pittman JG, DeRosa JT, Ordonneau P, Brown DL, Sacco RL; GAIN Americas and GAIN International Investigators. Gavestinel does not improve outcome after acute intracerebral hemorrhage: an analysis from the GAIN International and GAIN Americas studies. *Stroke*. 2005;36:1006–1010.
527. Albers GW, Clark WM, Atkinson RP, Madden K, Data JL, Whitehouse MJ. Dose escalation study of the NMDA glycine-site antagonist licoxstinel in acute ischemic stroke. *Stroke*. 1999;30:508–513.
528. Dyker AG, Lees KR. Safety and tolerability of GV150526 (a glycine site antagonist at the N-methyl-D-aspartate receptor) in patients with acute stroke. *Stroke*. 1999;30:986–992.
529. Lees KR. Cerestat and other NMDA antagonists in ischemic stroke. *Neurology*. 1997;49(suppl 4):S66–S69.
530. Muir KW, Lees KR. Excitatory amino acid antagonists for acute stroke. *Cochrane Database Syst Rev*. 2003;(3):CD001244.
531. Muir KW, Holzapfel L, Lees KR. Phase II clinical trial of sipatrigine (619C89) by continuous infusion in acute stroke. *Cerebrovasc Dis*. 2000;10:431–436.
532. Yasuda T, Gold HK, Leinbach RC, Saito T, Guerrero JL, Jang IK, Holt R, Fallon JT, Collen D. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody. *J Am Coll Cardiol*. 1990;16:1728–1735.
533. Lutsep HL. Repinotan Bayer. *Curr Opin Investig Drugs*. 2002;3:924–927.

534. Grotta J; Combination Therapy Stroke Trial Investigators. Combination Therapy Stroke Trial: recombinant tissue-type plasminogen activator with/without lubeluzole. *Cerebrovasc Dis*. 2001;12:258–263.
535. Diener HC, Hacke W, Hennerici M, Radberg J, Hantson L, De Keyser J; Lubeluzole International Study Group. Lubeluzole in acute ischemic stroke: a double-blind, placebo-controlled phase II trial. *Stroke*. 1996;27:76–81.
536. Grotta J; the US and Canadian Lubeluzole Ischemic Stroke Study Group. Lubeluzole treatment of acute ischemic stroke. *Stroke*. 1997;28:2338–2346.
537. Diener HC, Cortens M, Ford G, Grotta J, Hacke W, Kaste M, Koudstaal PJ, Wessel T. Lubeluzole in acute ischemic stroke treatment: a double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo. *Stroke*. 2000;31:2543–2551.
538. Gandolfo C, Sandercock P, Conti M. Lubeluzole for acute ischaemic stroke. *Cochrane Database Syst Rev*. 2002;(1):CD001924.
539. Wahlgren NG, Bornhov S, Sharma A, Cederin B, Rosolacci T, Ashwood T, Claesson L, for the CLASS Study Group. The Clomethiazole Acute Stroke Study (CLASS): efficacy results in 545 patients classified as total anterior circulation syndrome (TACS). *J Stroke Cerebrovasc Dis*. 1999;8:1–10.
540. Wahlgren NG, Diez-Tejedor E, Teitelbaum J, Arboix A, Leys D, Ashwood T, Grossman E. Results in 95 hemorrhagic stroke patients included in CLASS, a controlled trial of clomethiazole versus placebo in acute stroke patients. *Stroke*. 2000;31:82–85.
541. Wahlgren NG, Ranasinha KW, Rosolacci T, Franke CL, van Erven PM, Ashwood T, Claesson L. Clomethiazole acute stroke study (CLASS): results of a randomized, controlled trial of clomethiazole versus placebo in 1360 acute stroke patients. *Stroke*. 1999;30:21–28.
542. Deleted in proof.
543. Wester P, Strand T, Wahlgren NG, Ashwood T, Osswald G. An open study of clomethiazole in patients with acute cerebral infarction. *Cerebrovasc Dis*. 1998;8:188–190.
544. Zingmark PH, Ekblom M, Odergren T, Ashwood T, Lyden P, Karlsson MO, Jonsson EN. Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients. *Br J Clin Pharmacol*. 2003;56:173–183.
545. Lyden P, Shuaib A, Ng K, Levin K, Atkinson RP, Rajput A, Wechsler L, Ashwood T, Claesson L, Odergren T, Salazar-Grueso E; CLASS-I/HT Investigators. Clomethiazole Acute Stroke Study in ischemic stroke (CLASS-I): final results. *Stroke*. 2002;33:122–128.
546. Major ongoing stroke trials. *Stroke*. 2002;33:646–655.
547. Olinger CP, Adams HP Jr, Brott TG, Biller J, Barsan WG, Toffol GJ, Eberle RW, Marler JR. High-dose intravenous naloxone for the treatment of acute ischemic stroke. *Stroke*. 1990;21:721–725.
548. Clark WM, Raps EC, Tong DC, Kelly RE; the Cervene Stroke Study Investigators. Cervene (nalmefene) in acute ischemic stroke: final results of a phase III efficacy study. *Stroke*. 2000;31:1234–1239.
549. Clarke W, Ertag W, Orecchio E, Reys E. Cervene in acute ischemic stroke: results of a double-blind, placebo-controlled, dose-comparison study. *J Stroke Cerebrovasc Dis*. 1999;8:224–230.
550. Lees KR, Sharma AK, Barer D, Ford GA, Kostulas V, Cheng YF, Odergren T. Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke. *Stroke*. 2001;32:675–680.
551. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Hardemark HG, Wasiewski WW; Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators. NXY-059 for acute ischemic stroke. *N Engl J Med*. 2006;354:588–600.
552. Piriyaat P, Labiche LA, Burgin WS, Aronowski JA, Grotta JC. Pilot dose-escalation study of caffeine plus ethanol (caffeinol) in acute ischemic stroke. *Stroke*. 2003;34:1242–1245.
553. Muir KW, Lees KR. A randomized, double-blind, placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke. *Stroke*. 1995;26:1183–1188.
554. Muir KW, Lees KR. Dose optimization of intravenous magnesium sulfate after acute stroke. *Stroke*. 1998;29:918–923.
555. Lampl Y, Gilad R, Geva D, Eshel Y, Sadeh M. Intravenous administration of magnesium sulfate in acute stroke: a randomized double-blind study. *Clin Neuropharmacol*. 2001;24:11–15.
556. Muir KW, Lees KR, Ford I, Davis S; Intravenous Magnesium Efficacy in Stroke (IMAGES) Study Investigators. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. *Lancet*. 2004;363:439–445.
557. The RANTTAS Investigators. A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS). *Stroke*. 1996;27:1453–1458.
558. Haley EC Jr; RANTTAS II Investigators. High-dose tirilazad for acute stroke (RANTTAS II). *Stroke*. 1998;29:1256–1257.
559. Bath PM, Iddenden R, Bath FJ, Orgogozo JM; Tirilazad International Steering Committee. Tirilazad for acute ischaemic stroke. *Cochrane Database Syst Rev*. 2001;(4):CD002087.
560. Yamaguchi T, Sano K, Takakura K, Saito I, Shinohara Y, Asano T, Yasuhara H; Ebselen Study Group. Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. *Stroke*. 1998;29:12–17.
561. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction: randomized, placebo-controlled, double-blind study at multicenters. *Cerebrovasc Dis*. 2003;15:222–229.
562. Clark WM, Warach SJ, Pettigrew LC, Gammans RE, Sabounjian LA; Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. *Neurology*. 1997;49:671–678.
563. Clark WM, Williams BJ, Selzer KA, Zweifler RM, Sabounjian LA, Gammans RE. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. *Stroke*. 1999;30:2592–2597.
564. Clark WM, Wechsler LR, Sabounjian LA, Schwiderski UE; Citicoline Stroke Study Group. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. *Neurology*. 2001;57:1595–1602.
565. Davalos A, Castillo J, Alvarez-Sabin J, Secades JJ, Mercadal J, Lopez S, Cobo E, Warach S, Sherman D, Clark WM, Lozano R. Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. *Stroke*. 2002;33:2850–2857.
566. Lenzi GL, Grigoletto F, Gent M, Roberts RS, Walker MD, Easton JD, Carolei A, Dorsey FC, Rocca WA, Bruno R, et al. Early treatment of stroke with monosialoganglioside GM-1: efficacy and safety results of the Early Stroke Trial. *Stroke*. 1994;25:1552–1558.
567. Ganglioside GM1 in acute ischemic stroke: the SASS Trial. *Stroke*. 1994;25:1141–1148.
568. Bassi S, Albizzati MG, Sbacchi M, Frattola L, Massarotti M. Double-blind evaluation of monosialoganglioside (GM1) therapy in stroke. *J Neurosci Res*. 1984;12:493–498.
569. Argentino C, Sacchetti ML, Toni D, Savoini G, D'Arcangelo E, Erminio F, Federico F, Milone FF, Gallai V, Gambi D, et al. GM1 ganglioside therapy in acute ischemic stroke: Italian Acute Stroke Study–Hemodilution + Drug. *Stroke*. 1989;20:1143–1149.
570. Candelise L, Ciccone A. Gangliosides for acute ischaemic stroke. *Cochrane Database Syst Rev*. 2001;(4):CD000094.
571. De Deyn PP, Reuck JD, Deberdt W, Vlietinck R, Orgogozo JM; members of the Piracetam in Acute Stroke Study (PASS) Group. Treatment of acute ischemic stroke with piracetam. *Stroke*. 1997;28:2347–2352.
572. De Reuck J, Van Vleymen B. The clinical safety of high-dose piracetam: its use in the treatment of acute stroke. *Pharmacopsychiatry*. 1999;32(suppl 1):33–37.
573. Huber W. The role of piracetam in the treatment of acute and chronic aphasia. *Pharmacopsychiatry*. 1999;32(suppl 1):38–43.
574. Orgogozo JM. Piracetam in the treatment of acute stroke. *Pharmacopsychiatry*. 1999;32(suppl 1):25–32.
575. Martinez-Vila E, Sieira PI. Current status and perspectives of neuroprotection in ischemic stroke treatment. *Cerebrovasc Dis*. 2001;11(suppl 1):60–70.
576. Ricci S, Celani MG, Cantisani AT, Righetti E. Piracetam for acute ischaemic stroke. *Cochrane Database Syst Rev*. 2002;(4):CD000419.
577. Enlimomab Acute Stroke Trial Investigators. Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. *Neurology*. 2001;57:1428–1434.
578. Krams M, Lees KR, Hacke W, Grieve AP, Orgogozo J, Ford GA. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. *Stroke*. 2003;34:2543–2548.
579. Ladurner G, Kalvach P, Moessler H; Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. *J Neural Transm*. 2005;112:415–428.
580. Bogousslavsky J, Victor SJ, Salinas EO, Pallay A, Donnan GA, Fieschi C, Kaste M, Orgogozo JM, Chamorro A, Desmet A; European-Australian Fiblast (Trafermin) in Acute Stroke Group. Fiblast (trafermin) in acute stroke: results of the European-Australian phase II/III safety and efficacy trial. *Cerebrovasc Dis*. 2002;14:239–251.

581. Schmid-Elsaesser R, Hungerhuber E, Zausinger S, Baethmann A, Reulen HJ. Combination drug therapy and mild hypothermia: a promising treatment strategy for reversible, focal cerebral ischemia. *Stroke*. 1999;30:1891-1899.
582. Keller E, Imhof HG, Gasser S, Terzic A, Yonekawa Y. Endovascular cooling with heat exchange catheters: a new method to induce and maintain hypothermia. *Intensive Care Med*. 2003;29:939-943.
583. Feigin VL, Anderson CS, Rodgers A, Anderson NE, Gunn AJ. The emerging role of induced hypothermia in the management of acute stroke. *J Clin Neurosci*. 2002;9:502-507.
584. Fisher M. Ongoing trials and future directions for acute ischemic stroke treatment. *Adv Neurol*. 2003;92:401-408.
585. Davalos A, Cendra E, Teruel J, Martinez M, Genis D. Deteriorating ischemic stroke: risk factors and prognosis. *Neurology*. 1990;40:1865-1869.
586. Roden-Jullig A. Progressing stroke: epidemiology. *Cerebrovasc Dis*. 1997;7(suppl 5):2-5.
587. Castillo J. Deteriorating stroke: diagnostic criteria, predictors, mechanisms and treatment. *Cerebrovasc Dis*. 1999;9(suppl 3):1-8.
588. Yamamoto H, Bogousslavsky J, van Melle G. Different predictors of neurological worsening in different causes of stroke. *Arch Neurol*. 1998;55:481-486.
589. Hack W, Kaste M, Bogousslavsky J, Brainin M, Chamorro A, Lees K, Leys D, Kwicinski H, Toni P, Langhorne P, Diener C, Hennerici M, Ferro J, Sivenius J, Gunnar N, Bath P, Olsen TS, Gugging M; European Stroke Initiative Executive Committee and the EUSI Writing Committee. European Stroke Initiative recommendations for stroke management: update 2003. *Cerebrovasc Dis*. 2003;16:311-337.
590. van der Worp HB, Kappelle LJ. Complications of acute ischaemic stroke. *Cerebrovasc Dis*. 1998;8:124-132.
591. Johnston KC, Li JY, Lyden PD, Hanson SK, Feasby TE, Adams RJ, Faught RE Jr, Haley EC Jr; RANTTAS Investigators. Medical and neurological complications of ischemic stroke: experience from the RANTTAS trial. *Stroke*. 1998;29:447-453.
592. Langhorne P, Stott DJ, Robertson L, MacDonald J, Jones L, McAlpine C, Dick F, Taylor GS, Murray G. Medical complications after stroke: a multicenter study. *Stroke*. 2000;31:1223-1229.
593. Zorowitz RD, Tietjen GE. Medical complications after stroke. *J Stroke Cerebrovasc Dis*. 1999;8:192-196.
594. Stroke Unit Trialists Collaboration. How do stroke units improve patient outcomes? A collaborative systematic review of the randomized trials. *Stroke*. 1997;28:2139-2144.
595. Stroke Unit Trialists' Collaboration. Collaborative systematic review of the randomised trials of organised inpatient (stroke unit) care after stroke. *BMJ*. 1997;314:1151-1159.
596. Organised inpatient (stroke unit) care for stroke. *Cochrane Database Syst Rev*. 2002;(1):CD000197.
597. Ronning OM, Guldvog B. Stroke unit versus general medical wards, II: neurological deficits and activities of daily living: a quasi-randomized controlled trial. *Stroke*. 1998;29:586-590.
598. Ronning OM, Guldvog B. Stroke units versus general medical wards, I: twelve- and eighteen-month survival: a randomized, controlled trial. *Stroke*. 1998;29:58-62.
599. Indredavik B, Slordahl SA, Bakke F, Rokseth R, Haheim LL. Stroke unit treatment: long-term effects. *Stroke*. 1997;28:1861-1866.
600. Indredavik B, Bakke F, Solberg R, Rokseth R, Haheim LL, Holme I. Benefit of a stroke unit: a randomized controlled trial. *Stroke*. 1991;22:1026-1031.
601. Indredavik B, Bakke F, Slordahl SA, Rokseth R, Haheim LL. Stroke unit treatment: 10-year follow-up. *Stroke*. 1999;30:1524-1527.
602. Indredavik B, Bakke F, Slordahl SA, Rokseth R, Haheim LL. Stroke unit treatment improves long-term quality of life: a randomized controlled trial. *Stroke*. 1998;29:895-899.
603. Indredavik B. Stroke units: the Norwegian experience. *Cerebrovasc Dis*. 2003;15(suppl 1):19-20.
604. Stegmayr B, Asplund K, Hulter-Asberg K, Norrving B, Peltonen M, Terent A, Wester PO; Riks-Stroke Collaboration. Stroke units in their natural habitat: can results of randomized trials be reproduced in routine clinical practice? *Stroke*. 1999;30:709-714.
605. Rudd AG, Hoffman A, Irwin P, Lowe D, Pearson MG. Stroke unit care and outcome: results from the 2001 National Sentinel Audit of Stroke (England, Wales, and Northern Ireland). *Stroke*. 2005;36:103-106.
606. Koton S, Tanne D, Bornstein NM, Green MS. Triggering risk factors for ischemic stroke: a case-crossover study. *Neurology*. 2004;63:2006-2010.
607. Gilligan AK, Thrift AG, Sturm JW, Dewey HM, Macdonell RA, Donnan GA. Stroke units, tissue plasminogen activator, aspirin and neuroprotection: which stroke intervention could provide the greatest community benefit? *Cerebrovasc Dis*. 2005;20:239-244.
608. Davis SM, Donnan GA. Stroke unit design: high tech versus low tech. *Stroke*. 2004;35:1021.
609. Indredavik B. Intensive monitoring should not be the routine. *Stroke*. 2004;35:1019-1020.
610. Kwan J, Sandercock P. In-hospital care pathways for stroke. *Cochrane Database Syst Rev*. 2004;(4):CD002924.
611. California Acute Stroke Pilot Registry Investigators. The impact of standardized stroke orders on adherence to best practices. *Neurology*. 2005;65:360-365.
612. Minkman MM, Schouten LM, Huijsman R, van Splunteren PT. Integrated care for patients with a stroke in the Netherlands: results and experiences from a national Breakthrough Collaborative Improvement project. *Int J Integr Care*. 2005;5:e14.
613. Langhorne P. Measures to improve recovery in the acute phase of stroke. *Cerebrovasc Dis*. 1999;9(suppl 5):2-5.
614. Zorowitz RD, Hughes MB, Idank D, Ikai T, Johnston MV. Shoulder pain and subluxation after stroke: correlation or coincidence? *Am J Occup Ther*. 1996;50:194-201.
615. Linn SL, Granat MH, Lees KR. Prevention of shoulder subluxation after stroke with electrical stimulation. *Stroke*. 1999;30:963-968.
616. Tutuarima JA, van der Meulen JH, de Haan RJ, van Straten A, Limburg M. Risk factors for falls of hospitalized stroke patients. *Stroke*. 1997;28:297-301.
617. Choi-Kwon S, Yang YH, Kim EK, Jeon MY, Kim JS. Nutritional status in acute stroke: undernutrition versus overnutrition in different stroke subtypes. *Acta Neurol Scand*. 1998;98:187-192.
618. Gariballa SE, Parker SG, Taub N, Castleden C. Influence of nutritional status on clinical outcome after acute stroke. *Am J Clin Nutr*. 1998;68:275-281.
619. Martino R, Foley N, Bhogal S, Diamant N, Speechley M, Teasell R. Dysphagia after stroke: incidence, diagnosis, and pulmonary complications. *Stroke*. 2005;36:2756-2763.
620. Mann G, Hankey GJ, Cameron D. Swallowing function after stroke: prognosis and prognostic factors at 6 months. *Stroke*. 1999;30:744-748.
621. Daniels SK, Brailey K, Foundas AL. Lingual discoordination and dysphagia following acute stroke: analyses of lesion localization. *Dysphagia*. 1999;14:85-92.
622. Daniels SK, Ballo LA, Mahoney MC, Foundas AL. Clinical predictors of dysphagia and aspiration risk: outcome measures in acute stroke patients. *Arch Phys Med Rehabil*. 2000;81:1030-1033.
623. Elmstahl S, Bulow M, Ekberg O, Petersson M, Tegner H. Treatment of dysphagia improves nutritional conditions in stroke patients. *Dysphagia*. 1999;14:61-66.
624. Addington WR, Stephens RE, Gilliland KA. Assessing the laryngeal cough reflex and the risk of developing pneumonia after stroke: an interhospital comparison. *Stroke*. 1999;30:1203-1207.
625. O'Mahony D, McIntyre AS. Artificial feeding for elderly patients after stroke. *Age Ageing*. 1995;24:533-535.
626. James A, Kapur K, Hawthorne AB. Long-term outcome of percutaneous endoscopic gastrostomy feeding in patients with dysphagic stroke. *Age Ageing*. 1998;27:671-676.
627. Wijdicks EF, McMahon MM. Percutaneous endoscopic gastrostomy after acute stroke: complications and outcome. *Cerebrovasc Dis*. 1999;9:109-111.
628. Tsao JW, Hemphill JC 3rd, Johnston SC, Smith WS, Bonovich DC. Initial Glasgow Coma Scale score predicts outcome following thrombolysis for posterior circulation stroke. *Arch Neurol*. 2005;62:1126-1129.
629. Dennis MS, Lewis SC, Warlow C; FOOD Trial Collaboration. Routine oral nutritional supplementation for stroke patients in hospital (FOOD): a multicentre randomised controlled trial. *Lancet*. 2005;365:755-763.
630. Dennis MS, Lewis SC, Warlow C; FOOD Trial Collaboration. Effect of timing and method of enteral tube feeding for dysphagic stroke patients (FOOD): a multicentre randomised controlled trial. *Lancet*. 2005;365:764-772.
631. Harari D, Norton C, Lockwood L, Swift C. Treatment of constipation and fecal incontinence in stroke patients: randomized controlled trial. *Stroke*. 2004;35:2549-2555.
632. Nakagawa T, Sekizawa K, Arai H, Kikuchi R, Manabe K, Sasaki H. High incidence of pneumonia in elderly patients with basal ganglia infarction. *Arch Intern Med*. 1997;157:321-324.

633. Aslanyan S, Weir CJ, Diener HC, Kaste M, Lees KR; GAIN International Steering Committee and Investigators. Pneumonia and urinary tract infection after acute ischaemic stroke: a tertiary analysis of the GAIN International trial. *Eur J Neurol*. 2004;11:49–53.
634. Field TS, Green TL, Roy K, Pedersen J, Hill MD. Trends in hospital admission for stroke in Calgary. *Can J Neurol Sci*. 2004;31:387–393.
635. Chamorro A, Horcajada JP, Obach V, Vargas M, Revilla M, Torres F, Cervera A, Planas AM, Mensa J. The Early Systemic Prophylaxis of Infection After Stroke study: a randomized clinical trial. *Stroke*. 2005;36:1495–1500.
636. Ween JE, Alexander MP, D'Esposito M, Roberts M. Incontinence after stroke in a rehabilitation setting: outcome associations and predictive factors. *Neurology*. 1996;47:659–663.
637. Wijdicks EF, Scott JP. Pulmonary embolism associated with acute stroke. *Mayo Clin Proc*. 1997;72:297–300.
638. Desmukh M, Bisognani M, Landau P, Orchard TJ. Deep vein thrombosis in rehabilitating stroke patients: incidence, risk factors and prophylaxis. *Am J Phys Med Rehabil*. 1991;70:313–316.
639. Warlow C, Ogston D, Douglas AS. Deep venous thrombosis of the legs after strokes, part I: incidence and predisposing factors. *BMJ*. 1976;1:1178–1181.
640. Kelly J, Rudd A, Lewis RR, Coshall C, Moody A, Hunt BJ. Venous thromboembolism after acute ischemic stroke: a prospective study using magnetic resonance direct thrombus imaging. *Stroke*. 2004;35:2320–2325.
641. Kelly J, Rudd A, Lewis R, Hunt BJ. Venous thromboembolism after acute stroke. *Stroke*. 2001;32:262–267.
642. Sun KK, Wang C, Guli XT, Luo Q. Risk factors and clinical features of deep venous thrombosis: a report of 388 cases [in Chinese]. *Zhonghua Jie He He Hu Xi Za Zhi*. 2004;27:727–730.
643. Jacobs BS, Baker PL, Roychoudhury C, Mehta RH, Levine SR. Improved quality of stroke care for hospitalized Medicare beneficiaries in Michigan. *Stroke*. 2005;36:1227–1231.
644. Roychoudhury C, Jacobs BS, Baker PL, Schultz D, Mehta RH, Levine SR. Acute ischemic stroke in hospitalized medicare patients: evaluation and treatment. *Stroke*. 2004;35:e22–23.
645. Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a cost-effectiveness analysis. *Ann Intern Med*. 1999;130:789–799.
646. Hyers TM, Agnelli G, Hull RD, Weg JG, Morris TA, Samama M, Tapson V. Antithrombotic therapy for venous thromboembolic disease. *Chest*. 1998;114(suppl):561S–578S.
647. Sandercock PA, van den Belt AG, Lindley RI, Slattery J. Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials. *J Neurol Neurosurg Psychiatry*. 1993;56:17–25.
648. Counsell C, Sandercock P. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. *Cochrane Database Syst Rev*. 2001;(4):CD000119.
649. McCarthy ST, Turner JJ, Robertson D, Hawkey CJ, Macey DJ. Low-dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke. *Lancet*. 1977;2:800–801.
650. McCarthy ST, Turner J. Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke. *Age Ageing*. 1986;15:84–88.
651. Sandset PM, Dahl T, Stiris M, Rostad B, Scheel B, Abildgaard U. A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke. *Semin Thromb Hemost*. 1990;16(suppl):25–33.
652. Turpie AG. Prophylaxis of venous thromboembolism in stroke patients. *Semin Thromb Hemost*. 1997;23:155–157.
653. Turpie AG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Magnani HN, Hull RD, Gent M. Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. *Lancet*. 1987;1:523–526.
654. Kamphuisen PW, Agnelli G, Sebastianelli M. Prevention of venous thromboembolism after acute ischemic stroke. *J Thromb Haemost*. 2005;3:1187–1194.
655. Davis SM, Donnan GA. Effective prophylaxis for deep venous thrombosis after stroke: both low-dose anticoagulation and stockings for most cases. *Stroke*. 2004;35:2910.
656. Dennis MS. Effective prophylaxis for deep vein thrombosis after stroke: low-dose anticoagulation rather than stockings alone: against. *Stroke*. 2004;35:2912–2913.
657. Adams HP Jr. Effective prophylaxis for deep vein thrombosis after stroke: low-dose anticoagulation rather than stockings alone: for. *Stroke*. 2004;35:2911–2912.
658. Harvey RL. Prevention of venous thromboembolism after stroke. *Top Stroke Rehabil*. 2003;10:61–69.
659. Harvey RL, Lovell LL, Belanger N, Roth EJ. The effectiveness of anticoagulant and antiplatelet agents in preventing venous thromboembolism during stroke rehabilitation: a historical cohort study. *Arch Phys Med Rehabil*. 2004;85:1070–1075.
660. Busch M, Masuhr F. Thromboprophylaxis and early antithrombotic therapy in patients with acute ischemic stroke and cerebral venous and sinus thrombosis. *Eur J Med Res*. 2004;9:199–206.
661. Ridker PM, Goldhaber SZ, Glynn RJ. Low-intensity versus conventional-intensity warfarin for prevention of recurrent venous thromboembolism. *N Engl J Med*. 2003;349:2164–2167; author reply 2164–2167.
662. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. *BMJ*. 1994;308:235–246.
663. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. *Lancet*. 2000;355:1295–1302.
664. Black PM, Crowell RM, Abbott WM. External pneumatic calf compression reduces deep venous thrombosis in patients with ruptured intracranial aneurysms. *Neurosurgery*. 1986;18:25–28.
665. Kamran SI, Downey D, Ruff RL. Pneumatic sequential compression reduces the risk of deep vein thrombosis in stroke patients. *Neurology*. 1998;50:1683–1688.
666. Mazzone C, Chiodo Grandi F, Sandercock P, Miccio M, Salvi R. Physical methods for preventing deep vein thrombosis in stroke. *Cochrane Database Syst Rev*. 2002;(1):CD001922.
667. Weimar C, Miesch T, Buchthal J, Ehrenfeld CE, Schmid E, Diener HC; German Stroke Study Collaboration. Neurologic worsening during the acute phase of ischemic stroke. *Arch Neurol*. 2005;62:393–397.
668. Heo JH, Han SW, Lee SK. Free radicals as triggers of brain edema formation after stroke. *Free Radic Biol Med*. 2005;39:51–70.
669. Maramattom BV, Bahn MM, Wijdicks EF. Which patient fares worse after early deterioration due to swelling from hemispheric stroke? *Neurology*. 2004;63:2142–2145.
670. Heinsius T, Bogousslavsky J, Van Melle G. Large infarcts in the middle cerebral artery territory: etiology and outcome patterns. *Neurology*. 1998;50:341–350.
671. Manno EM, Nichols DA, Fulgham JR, Wijdicks EF. Computed tomographic determinants of neurologic deterioration in patients with large middle cerebral artery infarctions. *Mayo Clin Proc*. 2003;78:156–160.
672. Wijdicks EF, Diringner MN. Middle cerebral artery territory infarction and early brain swelling: progression and effect of age on outcome. *Mayo Clin Proc*. 1998;73:829–836.
673. Qureshi AI, Suarez JJ, Yahia AM, Mohammad Y, Uzun G, Suri MF, Zaidat OO, Ayata C, Ali Z, Wityk RJ. Timing of neurologic deterioration in massive middle cerebral artery infarction: a multicenter review. *Crit Care Med*. 2003;31:272–277.
674. Ropper AH, Shafran B. Brain edema after stroke: clinical syndrome and intracranial pressure. *Arch Neurol*. 1984;41:26–29.
675. Berrouschot J, Sterker M, Bettin S, Koster J, Schneider D. Mortality of space-occupying ('malignant') middle cerebral artery infarction under conservative intensive care. *Intensive Care Med*. 1998;24:620–623.
676. Ryou JW, Na DG, Kim SS, Lee KH, Lee SJ, Chung CS, Choi DS. Malignant middle cerebral artery infarction in hyperacute ischemic stroke: evaluation with multiphasic perfusion computed tomography maps. *J Comput Assist Tomogr*. 2004;28:55–62.
677. Kasner SE, Demchuk AM, Berrouschot J, Schmutzhard E, Harms L, Verro P, Chalela JA, Abbur R, McGrade H, Christou I, Krieger DW. Predictors of fatal brain edema in massive hemispheric ischemic stroke. *Stroke*. 2001;32:2117–2123.
678. Gujjar AR, Deibert E, Manno EM, Duff S, Diringner MN. Mechanical ventilation for ischemic stroke and intracerebral hemorrhage: indications, timing, and outcome. *Neurology*. 1998;51:447–451.
679. Frank JI. Large hemispheric infarction, deterioration, and intracranial pressure. *Neurology*. 1995;45:1286–1290.
680. Schwab S, Aschoff A, Spranger M, Albert F, Hacke W. The value of intracranial pressure monitoring in acute hemispheric stroke. *Neurology*. 1996;47:393–398.

681. Bauer RB, Tellez H. Dexamethasone as treatment in cerebrovascular disease, II: a controlled study in acute cerebral infarction. *Stroke*. 1973;4:547-555.
682. Bayer AJ, Pathy MS, Newcombe R. Double-blind randomised trial of intravenous glycerol in acute stroke. *Lancet*. 1987;1:405-408.
683. Larive LL, Rhoney DH, Parker D Jr, Coplin WM, Carhuapoma JR. Introducing hypertonic saline for cerebral edema: an academic center experience. *Neurocrit Care*. 2004;1:435-440.
684. Larsson O, Marinovich N, Barber K. Double-blind trial of glycerol therapy in early stroke. *Lancet*. 1976;1:832-834.
685. Manno EM, Adams RE, Derdeyn CP, Powers WJ, Diringer MN. The effects of mannitol on cerebral edema after large hemispheric cerebral infarct. *Neurology*. 1999;52:583-587.
686. Mathew NT, Rivera VM, Meyer JS, Charney JZ, Hartmann A. Double-blind evaluation of glycerol therapy in acute cerebral infarction. *Lancet*. 1972;2:1327-1329.
687. Mulley G, Wilcox RG, Mitchell JR. Dexamethasone in acute stroke. *BMJ*. 1978;2:994-996.
688. Norris JW. Steroid therapy in acute cerebral infarction. *Arch Neurol*. 1976;33:69-71.
689. Norris JW, Hachinski VC. High dose steroid treatment in cerebral infarction. *BMJ (Clin Res Ed)*. 1986;292:21-23.
690. Schwab S, Spranger M, Schwarz S, Hacke W. Barbiturate coma in severe hemispheric stroke: useful or obsolete? *Neurology*. 1997;48:1608-1613.
691. Marshall LF, Smith RW, Rauscher LA, Shapiro HM. Mannitol dose requirements in brain-injured patients. *J Neurosurg*. 1978;48:169-172.
692. Carter BS, Ogilvy CS, Candia GJ, Rosas HD, Buonanno F. One-year outcome after decompressive surgery for massive nondominant hemispheric infarction. *Neurosurgery*. 1997;40:1168-1175; discussion 1175-1176.
693. Delashaw JB, Broaddus WC, Kassell NF, Haley EC, Pendleton GA, Vollmer DG, Maggio WW, Grady MS. Treatment of right hemispheric cerebral infarction by hemicraniectomy. *Stroke*. 1990;21:874-881.
694. Hacke W, Schwab S, Horn M, Spranger M, De Georgia M, von Kummer R. 'Malignant' middle cerebral artery territory infarction: clinical course and prognostic signs. *Arch Neurol*. 1996;53:309-315.
695. Kalia KK, Yonas H. An aggressive approach to massive middle cerebral artery infarction. *Arch Neurol*. 1993;50:1293-1297.
696. Kondziolka D, Fazl M. Functional recovery after decompressive craniectomy for cerebral infarction. *Neurosurgery*. 1988;23:143-147.
697. Rieke K, Schwab S, Krieger D, von Kummer R, Aschoff A, Schuchardt V, Hacke W. Decompressive surgery in space-occupying hemispheric infarction: results of an open, prospective trial. *Crit Care Med*. 1995;23:1576-1587.
698. Rieke K, Krieger D, Aschoff A, et al. Therapeutic strategies in space-occupying cerebellar infarction based on clinical, neuroradiological, and neurophysiological data. *Cerebrovasc Dis*. 1993;3:45-55.
699. Robertson SC, Lennarson P, Hasan DM, Traynelis VC. Clinical course and surgical management of massive cerebral infarction. *Neurosurgery*. 2004;55:55-61; discussion 61-62.
700. Sakai K, Iwahashi K, Terada K, Gohda Y, Sakurai M, Matsumoto Y. Outcome after external decompression for massive cerebral infarction. *Neurol Med Chir (Tokyo)*. 1998;38:131-135; discussion 135-136.
701. Schwab S, Rieke K, Aschoff A. Hemicraniectomy in space-occupying hemispheric infarction. *Cerebrovasc Dis*. 1996;6:325-329.
702. Schwab S, Steiner T, Aschoff A, Schwarz S, Steiner HH, Jansen O, Hacke W. Early hemicraniectomy in patients with complete middle cerebral artery infarction. *Stroke*. 1998;29:1888-1893.
703. Fandino J, Keller E, Barth A, Landolt H, Yonekawa Y, Seiler RW. Decompressive craniotomy after middle cerebral artery infarction: retrospective analysis of patients treated in three centres in Switzerland. *Swiss Med Wkly*. 2004;134:423-429.
704. Kilincer C, Asil T, Utku U, Hamamcioglu MK, Turgut N, Hicdonmez T, Simsek O, Ekuklu G, Cobanoglu S. Factors affecting the outcome of decompressive craniectomy for large hemispheric infarctions: a prospective cohort study. *Acta Neurochir (Wien)*. 2005;147:587-594; discussion 594.
705. Curry WT Jr, Sethi MK, Ogilvy CS, Carter BS. Factors associated with outcome after hemicraniectomy for large middle cerebral artery territory infarction. *Neurosurgery*. 2005;56:681-692; discussion 681-692.
706. Hofmeijer J, van der Worp HB, Kappelle LJ. Treatment of space-occupying cerebral infarction. *Crit Care Med*. 2003;31:617-625.
707. Greenberg J, Skubick D, Shenkin H. Acute hydrocephalus in cerebellar infarct and hemorrhage. *Neurology*. 1979;29:409-413.
708. Hornig CR, Rust DS, Busse O, Jauss M, Laun A. Space-occupying cerebellar infarction: clinical course and prognosis. *Stroke*. 1994;25:372-374.
709. Horwitz NH, Ludolph C. Acute obstructive hydrocephalus caused by cerebellar infarction: treatment alternatives. *Surg Neurol*. 1983;20:13-19.
710. Mathew P, Teasdale G, Bannan A, Oluoch-Olunya D. Neurosurgical management of cerebellar haematoma and infarct. *J Neurol Neurosurg Psychiatry*. 1995;59:287-292.
711. Chen HJ, Lee TC, Wei CP. Treatment of cerebellar infarction by decompressive suboccipital craniectomy. *Stroke*. 1992;23:957-961.
712. Pranesh MB, Dinesh Nayak S, Mathew V, Prakash B, Natarajan M, Rajmohan V, Murali R, Pehraj A. Hemicraniectomy for large middle cerebral artery territory infarction: outcome in 19 patients. *J Neurol Neurosurg Psychiatry*. 2003;74:800-802.
713. Cho DY, Chen TC, Lee HC. Ultra-early decompressive craniectomy for malignant middle cerebral artery infarction. *Surg Neurol*. 2003;60:227-232; discussion 232-233.
714. Cockroft KM. Hemicraniectomy after massive hemispheric cerebral infarction: are we ready for a prospective randomised controlled trial? *J Neurol Neurosurg Psychiatry*. 2004;75:179-180.
715. Uhl E, Kreth FW, Elias B, Goldammer A, Hempelmann RG, Liefner M, Nowak G, Oertel M, Schmieder K, Schneider GH. Outcome and prognostic factors of hemicraniectomy for space occupying cerebral infarction. *J Neurol Neurosurg Psychiatry*. 2004;75:270-274.
716. Gupta R, Connolly ES, Mayer S, Elkind MSV. Hemicraniectomy for massive middle cerebral artery territory infarction: a systematic review. *Stroke*. 2004;35:539-543.
717. Beghi E, Bogliun G, Cavaletti G, Sanguineti I, Tagliabue M, Agostoni F, Macchi I. Hemorrhagic infarction: risk factors, clinical and tomographic features, and outcome: a case-control study. *Acta Neurol Scand*. 1989;80:226-231.
718. Jaillard A, Cornu C, Durieux A, Moulin T, Boutitie F, Lees KR, Hommel M; MAST-E Group. Hemorrhagic transformation in acute ischemic stroke: the MAST-E study. *Stroke*. 1999;30:1326-1332.
719. Lodder J, Krijne-Kubat B, Broekman J. Cerebral hemorrhagic infarction at autopsy: cardiac embolic cause and the relationship to the cause of death. *Stroke*. 1986;17:626-629.
720. Motto C, Aritzu E, Boccardi E, De Grandi C, Piana A, Candelise L. Reliability of hemorrhagic transformation diagnosis in acute ischemic stroke. *Stroke*. 1997;28:302-306.
721. Motto C, Ciccone A, Aritzu E, Boccardi E, De Grandi C, Piana A, Candelise L; MAST-I Collaborative Group. Hemorrhage after an acute ischemic stroke. *Stroke*. 1999;30:761-764.
722. Okada Y, Yamaguchi T, Minematsu K, Miyashita T, Sawada T, Sadoshima S, Fujishima M, Omae T. Hemorrhagic transformation in cerebral embolism. *Stroke*. 1989;20:598-603.
723. Toni D, Fiorelli M, Bastianello S, Sacchetti ML, Sette G, Argentino C, Montinaro E, Bozzao L. Hemorrhagic transformation of brain infarct: predictability in the first 5 hours from stroke onset and influence on clinical outcome. *Neurology*. 1996;46:341-345.
724. Hornig CR, Dorndorf W, Agnoli AL. Hemorrhagic cerebral infarction: a prospective study. *Stroke*. 1986;17:179-185.
725. Bogousslavsky J, Regli F. Anticoagulant-induced intracerebral bleeding in brain ischemia: evaluation in 200 patients with TIAs, emboli from the heart, and progressing stroke. *Acta Neurol Scand*. 1985;71:464-471.
726. Derex L, Hermier M, Adeleine P, Pialat JB, Wiart M, Berthezene Y, Philippeau F, Honnorat J, Froment JC, Trouillas P, Nighoghossian N. Clinical and imaging predictors of intracerebral haemorrhage in stroke patients treated with intravenous tissue plasminogen activator. *J Neurol Neurosurg Psychiatry*. 2005;76:70-75.
727. Warach S, Latour LL. Evidence of reperfusion injury, exacerbated by thrombolytic therapy, in human focal brain ischemia using a novel imaging marker of early blood-brain barrier disruption. *Stroke*. 2004;35(suppl 1):2659-2661.
728. Bayramoglu M, Karatas M, Leblebici B, Cetin N, Sozay S, Turhan N. Hemorrhagic transformation in stroke patients. *Am J Phys Med Rehabil*. 2003;32:48-52.

729. Koh MG, Phan TG, Atkinson JL, Wijidicks EF. Neuroimaging in deteriorating patients with cerebellar infarcts and mass effect. *Stroke*. 2000;31:2062–2067.
730. Vo KD, Santiago F, Lin W, Hsu CY, Lee Y, Lee JM. MR imaging enhancement patterns as predictors of hemorrhagic transformation in acute ischemic stroke. *AJNR Am J Neuroradiol*. 2003;24:674–679.
731. Burn J, Dennis M, Bamford J, Sandercock P, Wade D, Warlow C. Epileptic seizures after a first stroke: the Oxfordshire Community Stroke Project. *BMJ*. 1997;315:1582–1587.
732. Davalos A, de Cendra E, Molins A, et al. Epileptic seizures at the onset of stroke. *Cerebrovasc Dis*. 1992;2:327–331.
733. Kilpatrick CJ, Davis SM, Hopper JL, Rossiter SC. Early seizures after acute stroke: risk of late seizures. *Arch Neurol*. 1992;49:509–511.
734. Pohlmann-Eden B, Cochius J, Hoch D, Hennerici MG. Stroke and epilepsy: critical review of the literature. *Cerebrovasc Dis*. 1997;7:2–9.
735. Awada A, Omojola MF, Obeid T. Late epileptic seizures after cerebral infarction. *Acta Neurol Scand*. 1999;99:265–268.
736. Camilo O, Goldstein LB. Seizures and epilepsy after ischemic stroke. *Stroke*. 2004;35:1769–1775.
737. Cordonnier C, Henon H, Derambure P, Pasquier F, Leys D. Influence of pre-existing dementia on the risk of post-stroke epileptic seizures. *J Neurol Neurosurg Psychiatry*. 2005;76:1649–1653.
738. Rumbach L, Sablot D, Berger E, Tatu L, Vuillier F, Moulin T. Status epilepticus in stroke: report on a hospital-based stroke cohort. *Neurology*. 2000;54:350–354.